N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS

FIELD OF THE INVENTION

The present invention relates to a new series of N-containing heteroaryl derivatives, as well as to processes for their preparation, to pharmaceutical compositions comprising them and to their use in therapy.

BACKGROUND OF THE INVENTION

The Janus kinases (JAKs) are cytoplasmic protein tyrosine kinases that play pivotal roles in pathways that modulate cellular functions in the lympho-hematopoietic system that are critical for cell proliferation and cell survival. JAKs are involved in the initiation of cytokine-triggered signaling events by activating through tyrosine phosphorylation the signal transducers and activators of transcription (STAT) proteins. JAK/STAT signaling has been implicated in the mediation of many abnormal immune responses such as transplant rejection and autoimmune diseases, as well as in solid and hematologic malignancies such as leukemias and lymphomas and in myeloproliferative disorders, and has thus emerged as an interesting target for drug intervention.

Four members of the JAK family have been identified so far: JAK1, JAK2, JAK3 and Tyk2. Unlike JAK1, JAK2 and Tyk2, whose expression is ubiquitous, JAK3 is mainly found in hematopoietic cells. JAK3 is associated in a non-covalent manner with the γc subunit of the receptors of IL-2, IL-4, IL-7, IL-9, IL-13 and IL-15. These cytokines play an important role in the proliferation and differentiation of T lymphocytes. JAK3-deficient mouse T cells do not respond to IL-2. This cytokine is fundamental in the regulation of T lymphocytes. In this regard, it is known that antibodies directed against the IL-2 receptor are able to prevent transplant rejection. In patients with X severe combined immunodeficiency (X-SCID), very low levels of JAK3 expression as well as genetic defects in the γc subunit of the receptor have been identified, which indicates that immunosuppression is a consequence of an alteration in the JAK3 signaling pathway.

Animal studies have suggested that JAK3 not only plays a critical role in T and B lymphocyte maturation, but also that JAK3 is required to maintain lymphocyte function. Modulation of the immunological activity through this new mechanism can prove useful in the treatment of T cell proliferative disorders such as transplant rejection and autoimmune diseases.

JAK3 has also been shown to play an important role in mast cells, because antigen-induced degranulation and mediator release have been found to be substantially reduced in mast cells from JAK3 deficient mice. JAK3 deficiency does not affect mast cell proliferation nor IgE receptor expression levels. On the other hand, JAK3−/− and JAK3+/+ mast cells contain the same intracellular mediators. Therefore, JAK3 appears to be essential in the IgE-induced release of mediators in mast cells and its inhibition would be, thus, an effective treatment for allergic reactions.

In conclusion, JAK3 kinase inhibitors have been recognised as a new class of effective immunosuppressive agents useful for transplant rejection prevention and in the treatment of immune, autoimmune, inflammatory and proliferative diseases such as psoriasis, psoriatic arthritis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases, systemic lupus erythematosus, type I diabetes and complications from diabetes, allergic reactions and leukemia (see e.g. O'Shea J. J. et al., Nat. Rev. Drug. Discov. 2004, 3(7):555-64; Cetkovic-Cvrlje M. et al, Curr. Pharm, Des. 2004, 10(15):1767-84; Cetkovic-Cvrlje M. at al, Arch. Immunol. Ther. Exp. (Warsz), 2004, 52(2):69-82).

Accordingly, it would be desirable to provide novel compounds that are capable of inhibiting JAK/STAT signaling pathways, and in particular which are capable of inhibiting JAK3 activity, and which are good drug candidates. Compounds should exhibit good activity in in vitro and in vivo pharmacological assays, good oral absorption when administered by the oral route, as well as be metabolically stable and exhibit a favourable pharmacokinetic profile. Moreover, compounds should not be toxic and exhibit few side effects.

DESCRIPTION OF THE INVENTION

One aspect of the invention relates to a compound of formula I or II

embedded image

wherein

A is carbon and B is nitrogen, or A is nitrogen and B is carbon;

W is CH or N;

R₁and R₂independently are hydrogen, C_1-4alkyl, hydroxyC_1-4alkyl, cyanoC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, halogen, —CN, —OR₈, or —SR₈;

R₃is C_1-4alkyl, R₉—C_1-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₀;

R₄is hydrogen, C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, cyanoC_1-4alkyl, R₁₂R₇N—C_0-4alkyl, R₁₃CONR₇—C_0-4alkyl, R₁₃R₇NCO—C_0-4alkyl, R₁₂R₇NCONR₇—C_0-4alkyl, R₁₃CO₂NR₇—C_0-4alkyl, R₁₃SO₂NR₇—C_0-4alkyl, —OR₁₂or Cy₂-C_0-4alkyl; wherein Cy₂is optionally substituted with one or more R₁₁;

R₅is hydrogen, C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, cyanoC_1-4alkyl, halogen, —CN, —OR₁₂, —NR₇R₁₂, or Cy₂-C_0-4alkyl, wherein Cy₂is optionally substituted with one or more R₁₁;

R₆is hydrogen, C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, R₁₂R₇N—C_1-4alkyl, R₁₆CO—C_0-4alkyl, R₁₆CO₂—C_0-4alkyl, R₁₆CO—O—C_1-4alkyl, cyanoC_1-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₁;

R₇is hydrogen or C_1-4alkyl;

R₈is hydrogen, C_1-4alkyl, haloC_1-4alkyl, hydroxyC_1-4alkyl, or C_1-4alkoxyC_1-4alkyl;

R₉is halogen, —CN, —CONR₇R₁₂, —COR₁₃, —CO₂R₁₂, —OR₁₂, —OCONR₇R₁₂, —SO₂R₁₃, —SO₂NR₇R₁₂, —NR₇R₁₂, —NR₇COR₁₂, —NR₇CONR₇R₁₂, —NR₇CO₂R₁₃or —NR₇SO₂R₁₃;

R₁₀is C_1-4alkyl or R₉—C_0-4alkyl;

R₁₁is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, cyanoC_1-4alkyl, halogen, —CN, —CONR₇R₁₄, —COR₁₄, —CO₂R₁₅, —OR₁₄, —OCONR₇R₁₄, —SO₂R₁₅, —SO₂NR₇R₁₄, —NR₇R₁₄, —NR₇COR₁₄, —NR₇CONR₇R₁₄, —NR₇CO₂R₁₅or —NR₇SO₂R₁₅;

R₁₂is hydrogen or R₁₃;

R₁₃is C_1-5alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, cyanoC_1-4alkyl, Cy₂-C_0-4alkyl or R₁₄R₇N—C_1-4alkyl; wherein Cy₂is optionally substituted with one or more R₁₁;

R₁₄is hydrogen or R₁₅;

R₁₅is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or cyanoC_1-4alkyl;

R₁₆is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl or cyanoC_1-4alkyl;

Cy₁is a 3- to 7-membered monocyclic or 6- to 11-membered bicyclic ring, which is saturated, partially unsaturated or aromatic, and which is carbocyclic or heterocyclic containing from 1 to 4 heteroatoms independently selected from N, S and O, wherein said ring is bonded to the rest of the molecule through any available C atom, and wherein one or more C or S ring atoms are optionally oxidized forming CO, SO or SO₂; and

Cy₂is a 3- to 7-membered monocyclic or 6- to 11-membered bicyclic ring, which is saturated, partially unsaturated or aromatic, and which is carbocyclic or heterocyclic containing from 1 to 4 heteroatoms independently selected from N, S and O, wherein said ring is bonded to the rest of the molecule through any available C or N atom, and wherein one or more C or S ring atoms are optionally oxidized forming CO, SO or SO₂

The compounds of formula I or II are JAK, particularly JAK3, kinase inhibitors and therefore can be useful for the treatment or prevention of any disease mediated by JAKs, and particularly JAK3.

Thus, another aspect of the invention relates to a compound of formula I or II

embedded image

wherein

A is carbon and B is nitrogen, or A is nitrogen and B is carbon;

W is CH or N;

R₁and R₂independently are hydrogen, C_1-4alkyl, haloC_1-4alkyl, hydroxyC_1-4alkyl, cyanoC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, halogen, —CN, —OR₈, or —SR₈;

R₃is C_1-4alkyl, R₉—C_1-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₀;

R₄is hydrogen, C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, cyanoC_1-4alkyl, R₁₂R₇N—C_0-4alkyl, R₁₃CONR₇—C_0-4alkyl, R₁₃R₇NCO—C_0-4alkyl, R₁₂R₇NCONR₇—C_0-4alkyl, R₁₃CO₂NR₇—C_0-4alkyl, R₁₃SO₂NR₇—C_0-4alkyl, —OR₁₂or Cy₂-C_1-4alkyl; wherein Cy₂is optionally substituted with one or more R₁₁;

R₇is hydrogen or C_1-4alkyl;

R₈is hydrogen, C_1-4alkyl, haloC_1-4alkyl, hydroxyC_1-4alkyl, or C_1-4alkoxyC_1-4alkyl;

R₁₀is C_1-4alkyl or R₉—C_0-4alkyl;

R₁₁is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, cyanoC_1-4alkyl, halogen, —CN, —CONR₇R₁₄, —COR₁₄, —CO₂R₁₆, —OR₁₄, —OCONR₇R₁₄, —SO₂R₁₅, —SO₂NR₇R₁₄, —NR₇R₁₄, —NR₇COR₁₄, —NR₇CONR₇R₁₄, —NR₇CO₂R₁₅or —NR₇SO₂R₁₅;

R₁₂is hydrogen or R₁₃,

R₁₄is hydrogen or R₁₅;

R₁₅is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or cyanoC_1-4alkyl;

R₁₆is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl or cyanoC_1-4alkyl;

for use in therapy.

Another aspect of the invention relates to a pharmaceutical composition which comprises a compound of formula I or II or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.

Another aspect of the present invention relates to the use of a compound of formula I or II or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment or prevention of a disease mediated by JAKs, particularly JAK3. More preferably, the disease mediated by JAKs, particularly JAK3, is at least one disease selected from transplant rejection, immune, autoimmune or inflammatory diseases, neurodegenerative diseases, or proliferative disorders, in a further preferred embodiment, the disease mediated by JAKs, particularly JAK3, is selected from transplant rejection or immune, autoimmune or inflammatory diseases. In a further preferred embodiment, the disease mediated by JAKs, particularly JAK3, is a proliferative disorder.

Another aspect of the present invention relates to the use of a compound of formula I or II or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment or prevention of at least one disease selected from transplant rejection, immune, autoimmune or inflammatory diseases, neurodegenerative diseases, or proliferative disorders. In a preferred embodiment, the disease is selected from transplant rejection or immune, autoimmune or inflammatory diseases. In a further preferred embodiment, the disease is a proliferative disorder.

Another aspect of the present invention relates to the use of a compound of formula I or II or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment or prevention of a disease selected from transplant rejection, rheumatoid arthritis, psoriatic arthritis, psoriasis, type I diabetes, complications from diabetes, multiple sclerosis, systemic lupus erythematosus, atopic dermatitis, mast cell-mediated allergic reactions, inflammatory or autoimmune ocular diseases, leukemias, lymphomas, and thromboembolic and allergic complications associated with leukemias and lymphomas.

Another aspect of the present invention relates to a compound of formula I or II or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of a disease mediated by JAKs, particularly JAK3. More preferably, the disease mediated by JAKs, particularly JAK3, is at least one disease selected from transplant rejection, immune, autoimmune or inflammatory diseases, neurodegenerative diseases, or proliferative disorders. In a further preferred embodiment, the disease mediated by JAKs, particularly JAK3, is selected from transplant rejection or immune, autoimmune or inflammatory diseases. In a further preferred embodiment, the disease mediated by JAKs, particularly JAK3, is a proliferative disorder.

Another aspect of the present invention relates to a compound of formula I or II or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of at least one disease selected from transplant rejection, immune, autoimmune or inflammatory diseases, neurodegenerative diseases, or proliferative disorders. In a preferred embodiment, the disease is selected from transplant rejection or immune, autoimmune or inflammatory diseases, in a further preferred embodiment, the disease is a proliferative disorder.

Another aspect of the present invention relates to a compound of formula I or Er or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of a disease selected from transplant rejection, rheumatoid arthritis, psoriatic arthritis, psoriasis, type I diabetes, complications from diabetes, multiple sclerosis, systemic lupus erythematosus, atopic dermatitis, mast cell-mediated allergic reactions, inflammatory or autoimmune ocular diseases, leukemias, lymphomas, and thromboembolic and allergic complications associated with leukemias and lymphomas.

Another aspect of the present invention relates to the use of a compound of formula I or II or a pharmaceutically acceptable salt thereof for the treatment or prevention of a disease mediated by JAKs, particularly JAK3. More preferably, the disease mediated by JAKs, particularly JAK3, is at least one disease selected from transplant rejection, immune, autoimmune or inflammatory diseases, neurodegenerative diseases, or proliferative disorders. In a further preferred embodiment, the disease mediated by JAKs, particularly JAK3, is selected from transplant rejection or immune, autoimmune or inflammatory diseases. In a further preferred embodiment, the disease mediated by JAKs, particularly JAK3, is a proliferative disorder.

Another aspect of the present invention relates to the use of a compound of formula I or II or a pharmaceutically acceptable salt thereof for the treatment or prevention of at least one disease selected from transplant rejection, immune, autoimmune or inflammatory diseases, neurodegenerative diseases, or proliferative disorders. In a preferred embodiment, the disease is selected from transplant rejection or immune, autoimmune or inflammatory diseases. In a further preferred embodiment, the disease is a proliferative disorder.

Another aspect of the present invention relates to the use of a compound of formula I or II or a pharmaceutically acceptable salt thereof for the treatment or prevention of a disease selected from transplant rejection, rheumatoid arthritis, psoriatic arthritis, psoriasis, type I diabetes, complications from diabetes, multiple sclerosis, systemic lupus erythematosus, atopic dermatitis, mast cell-mediated allergic reactions, inflammatory or autoimmune ocular diseases, leukemias, lymphomas, and thromboembolic and allergic complications associated with leukemias and lymphomas.

Another aspect of the present invention relates to a method of treating or preventing a disease mediated by JAKs, particularly JAK3, in a subject in need thereof, especially a human being, which comprises administering to said subject an amount of a compound of formula I or II or a pharmaceutically acceptable salt thereof effective to treat said disease. More preferably, the disease mediated by JAKs, particularly JAK3, is at least one disease selected from transplant rejection, immune, autoimmune or inflammatory diseases, neurodegenerative diseases, or proliferative disorders. In a further preferred embodiment, the disease mediated by JAKs, particularly JAK3, is selected from transplant rejection or immune, autoimmune or inflammatory diseases. In a further preferred embodiment, the disease mediated by JAKs, particularly JAK3, is a proliferative disorder.

Another aspect of the present invention relates to a method of treating or preventing at least one disease selected from transplant rejection, immune, autoimmune or inflammatory diseases, neurodegenerative diseases, or proliferative disorders in a subject in need thereof, especially a human being, which comprises administering to said subject an amount of a compound of formula I or II or a pharmaceutically acceptable salt thereof effective to treat said disease. In a preferred embodiment, the disease is selected from transplant rejection or immune, autoimmune or inflammatory diseases. In a further preferred embodiment, the disease is a proliferative disorder.

Another aspect of the present invention relates to a method of treating or preventing a disease selected from transplant rejection, rheumatoid arthritis, psoriatic arthritis, psoriasis, type I diabetes, complications from diabetes, multiple sclerosis, systemic lupus erythematosus, atopic dermatitis, mast cell-mediated allergic reactions, inflammatory or autoimmune ocular diseases, leukemias, lymphomas, and thromboembolic and allergic complications associated with leukemias and lymphomas in a subject in need thereof, especially a human being, which comprises administering to said subject an amount of a compound of formula I or II or a pharmaceutically acceptable salt thereof effective to treat said disease.

Another aspect of the present invention relates to a process for the preparation of a compound of formula I or II as defined above, which comprises:

(a) for a compound of formula I, reacting a compound of formula VI with a compound of formula III

embedded image

wherein A, B, W, R₁, R₂, R₃, R₄and R₅have the meaning previously described in relation with a compound of formula I or II; or

(b) for a compound of formula I, reacting a compound of formula VI with a compound of formula IV

embedded image

wherein A, B, W, R₁, R₂, R₃, R₄and R₅have the meaning previously described in relation with a compound of formula I or II; or

(c) when in a compound of formula II R₆is hydrogen (a compound of formula IIa) reacting a compound of formula VI, as defined above, with a synthetic equivalent for the CO synthon.

embedded image

wherein A, B, W, R₁, R₂, R₃and R₅have the meaning previously described in relation with a compound of formula I or II; or

(d) when in a compound of formula II R₆is other than hydrogen, reacting a compound of formula IIa with a compound of formula V (R₆—X) in the presence of a base, wherein X is a leaving group; or

(e) converting, in one or a plurality of steps, a compound of formula I or II into another compound of formula I or II.

In the above definitions, the term C_1-5alkyl, as a group or part of a group, means a straight or branched alkyl chain which contains from 1 to 5 carbon atoms and includes among others the groups methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl and iso-pentyl. Likewise, the term C_1-4alkyl, as a group or part of a group, means a straight or branched alkyl chain which contains from 1 to 4 carbon atoms and includes the groups methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl.

A C_1-4alkoxy group, as a group or part of a group, means a group of formula —OC_1-4alkyl, wherein the C_1-4alkyl moiety has the same meaning as previously described. Examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy and tert-butoxy.

A C_1-4alkoxyC_1-4alkyl group means a group resulting from the replacement of one or more hydrogen atoms from a C_1-4alkyl group with one or more C_1-4alkoxy groups as defined above, which can be the same or different. Examples include, among others, the groups methoxymethyl, ethoxymethyl, propoxymethyl, isopropoxymethyl butoxymethyl, isobutoxymethyl, sec-butoxymethyl, tert-butoxymethyl, dimethoxymethyl, 1-methoxyethyl, 2-methoxyethyl, 2-ethoxyethyl, 1,2-diethoxyethyl, 1-butoxyethyl, 2-sec-butoxyethyl, 3-methoxypropyl, 2-butoxypropyl, 1-methoxy-2-ethoxypropyl, 3-tert-butoxypropyl and 4-methoxybutyl.

Halogen or its abbreviation halo means fluoro, chloro, bromo or iodo.

A haloC_1-4alkyl group means a group resulting from the replacement of one or more hydrogen atoms from a C_1-4alkyl group with one or more halogen atoms (i.e., fluoro, chloro, bromo or iodo), which can be the same or different. Examples include, among others, the groups trifluoromethyl, fluoromethyl, 1-chloroethyl, 2-chloroethyl, 1-fluoroethyl, 2-fluoroethyl, 2-bromoethyl, 2-iodoethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, 3-fluoropropyl, 3-chloropropyl, 2,2,3,3-tetrafluoropropyl, 2,2,3,3,3-pentafluoropropyl, heptafluoropropyl, 4-fluorobutyl, nonafluorobutyl, 1-chloro-2-fluoroethyl and 2-bromo-1-chloro-1-fluoropropyl.

A hydroxyC_1-4alkyl group means a group resulting from the replacement of one or more hydrogen atoms from a C_1-4alkyl group with one or more hydroxy groups. Examples include, among others, the groups hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1,2-dihydroxyethyl, 3-hydroxypropyl, 2-hydroxypropyl, 1-hydroxypropyl, 2,3-dihydroxypropyl, 4-hydroxybutyl, 3-hydroxybutyl, 2-hydroxybutyl and 1-hydroxybutyl.

A cyanoC_1-4alkyl group means a group resulting from the replacement of one or more hydrogen atoms from a C_1-4alkyl group with one or more cyano groups. Examples include, among others, the groups cyanomethyl, dicyanomethyl, 1-cyanoethyl, 2-cyanoethyl, 3-cyanopropyl, 2,3-dicyanopropyl and 4-cyanobutyl.

A haloC_1-4alkoxy group means a group resulting from the replacement of one or more hydrogen atoms from a C_1-4alkoxy group with one or more halogen atoms (i.e. fluoro, chloro, bromo or iodo), which can be the same or different. Examples include, among others, the groups trifluoromethoxy, fluoromethoxy, 1-chloroethoxy, 2-chloroethoxy, 1-fluoroethoxy, 2-fluoroethoxy, 2-bromoethoxy, 2-iodoethoxy, 2,2,2-trifluoroethoxy, pentafluoroethoxy, 3-fluoropropoxy, 3-chloropropoxy, 2,2,3,3-tetrafluoropropoxy, 2,2,3,3,3-pentafluoropropoxy, heptafluoropropoxy, 4-fluorobutoxy, nonafluorobutoxy, 1-chloro-2-fluoroethoxy and 2-bromo-1-chloro-1-fluoropropoxy.

The term C₀alkyl indicates that the alkyl group is absent.

Thus, the term R₉—C_1-4alkyl includes R₉and R₉—C_1-4alkyl. The term R₉—C_1-4alkyl relates to a group resulting from the substitution of one hydrogen atom of a C_1-4alkyl group with one R₉group.

The terms R₁₂R₇N—C_0-4alkyl, R₁₃CONR₇—C_0-4alkyl, R₁₃R₇NCO—C_0-4alkyl, R₁₂R₇NCONR₇—C_0-4alkyl, R₁₃CO₂NR₇—C_0-4alkyl, R₁₃SO₂NR₇—C_0-4alkyl, R₁₆CO—C_0-4alkyl and R₁₆CO₂—C_0-4alkyl include —NR₇R₁₂and R₁₂R₇N—C_1-4alkyl, —NR₇COR₁₃and R₁₃CONR₇—C_1-4alkyl, —CONR₇R₁₃and R₁₃R₇NCO—C_1-4alkyl, —NR₇CONR₇R₁₂and R₁₂R₇NCONR₇—C_1-4alkyl, —NR₂CO₂R₁₃and R₁₃CO₂NR₇—C_1-4alkyl, —NR₇SO₂R₁₃and R₁₃SO₂NR₂—C_1-4alkyl, —COR₁₆and R₁₆CO—C_1-4alkyl, and —CO₂R₁₆and R₁₆CO₂—C_1-4alkyl, respectively.

A group R₁₂R₇N—C_1-4alkyl, R₁₄R₇N—C_1-4alkyl, R₁₃CONR₇—C_1-4alkyl, R₁₃R₇NCO—C_1-4alkyl, R₁₂R₇NCONR₇—C_1-4alkyl, R₁₃CO₂NR₇—C_1-4alkyl, R₁₃SO₂NR₇—C_1-4alkyl, R₁₆CO—C_1-4alkyl, R₁₆CO₂—C_1-4alkyl or R₁₆CO—O—C_1-4alkyl means a group resulting from the replacement of one hydrogen atom from a C_0-4alkyl group with one —NR₇R₁₂, —NR₇R₁₄, —NR₇COR₁₃, —CONR₇R₁₃, —NR₇CONR₇R₁₂, —NR₇CO₂R₁₃—NR₇SO₂R₁₃, —COR₁₆, —CO₂R₁₆or —OCOR₁₆group, respectively.

A Cy₁group refers to a 3- to 7-membered monocyclic or 6- to 11-membered bicyclic carbocyclic or heterocyclic ring, which is saturated, partially unsaturated or aromatic. When heterocyclic, it contains from 1 to 4 heteroatoms independently selected from N, S and a Bicyclic rings are formed either by two rings fused through two adjacent C or N atoms, or through two non-adjacent C or N atoms forming a bridged ring, or else they are formed by two rings bonded through a single common C atom forming a spiro ring, Cy₁is bonded to the rest of the molecule through any available C atom. When Cy₁is saturated or partially unsaturated, one or more C or S atoms of said ring are optionally oxidized forming CO, SO or SO₂groups. Cy₁is optionally substituted as disclosed above in the definition of a compound of formula I or II, said substituents can be the same or different and can be placed on any available position of the ring system.

A Cy₂group refers to a 3- to 7-membered monocyclic or 6- to 11-membered bicyclic carbocyclic or heterocyclic ring, which is saturated, partially unsaturated or aromatic. When heterocyclic, it contains from 1 to 4 heteroatoms independently selected from N, S and O. Bicyclic rings are formed either by two rings fused through two adjacent C or N atoms, or through two non-adjacent C or N atoms forming a bridged ring, or else they are formed by two rings bonded through a single common C atom forming a spiro ring. Cy₂is bonded to the rest of the molecule through any available C or N atom. When Cy₂is saturated or partially unsaturated, one or more C or S atoms of said ring are optionally oxidized forming CO, SO or SO₂groups. Cy₂is optionally substituted as disclosed above in the definition of a compound of formula I or II, said substituents can be the same or different and can be placed on any available position of the ring system.

Examples of either Cy₁or Cy₂include, among others, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, azetidinyl, aziridinyl, oxiranyl, oxetanyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, oxazolidinyl, pyrazolidinyl, pyrrolidinyl, thiazolidinyl, dioxanyl, morpholinyl, thiomorpholinyl, 1,1-dioxothiomorpholinyl, piperazinyl, homopiperazinyl, piperidinyl, pyranyl, tetrahydropyranyl, homopiperidinyl, oxazinyl, oxazolinyl, pyrrolinyl, thiazolinyl, pyrazolinyl, imidazolinyl, isoxazolinyl, isothiazolinyl, 2-oxo-pyrrolidinyl, 2-oxo-piperidinyl, 4-oxo-piperidinyl, 2-oxo-piperazinyl, 2-oxo-1,2-dihydropyridinyl, 2-oxo-1,2-dihydropyrazinyl, 2-oxo-1,2-dihydropyrimidinyl, 3-oxo-2,3-dihydropyridazyl, phenyl, naphthyl, thienyl, furyl, pyrrolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, 1,3,4-oxadiazolyl, 1,3,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,2,4-thiadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, benzimidazolyl, benzooxazolyl, benzofuranyl, isobenzofuranyl, indolyl, isoindolyl, benzothiophenyl, benzothiazolyl, quinolinyl, isoquinolinyl, phtalazinyl, quinazolinyl, quinoxalinyl, cinoiinyl, naphthyridinyl, indazolyl, imidazopyridinyl, pyrrolopyridinyl, thienopyridinyl, imidazopyrimidinyl, imidazopyrazinyl, imidazopyridazinyl, pyrazolopyrazinyl, pyrazolopyridinyl, pyrazolopyrimidinyl, benzo[1,3]dioxolyl, phtalimidyl, 1-oxo-1,3-dihydroisobenzofuranyl, 1,3-dioxo-1,3-dihydroisobenzofuranyl, 1-oxo-2,3-dihydro-1H-isoindolyl, chromanyl, perhydroquinolinyl, 1-oxo-perhydroisoquinolinyl, 1-oxo-1,2-dihydroisoquinolinyl, 4-oxo-3,4-dihydroquinazolinyl, 2-aza-bicyclo[2.2.1]heptanyl, 5-aza-bicyclo[2.1.1]hexanyl, 2H-spiro[benzofuran-3,4′-piperidinyl], 3H-spiro[isobenzofuran-1,4′-piperidinyl], 1-oxo-2,8-diazaspiro[4.5]decanyl and 1-oxo-2,7-diazaspiro[4.5]decanyl.

When in the definitions used throughout the present specification for cyclic groups the examples given refer to a radical of a ring in general terms, for example piperidinyl, tetrahydropyranyl or indolyl, all the available bonding positions are included, unless a limitation is indicated in the corresponding definition for said cyclic group, for example that the ring is bonded through a C atom in Cy₁, in which case such limitation applies. Thus for example, in the definitions of Cy₂, which do not include any limitation regarding the bonding position, the term piperidinyl includes 1-piperidinyl, 2-piperidinyl, 3-piperidinyl and 4-piperidinyl; tetrahydropyranyl includes 2-tetrahydropyranyl, 3-tetrahydropyranyl and 4-tetrahydropyranyl; and indolyl includes 1-indolyl, 2-indolyl, 3-indolyl, 4-indolyl, 5-indolyl, 6-indolyl and 7-indolyl.

In the above definitions of Cy₁and Cy₂, when the examples listed refer to a bicycle in general terms, all possible dispositions of the atoms are included. Thus, for example, the term pyrazolopyridinyl includes groups such as 1H-pyrazolo[3,4-b]pyridinyl, 1H-pyrazolo[1,5-a]pyridinyl, 1H-pyrazolo[3,4-c]pyridinyl, 1H-pyrazolo[4,3-c]pyridinyl and 1H-pyrazolo[4,3-b]pyridinyl, the term imidazopyrazinyl includes groups such as 1H-imidazo[4,5-b]pyrazinyl, imidazo[1,2-a]pyrazinyl and imidazo[1,5-a]pyrazinyl and the term pyrazolopyrimidinyl includes groups such as 1H-pyrazolo[3,4-d]pyrimidinyl, 1H-pyrazolo[4,3-d]pyrimidinyl, pyrazolo[1,5-a]pyrimidinyl and pyrazolo[1,5-c]pyrimidinyl.

The term Cy₂-C_0-4alkyl includes Cy₂and Cy₂-C_1-4alkyl.

A Cy₂-C_1-4alkyl group means a group resulting from the replacement of one hydrogen atom from a C_1-4alkyl group with one Cy₂group. Examples include, among others, the groups (piperidinyl-4-ylmethyl, 2-(piperidinyl-4-yl)ethyl, 3-(piperidinyl-4-yl)propyl, 4-(piperidinyl-4-yl)butyl, (tetrahydropyran-4-ylmethyl, 2-(tetrahydropyran-4-yl)ethyl, 3-(tetrahydropyran-4-yl)propyl, 4-(tetrahydropyran-4-yl)butyl, benzyl, phenethyl, 3-phenylpropyl, 4-phenylbutyl, (indolinyl-1-ylmethyl, 2-(indolinyl-1-yl)ethyl, 3-(indolinyl-1-yl)propyl and 4-(indolinyl-1-yl)butyl.

In the definition of a compound of formula I or II, either A is carbon and B is nitrogen, or A is nitrogen and B is carbon, Thus, the compounds of formula I or II include the following types of compounds:

embedded image

The expression “optionally substituted with one or more” means that a group can be substituted with one or more, preferably with 1, 2, 3 or 4 substituents, more preferably with 1, 2 or 3 substituents, and still more preferably with 1 or 2 substituents, provided that said group has enough positions susceptible of being substituted. The substituents can be the same or different and are placed on any available position.

In certain embodiments of Cy₁mentioned below, a nitrogen atom that can be substituted means a nitrogen atom that has a hydrogen substituent.

Throughout the present specification, by the term “treatment” is meant eliminating, reducing or ameliorating the cause or the effects of a disease. For purposes of this invention treatment includes, but is not limited to, alleviation, amelioration or elimination of one or more symptoms of the disease; diminishment of the extent of the disease; stabilized (i.e. not worsening) state of disease; delay or slowing of disease progression; amelioration or palliation of the disease state; and remission of the disease (whether partial or total).

As used herein, “prevention” refers to preventing the occurrence of a disease in a subject that is predisposed to or has risk factors but does not yet display symptoms of the disease. Prevention includes also preventing the recurrence of a disease in a subject that has previously suffered said disease.

Any formula given herein is intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as ²H, ³H, ¹¹C, ¹³C, ¹⁴C, ¹⁵N, ¹⁸O, ¹⁷O, ³¹P, ³²P, ³⁵S, ¹⁸F, ³⁶Cl, and ¹²⁵I, respectively. Such isotopically labelled compounds are useful in metabolic studies (preferably with ¹⁴C), reaction kinetic studies (with, for example ²H or ³H), detection or imaging techniques [such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT)] including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an ¹⁸F or ¹¹C labeled compound may be particularly preferred for PET or SPECT studies. Further, substitution with heavier isotopes such as deuterium (i.e., ²H) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements. Isotopically labeled compounds of the invention can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent. In addition to the unlabeled form, all isotopically labeled forms of the compounds of formula I and II are included within the scope of the invention.

Any formula given herein is also intended to represent the corresponding tautomers forms. “Tautomer” refers to alternate forms of a molecule that differ in the position of a proton. Examples include, among others, enol-keto and imine-enamine tautomers, and the tautomeric forms of heteroaryl groups containing a —N═CH—NH— ring atom arrangement, such as pyrazoles, imidazoles, benzimidazoles, triazoles and tetrazoles.

The invention thus relates to the compounds of formula I or H as defined above.

In another embodiment, the invention relates to a compound of formula I or II

embedded image

wherein

A is carbon and B is nitrogen, or A is nitrogen and B is carbon;

W is CH or N;

R₁and R₂independently are hydrogen, C_1-4alkyl, haloC_1-4alkyl, hydroxyC_1-4alkyl, cyanoC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, halogen, —CN, —OR₈or —SR₈;

R₃is C_1-4alkyl, R₉—C_1-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₀;

R₆is hydrogen, C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, cyanoC_1-4alkyl, halogen, —CN, —OR₁₂, —NR₇R₁₂, or Cy₂-C_0-4alkyl, wherein Cy₂is optionally substituted with one or more R₁₁;

R₆is hydrogen, C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, R₁₂R₇N—C_1-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₁;

R₇is hydrogen or C_1-4alkyl;

R₈is hydrogen, C_1-4alkyl, hydroxyC_1-4alkyl, hydroxyC_1-4alkyl, or C_1-4alkoxyC_1-4alkyl;

R₉is halogen, —CN, —CONR₇R₁₂, —COR₁₃, —CO₂R₁₂, —OCONR₇R₁₂, —SO₂R₁₃, —SO₂NR₇R₁₂, —NR₇R₁₂, —NR₇COR₁₂—NR₇CONR₇R₁₂, —NR₇CO₂R₁₃or —NR₇SO₂R₁₃;

R₁₀is C_1-4alkyl or R₉—C_0-4alkyl;

R₁₂is hydrogen or R₁₃;

R₁₃is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, cyanoC_1-4alkyl, or Cy₂-C_0-4alkyl; wherein Cy₂is optionally substituted with one or more R₁₁;

R₁₄is hydrogen or R₁₅;

R₁₅is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or cyanoC_1-4alkyl;

in another embodiment, the invention relates to a compound of formula I or II

embedded image

wherein

A is carbon and B is nitrogen, or A is nitrogen and B is carbon;

W CH or N;

R₁and R₂independently are hydrogen, C_1-4alkyl, haloC_1-4alkyl, hydroxyC_1-4alkyl, cyanoC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, halogen, —CN, —OR₈or —SR₈;

R₃is C_1-4alkyl, R₉—C_1-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₀;

R₄is hydrogen, C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, cyanoC_1-4alkyl, R₁₂R₇N—C_0-4alkyl, R₁₃CONR₇—C_0-4alkyl, R₁₃R₇NCO—C_0-4alkyl, R₁₇R₇NCONR₇—C_0-4alkyl, R₁₃CO₂NR₇—C_0-4alkyl, R₁₃SO₂NR₇—C_0-4alkyl, —OR₁₂or Cy₂-C_0-4alkyl; wherein Cy₂is optionally substituted with one or more R₁₁;

R₆is hydrogen, C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, R₁₂R₇N—C_1-4alkyl, R₁₉CO—C_0-4alkyl, R₁₆CO₂—C_0-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₁;

R₇is hydrogen or C_1-4alkyl;

R₈is hydrogen, C_1-4alkyl, haloC_1-4alkyl, hydroxyC_1-4alkyl, or C_1-4alkoxyC_1-4alkyl;

R₁₀is C_1-4alkyl or R₉—C_0-4alkyl;

R₁₁is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, cyanoC_1-4alkyl, halogen, —CN, —CONR₇R₁₄, —COR₁₄, —CO₂R₁₅, —OCONR₇R₁₄, —SO₂NR₁₅, —SO₂NR₇R₁₄, —NR₇R₁₄, —NR₇COR₁₄, —NR₇CONR₇R₁₄, —NR₇CO₂R₁₅or —NR₇SO₂R₁₅;

R₁₂is hydrogen or R₁₃;

R₁₃is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, cyanoC_1-4alkyl, or Cy₂-C_0-4alkyl; wherein Cy₂is optionally substituted with one or more R₁₁;

R₁₄is hydrogen or R₁₅;

R₁₅is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or cyanoC_1-4alkyl;

R₁₆is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl or cyanoC_1-4alkyl;

In another embodiment, the invention relates to the compounds of formula I.

In another embodiment, the invention relates to the compounds of formula II.

In another embodiment, the invention relates to the compounds of formula I or II wherein A is carbon and B is nitrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein A is nitrogen and B is carbon.

In another embodiment, the invention relates to the compounds of formula I or II wherein W is CH.

In another embodiment, the invention relates to the compounds of formula I or II wherein W is N.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₁and R₂independently are hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₂is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₂is —CN.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, more preferably hydrogen or —CN; and R₂is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₁is hydrogen or —CN.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₁is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₁is hydrogen; and R₂is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₁is —CN; and R₂is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₃is R₉—C_1-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₀.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₃is R₉—C_1-4alkyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₃is Cy₁, which is optionally substituted with one or more R₁₀.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₃is Cy₁and Cy₁is a 3- to 7-membered monocyclic or 6- to 11-membered bicyclic ring, which is saturated, partially unsaturated or aromatic, and which is carbocyclic or heterocyclic containing from 1 to 4 heteroatoms independently selected from N, S and O, wherein said ring is bonded to the rest of the molecule through any available C atom, and wherein one or more C or S ring atoms are optionally oxidized forming CO, SO or SO₂; wherein said Cy₁is optionally substituted with one or more R₁₀provided that if the ring contains a nitrogen atom that can be substituted, then said nitrogen atom is substituted with one R₁₀.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₃is Cy₁; and Cy₁in R₃is a 3- to 7-membered monocyclic ring, which is saturated, partially unsaturated or aromatic, and which is carbocyclic or heterocyclic containing from 1 to 3 heteroatoms independently selected from N, S and O, wherein said ring is bonded to the rest of the molecule through any available C atom, and wherein one or more C or S ring atoms are optionally oxidized forming CO, SO or SO₂; and wherein said Cy₁is optionally substituted with one or more R₁₀.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₃is Cy₁; and Cy₁in R₃is a 3- to 7-membered saturated monocyclic ring, which is carbocyclic or heterocyclic containing from 1 to 3 heteroatoms independently selected from N, S and O, wherein said ring is bonded to the rest of the molecule through any available C atom, and wherein one or more C or S ring atoms are optionally oxidized forming CO, SO or SO₂; and wherein said Cy₁is optionally substituted with one or more R₁₀.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₃is Cy₁; and Cy₁in R₃is a 5- to 6-membered saturated monocyclic ring, which is carbocyclic or heterocyclic containing from 1 to 3 heteroatoms independently selected from N, S and O, wherein said ring is bonded to the rest of the molecule through any available C atom, and wherein one or more C or S ring atoms are optionally oxidized forming CO, SO or SO₂; and wherein said Cy₁is optionally substituted with one or more R₁₀.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₃is Cy₁; and Cy₁in R₃is a 5- to 6-membered saturated monocyclic ring, which is carbocyclic or heterocyclic containing from 1 to 3 heteroatoms independently selected from N, S and O, at least one of which is N; wherein said ring is bonded to the rest of the molecule through any available C atom, and wherein one or more C or S ring atoms are optionally oxidized forming CO, SO or SO₂; and wherein said Cy₁is optionally substituted with one or more R₁₀.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₃is Cy₁; and Cy₁in R₃is a 3- to 7-membered, preferably 5- to 6-membered saturated monocyclic ring, which is heterocyclic containing from 1 to 3 heteroatoms independently selected from N, S and O, at least one of which is N; wherein said ring is bonded to the rest of the molecule through any available C atom, and wherein one or more C or S ring atoms are optionally oxidized forming CO, SO or SO₂; and wherein said Cy₁is optionally substituted with one or more R₁₀.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₃is piperidinyl or pyrrolidinyl, preferably piperidin-3-yl or pyrrolidin-3-yl, which are substituted with one R₁₀on the N atom of the piperidinyl or pyrrolidinyl ring and which are optionally further substituted with one or more R₁₀groups.

In another embodiment, the invention relates to the compounds of formula II wherein R₃is piperidinyl or pyrrolidinyl, preferably piperidin-3-yl or pyrrolidin-3-yl, which are substituted with one R₁₀on the N atom of the piperidinyl or pyrrolidinyl ring and which are optionally further substituted with one or more R₁₀groups.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₃is piperidinyl, preferably piperidin-3-yl, which are optionally substituted with one or more R₁₀.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₃is piperidinyl, preferably piperidin-3-yl, substituted with one R₁₀on the N atom of the piperidinyl ring and optionally further substituted with one or more R₁₀groups.

In another embodiment, the invention relates to the compounds of formula II wherein R₃is piperidinyl, preferably piperidin-3-yl, which are optionally substituted with one or more R₁₀.

In another embodiment, the invention relates to the compounds of formula II wherein R₃is piperidinyl, preferably piperidin-3-yl, substituted with one R₁₀on the N atom of the piperidinyl ring and optionally further substituted with one or more R₁₀groups.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₃is a cycle of formula

embedded image

wherein Cy_1aand Cy_1bare optionally substituted with one or more further R₁₀.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₃is a cycle of formula

embedded image

In another embodiment, the invention relates to the compounds of formula II wherein R₃is a cycle of formula

embedded image

wherein Cy_1aand Cy_1bare optionally substituted with one or more further R₁₀.

In another embodiment, the invention relates to the compounds of formula II wherein R₃is a cycle of formula

embedded image

In another embodiment, the invention relates to the compounds of formula I or II wherein R₃is a cycle of formula Cy_1a.

In another embodiment, the invention relates to the compounds of formula II wherein R₃is a cycle of formula Cy_1a.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₃is a cycle of formula

embedded image

In another embodiment, the invention relates to the compounds of formula II wherein R₃is a cycle of formula

embedded image

In another embodiment, the invention relates to the compounds of formula I or II wherein R₃is a cycle of formula Cy_1aand Cy_1ahas the (S)-stereochemistry.

In another embodiment, the invention relates to the compounds of formula II wherein R₃is a cycle of formula Cy_1aand Cy_1ahas the (S)-stereochemistry.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₃is a cycle of formula Cy_1b.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₃is Cy₂-C_1-4alkyl, wherein Cy₂is optionally substituted with one or more R₁₀.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₃is Cy₂-C_1-4alkyl; and Cy₂is a 3- to 7-membered monocyclic ring, which is saturated, partially unsaturated or aromatic, and which is carbocyclic or heterocyclic containing from 1 to 3 heteroatoms independently selected from N, S and O, wherein said ring is bonded to the rest of the molecule through any available C o N atom, and wherein one or more C or S ring atoms are optionally oxidized forming CO, SO or SO₂; and wherein said Cy₂is optionally substituted with one or more R₁₀.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₄is hydrogen, C_1-4alkyl, R₁₂R₇N—C_0-4alkyl or Cy₂-C_0-4alkyl, preferably hydrogen, C_1-4alkyl, —NR₇R₁₂or Cy₂; wherein Cy₂is optionally substituted with one or more R₁₁.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₅is hydrogen or Cy₂; wherein Cy₂is optionally substituted with one or more R₁₁.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₅is hydrogen or Cy₂; and Cy₂is a 3- to 7-membered monocyclic ring, which is saturated, partially unsaturated or aromatic, and which is carbocyclic or heterocyclic containing from 1 to 3 heteroatoms independently selected from N, S and O, wherein said ring is bonded to the rest of the molecule through any available C o N atom, and wherein one or more C or S ring atoms are optionally oxidized forming CO, SO or SO₂; and wherein said Cy₂is optionally substituted with one or more R₁₁.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₆is C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, R₁₂R₇N—C_1-4alkyl, R₁₆CO—C_0-4alkyl, R₁₆CO₂—C_0-4alkyl, R₁₆CO—O—C_1-4alkyl, cyanoC_1-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₁.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₆is hydrogen, C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, R₁₂R₇N—C_1-4alkyl, R₁₆CO—C_0-4alkyl, R₁₆CO₂—C_0-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₁.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₆is C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, R₁₂R₇N—C_1-4alkyl, R₁₆CO—C_0-4alkyl, R₁₆CO₂—C_0-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₁.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₆is C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, R₁₂C₇N—C_1-4alkyl, R₁₆CO—C_0-4alkyl, R₁₆CO₂—C_0-4alkyl or R₁₆CO—O—C_1-4alkyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₆is hydrogen, C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or R₁₂R₇N—C_1-4alkyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₆is hydrogen or C_1-4alkyl, preferably hydrogen, methyl or ethyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₆is C_1-4alkyl, preferably methyl or ethyl.

In another embodiment, the invention relates to the compounds of formula II wherein R₆is C_1-4alkyl, preferably methyl or ethyl.

In another embodiment, the invention relates to the compounds of formula II wherein R₆is methyl.

In another embodiment, the invention relates to the compounds of formula II wherein R₆is ethyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₉is —CONR₇R₁₂, —COR₁₃, —CO₂R₁₂, —OR₁₂, —OCONR₇R₁₂, —SO₂R₁₃, —SO₂NR₇R₁₂, —NR₇R₁₂, —NR₇COR₁₂, —NR₇CONR₇R₁₂, —NR₇CO₂R₁₃or —NR₇SO₂R₁₃, preferably R₉is —COR₁₃.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₁₀is R₉—C_0-4alkyl, preferably R₉.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₁₀is R₉; and R₉in R₁₀is —COR₁₃or —SO₂R₁₃. In another embodiment, the invention relates to the compounds of formula I or II wherein R₁₀is R₉; and R₉in R₁₀is —COR₁₃.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₁₃is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, cyanoC_1-4alkyl or Cy₂-C_0-4alkyl; wherein Cy₂is optionally substituted with one or more R₁₁.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₁₃is C_1-5alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or cyanoC_1-4alkyl, preferably C_1-4alkyl or cyanoC_1-4alkyl, more preferably methyl, isopropyl or cyanomethyl, and still more preferably methyl or cyanomethyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₁₃is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or cyanoC_1-4alkyl, preferably C_1-4alkyl or cyanoC_1-4alkyl, more preferably methyl, isopropyl or cyanomethyl, and still more preferably methyl or cyanomethyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₁₃is methyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₁₃is isopropyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₁₃is cyanomethyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₁₃is Cy₂-C_0-4alkyl wherein Cy₂is optionally substituted with one or more R₁₁.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₉is —CONR₇R₁₂, —COR₁₃, —CO₂R₁₃, —OR₁₂, —OCONR₇R₁₂, —SO₂R₁₃, —SO₂NR₇R₁₂, —NR₇R₁₂, —NR₇COR₁₂, —NR₇CONR₇R₁₂, —NR₇CO₂R₁₃or —NR₇SO₂R₁₃, preferably —CO₂R₁₃; and

R₁₃is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or cyanoC_1-4alkyl, preferably C_1-4alkyl or cyanoC_1-4alkyl, and more preferably methyl or cyanomethyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₁₀is R₉; R₉in R₁₀is —COR₁₅; and R₁₃is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or cyanoC_1-4alkyl, preferably C_1-4alkyl or cyanoC_1-4alkyl, and more preferably methyl or cyanomethyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₃is R₉—C_1-4alkyl; and

R₉is —CONR₇R₁₂, —COR₁₃, —CO₂R₁₂, —OR₁₂, —OCONR₇R₁₂, —SO₂R₁₃, —SO₂NR₇R₁₂, —NR₇R₁₂, —NR₇COR₁₂, —NR₇CONR₇R₁₂, —NR₇CO₂R₁₃or —NR₇SO₂R₁₃.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₃is R₉—C_1-4alkyl;

R₉is —CONR₇R₁₂, —COR₁₃, —CO₂R₁₃, —OR₁₂, —OCONR₇R₁₂, —SO₂R₁₃, —SO₂NR₇R₁₂, —NR₇R₁₂, —NR₇COR₁₂, —NR₇CONR₇R₁₂, —NR₇CO₂R₁₃or —NR₇SO₂R₁₃; and

R₁₃is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or cyanoC_1-4alkyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₃is Cy₁, preferably piperidinyl or pyrrolidinyl, more preferably piperidinyl-3-yl or pyrrolidinyl-3yl; wherein Cy₁in R₃is optionally substituted with one or more R₁₀; and

R₁₀is R₉—C_0-4alkyl, preferably more preferably —COR₁₃or —SO₂R₁₃.

In another embodiment, the invention relates to the compounds of formula I or U wherein R₃is a cycle of formula

embedded image

and

R₁₀is R₉—C_0-4alkyl, preferably R₉, more preferably —COR₁₃or —SO₂R₁₃.

In another embodiment, the invention relates to the compounds of formula II wherein R₃is a cycle of formula

embedded image

and

R₁₀is R₉—C_1-4alkyl, preferably R₉, more preferably —COR₁₃or —SO₂R₁₂.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₃is a cycle of formula

embedded image

R₁₀is R₉—C_0-4alkyl, preferably R₉;

R₉is —COR₁₃or —SO₂R₁₃; and

R₁₃is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or cyanoC_1-4alkyl, preferably C_1-4alkyl or cyanoC_1-4alkyl, and more preferably methyl or cyanomethyl.

In another embodiment, the invention relates to the compounds of formula II wherein R₃is a cycle of formula

embedded image

R₁₀is R₉—C_0-4alkyl, preferably R₉;

R₉is —COR₁₃or —SO₂R₁₃; and

R₁₃is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or cyanoC_1-4alkyl, preferably C_1-4alkyl or cyanoC_1-4alkyl and more preferably methyl or cyanomethyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₃is a cycle of formula Cy_1a; and

R₁₀is R₉—C_0-4alkyl, preferably R₉, more preferably —COR₁₃or —SO₂R₁₃still more preferably —COR₁₃.

In another embodiment, the invention relates to the compounds of formula II wherein R₃is a cycle of formula Cy_1a; and

R₁₀is R₉—C_0-4alkyl, preferably R₉, more preferably —COR₁₃or —SO₂R₁₃still more preferably —COR₁₃.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₃is a cycle of formula Cy_1a;

R₁₀is R₉—C_0-4alkyl, preferably R₉, more preferably —COR₁₃or —SO₂R₁₃, still more preferably —COR₁₃; and

R₁₃is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or cyanoC_1-4alkyl, preferably C_1-4alkyl or cyanoC_1-4alkyl, and more preferably methyl or cyanomethyl.

In another embodiment, the invention relates to the compounds of formula II wherein R₃is a cycle of formula Cy_1a;

R₁₀is R₉—C_0-4alkyl, preferably R₉, more preferably —COR₁₃or —SO₂R₁₃, still more preferably —COR₁₃; and

R₁₃is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or cyanoC_1-4alkyl, preferably C_1-4alkyl or cyanoC_1-4alkyl, and more preferably methyl or cyanomethyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₃is a cycle of formula Cy_1awith (S)-stereochemistry;

R₁₀is R₉—C_0-4alkyl, preferably R₉, more preferably —COR₁₃or —SO₂R₁₃, still more preferably —COR₁₃; and

R₁₃is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or cyanoC_1-4alkyl, preferably C_1-4alkyl or cyanoC_1-4alkyl, and more preferably methyl or cyanomethyl.

In another embodiment, the invention relates to the compounds of formula II wherein R₃is a cycle of formula Cy_1awith (S)-stereochemistry;

R₁₀is R₉—C_0-4alkyl, preferably R₉, more preferably —COR₁₃or —SO₂R₁₃, still more preferably —COR₁₃; and

R₁₃is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or cyanoC_1-4alkyl, preferably C_1-4alkyl or cyanoC_1-4alkyl, and more preferably methyl or cyanomethyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₃is a cycle of formula Cy_1b; and

R₁₀is R₉—C_0-4alkyl, preferably R₉, more preferably —SO₂R₁₃,

In another embodiment, the invention relates to the compounds of formula II wherein R₃is a cycle of formula Cy_1b; and

R₁₀is R₉—C_0-4alkyl, preferably R₉, more preferably —SO₂R₁₃.

In another embodiment, the invention relates to the compounds of formula I or II wherein Cy₁is a 3- to 7-membered monocyclic ring, which is saturated, partially unsaturated or aromatic, and which is carbocyclic or heterocyclic containing from 1 to 3 heteroatoms independently selected from N, S and O, wherein said ring is bonded to the rest of the molecule through any available C atom, and wherein one or more C or S ring atoms are optionally oxidized forming CO, SO or SO₂.

In another embodiment, the invention relates to the compounds of formula I or II wherein Cy₁is a 3- to 7-membered saturated monocyclic ring, which is carbocyclic or heterocyclic containing from 1 to 3 heteroatoms independently selected from N, S and O, wherein said ring is bonded to the rest of the molecule through any available C atom, and wherein one or more Car S ring atoms are optionally oxidized forming CO, SO or SO₂.

In another embodiment, the invention relates to the compounds of formula I or II wherein Cy₁is a 5- to 6-membered saturated monocyclic ring, which is carbocyclic or heterocyclic containing from 1 to 3 heteroatoms independently selected from N, S and O, wherein said ring is bonded to the rest of the molecule through any available C atom, and wherein one or more C or S ring atoms are optionally oxidized forming CO, SO or SO₂.

In another embodiment, the invention relates to the compounds of formula I or II wherein Cy₁is a 5- to 6-membered saturated monocyclic ring, which is carbocyclic or heterocyclic containing from 1 to 3 heteroatoms independently selected from N, S and O, at least one of which is N; wherein said ring is bonded to the rest of the molecule through any available C atom, and wherein one or more C or S ring atoms are optionally oxidized forming CO, SO or SO₂.

In another embodiment, the invention relates to the compounds of formula I or II wherein Cy₁is a 5- to 6-membered saturated monocyclic ring, which is heterocyclic containing from 1 to 3 heteroatoms independently selected from N, S and O, at least one of which is N; wherein said ring is bonded to the rest of the molecule through any available C atom, and wherein one or more C or S ring atoms are optionally oxidized forming CO, SO or SO₂

In another embodiment, the invention relates to the compounds of formula I or II wherein Cy₁is piperidinyl or pyrrolidinyl, preferably piperidinyl-3-yl or pyrrolidinyl-3-yl.

In another embodiment, the invention relates to the compounds of formula I or II wherein Cy₂is a 3- to 7-membered monocyclic ring, which is saturated, partially unsaturated or aromatic, and which is carbocyclic or heterocyclic containing from 1 to 3 heteroatoms independently selected from N, S and O, wherein said ring is bonded to the rest of the molecule through any available C o N atom, and wherein one or more C or S ring atoms are optionally oxidized forming CO, SO or SO₂.

In another embodiment, the invention relates to the compounds of formula I or II wherein Cy₂is a 3- to 7-membered saturated monocyclic ring, which is carbocyclic or heterocyclic containing from 1 to 3 heteroatoms independently selected from N, S and O, wherein said ring is bonded to the rest of the molecule through any available C atom, and wherein one or more C or S ring atoms are optionally oxidized forming CO, SO or SO₂.

In another embodiment, the invention relates to the compounds of formula I or II wherein Cy₂is a 5- to 6-membered saturated monocyclic ring, which is carbocyclic or heterocyclic containing from 1 to 3 heteroatoms independently selected from N, S and O, wherein said ring is bonded to the rest of the molecule through any available C atom, and wherein one or more C or S ring atoms are optionally oxidized forming CO, SO or SO₂.

In another embodiment, the invention relates to the compounds of formula I or II wherein Cy₂is a 5- to 6-membered saturated monocyclic ring, which is carbocyclic or heterocyclic containing from 1 to 3 heteroatoms independently selected from N, S and O, at least one of which is N; wherein said ring is bonded to the rest of the molecule through any available C atom, and wherein one or more C or S ring atoms are optionally oxidized forming CO, SO or SO₂.

In another embodiment, the invention relates to the compounds of formula I or II wherein Cy₂is piperidinyl or pyrrolidinyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein;

A is nitrogen and B is carbon; and

R₁and R₂independently are hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

A is nitrogen and B is carbon;

R₁is hydrogen, C_1-4alkyl, haloC_1-4alkyl, hydroxyC_1-4alkyl, cyanoC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, halogen, —CN, —OR₈or —SR₈, preferably hydrogen, halogen, —CN, —OR₈or —SR₈, and more preferably hydrogen or —CN; and

R₂is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein A is nitrogen and B is carbon; R₁and R₂are hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

R₁and R₂independently are hydrogen, halogen, —CN, —OR₈or —SR₈, and more preferably hydrogen or —CN; and

R₃is R₉—C_1-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₀.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

R₂is hydrogen; and

R₃is Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₀.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₁and R₂are hydrogen; and R₃is R₉—C_1-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₀.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

R₂is hydrogen; and

R₃is R₉—C_1-4alkyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

R₂is hydrogen; and

R₃is Cy₁, which is optionally substituted with one or more R₁₀.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₁and R₂are hydrogen; and R₃is Cy₁, which is optionally substituted with one or more R₁₀.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

R₂is hydrogen;

R₃is Cy₁, wherein Cy₁in R₃is a 3- to 7-membered monocyclic ring, which is saturated, partially unsaturated or aromatic, and which is carbocyclic or heterocyclic containing from 1 to 3 heteroatoms independently selected from N, S and O, wherein said ring is bonded to the rest of the molecule through any available C atom, and wherein one or more C or S ring atoms are optionally oxidized forming CO, SO or SO₂; and wherein said Cy₁is optionally substituted with one or more R₁₀.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

R₂is hydrogen;

R₃is Cy₁, wherein Cy₁in R₃is a 3- to 7-membered, preferably 5- to 6-membered, saturated monocyclic ring, which is carbocyclic or heterocyclic containing from 1 to 3 heteroatoms independently selected from N, S and O, wherein said ring is bonded to the rest of the molecule through any available C atom, and wherein one or more C or S ring atoms are optionally oxidized forming CO, SO or SO₂; and more preferably Cy₁in R₃is piperidinyl or pyrrolidinyl, even more preferably piperidin-3-yl or pyrrolidin-3-yl; wherein said Cy₁is optionally substituted with one or more R₁₀.

In another embodiment, the invention relates to the compounds of formula I or II wherein A is nitrogen and B is carbon;

R₂is hydrogen; and

R₃is R₉—C_1-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₀.

In another embodiment, the invention relates to the compounds of formula I or II wherein A is nitrogen and B is carbon; R₁and R₂are hydrogen; and R₃is R₉—C_1-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₀.

In another embodiment, the invention relates to the compounds of formula I or II wherein A is nitrogen and B is carbon;

R₂is hydrogen; and

R₃is R₉—C_1-4alkyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein A is nitrogen and B is carbon; R₁and R₂are hydrogen; and R₃is R₉—C_1-4alkyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein A is nitrogen and B is carbon;

R₂is hydrogen; and

R₃is Cy₁, which is optionally substituted with one or more R₁₀.

In another embodiment, the invention relates to the compounds of formula I or II wherein A is nitrogen and B is carbon; R₁and R₂are hydrogen; and R₃is Cy₁, which is optionally substituted with one or more R₁₀.

In another embodiment, the invention relates to the compounds of formula I or II wherein A is nitrogen and B is carbon;

R₂is hydrogen; and

In another embodiment, the invention relates to the compounds of formula I or II wherein A is nitrogen and B is carbon;

R₂is hydrogen; and

R₃is Cy₁, wherein Cy₁in R₃is a 3- to 7-membered, preferably 5- to 6-membered, saturated monocyclic ring, which is carbocyclic or heterocyclic containing from 1 to 3 heteroatoms independently selected from N, S and O, wherein said ring is bonded to the rest of the molecule through any available O atom, and wherein one or more C or S ring atoms are optionally oxidized forming CO, SO or SO₂; and more preferably Cy₁in R₃is piperidinyl or pyrrolidinyl, even more preferably piperidin-3-yl or pyrrolidin-3-yl; wherein said Cy₁is optionally substituted with one or more R₁₀.

In another embodiment, the invention relates to the compounds of formula I or II wherein A is nitrogen and B is carbon;

R₂is hydrogen; and

R₃is a cycle of formula Cy_1a, preferably with (S)-stereochemistry.

In another embodiment, the invention relates to the compounds of formula II wherein A is nitrogen and B is carbon;

R₂is hydrogen; and

R₃is a cycle of formula Cy_1a, preferably with (S)-stereochemistry.

In another embodiment, the invention relates to the compounds of formula I or II wherein A is nitrogen and B is carbon; and

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein A is nitrogen and B is carbon;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen; and

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein A is nitrogen and B is carbon; R₁and R₂are hydrogen; and R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₆is hydrogen; and

R₆is hydrogen or C_1-4alkyl, preferably hydrogen, methyl or ethyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₁and R₂are hydrogen; R₅is hydrogen; and R₆is hydrogen or C_1-4alkyl, preferably hydrogen, methyl or ethyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₅is hydrogen; and

R₆is C_1-4alkyl, preferably methyl or ethyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein R₁and R₂are hydrogen; R₅is hydrogen; and R₆is C_1-4alkyl, preferably methyl or ethyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₃is R₉—C_1-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₀; and

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

R₁and R₂are hydrogen;

R₃is R₉—C_1-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₀; and

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₃is R₉—C_1-4alkyl; and

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₃is Cy₁, which is optionally substituted with one or more R₁₀; and

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

R₁and R₂are hydrogen;

R₃is Cy₁, which is optionally substituted with one or more R₁₀; and

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₃is a cycle of formula Cy_1a, preferably with (S)-stereochemistry; and

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula II wherein:

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₃is a cycle of formula Cy_1a, preferably with (S)-stereochemistry; and

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formulator II wherein A is nitrogen and B is carbon;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₃is hydrogen; and

R₈is hydrogen or C_1-4alkyl, preferably hydrogen, methyl or ethyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein A is nitrogen and B is carbon;

R₁and R₂are hydrogen;

R₅is hydrogen; and

R₆is hydrogen or C_1-4alkyl, preferably hydrogen, methyl or ethyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein A is nitrogen and B is carbon;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₅is hydrogen; and

R₆is C_1-4alkyl, preferably methyl or ethyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein A is nitrogen and B is carbon;

R₁and R₂are hydrogen;

R₅is hydrogen; and

R₆is C_1-4alkyl, preferably methyl or ethyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

W is CH;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₃is R₉—C_1-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₀; and

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

W is CH;

R₁and R₂are hydrogen;

R₃is R₉—C_1-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₀; and

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

W is CH;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₃is R₉—C_1-4alkyl; and

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

W is CH;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN, more preferably hydrogen; and R₂is hydrogen;

R₃is Cy₁, which is optionally substituted with one or more R₁₀; and

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

W is CH;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN, more preferably hydrogen; and R₂is hydrogen;

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

W is CH;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN, more preferably hydrogen; and R₂is hydrogen;

R₃is Cy₁, wherein Cy₁in R₃is a 3- to 7-membered, preferably 5- to 6-membered, saturated monocyclic ring, which is carbocyclic or heterocyclic containing from 1 to 3 heteroatoms independently selected from N, S and O, wherein said ring is bonded to the rest of the molecule through any available C atom, and wherein one or more C or S ring atoms are optionally oxidized forming CO, SO or SO₂; and more preferably Cy₁in R₃is piperidinyl or pyrrolidinyl, even more preferably piperidin-3-yl or pyrrolidin-3-yl; wherein said Cy₂is optionally substituted with one or more R₁₀; and

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

W is CH;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN, more preferably hydrogen; and R₂is hydrogen;

R₃is a cycle of formula Cy_1a, preferably with (S)-stereochemistry; and

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula II wherein:

W is CH;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN, more preferably hydrogen; and R₂is hydrogen;

R₃is a cycle of formula Cy_1a, preferably with (3)-stereochemistry; and

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

W is N;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₃is R₉—C_1-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₀; and

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

W is N;

R₁and R₂are hydrogen;

R₃is R₉—C_1-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₀; and

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

W is N;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₃is R₉—C_1-4alkyl; and

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

W is N;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN, more preferably hydrogen; and R₂is hydrogen;

R₃is Cy₁, which is optionally substituted with one or more R₁₀; and

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein;

W is N;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN, more preferably hydrogen; and R₂is hydrogen;

R₃is Cy₁, wherein Cy₁in R₃is a 3- to 7-membered monocyclic ring, which is saturated, partially unsaturated or aromatic, and which is carbocyclic or heterocyclic containing from 1 to 3 heteroatoms independently selected from N, S and O, wherein said ring is bonded to the rest of the molecule through any available O atom, and wherein one or more C or S ring atoms are optionally oxidized forming CO, SO or SO₂; and wherein said Cy₁is optionally substituted with one or more R₁₀; and

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

W is N;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN, more preferably hydrogen; and R₂is hydrogen;

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein;

A is nitrogen and B is carbon;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₃is R₉—C_1-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₀; and

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

A is nitrogen and B is carbon;

R₁and R₂are hydrogen;

R₃is R₉—C_1-4alkyl, Cy₁or Cy₂-C_0-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₀; and

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula for II wherein:

A is nitrogen and B is carbon;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₃is R₉—C_1-4alkyl; and

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

A is nitrogen and B is carbon;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN, more preferably hydrogen; and R₂is hydrogen;

R₃is Cy₁, which is optionally substituted with one or more R₁₀; and

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

A is nitrogen and B is carbon;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN, more preferably hydrogen; and R₂is hydrogen;

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

A is nitrogen and B is carbon;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN, more preferably hydrogen; and R₂is hydrogen;

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

A is nitrogen and B is carbon;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN, more preferably hydrogen; and R₂is hydrogen;

R₃is a cycle of formula Cy_1a, preferably with (S)-stereochemistry; and

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula II wherein:

A is nitrogen and B is carbon;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN, more preferably hydrogen; and R₂is hydrogen;

R₃is a cycle of formula Cy_1a, preferably with (8)-stereochemistry; and

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₃is R₉—C_1-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₀;

R₄is hydrogen, C_1-4alkyl, R₁₂R₇N—C_0-4alkyl or Cy₂-C_0-4alkyl, preferably hydrogen, C_1-4alkyl, —NR₇R₁₂or Cy₂; wherein Cy₂are optionally substituted with one or more R₁₁;

R₅is hydrogen; and

R₆is hydrogen, C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or R₁₂R₇N—C_1-4alkyl, preferably hydrogen or C_1-4alkyl and more preferably hydrogen, methyl or ethyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

R₁and R₂are hydrogen;

R₃is R₉—C_1-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₀;

R₄is hydrogen, C_1-4alkyl, R₁₂R₇N—C_0-4alkyl or Cy₂-C_0-4alkyl, preferably hydrogen, C_1-4alkyl, —NR₇R₁₂or Cy₂; wherein Cy₂are optionally substituted with one or more R₁₁;

R₅is hydrogen; and

R₅is hydrogen, C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or R₁₂R₇N—C_1-4alkyl, preferably hydrogen or C_1-4alkyl and more preferably hydrogen, methyl or ethyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₃is R₉—C_1-4alkyl;

R₄is hydrogen, C_1-4alkyl, R₁₂R₇N—C_0-4alkyl or Cy₂-C_0-4alkyl, preferably hydrogen, C_1-4alkyl, —NR₇R₁₂or Cy₂; wherein Cy₂are optionally substituted with one or more R₁₁;

R₅is hydrogen; and

R₆is hydrogen, C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or R₁₂R₇N—C_1-4alkyl, preferably hydrogen or C_1-4alkyl and more preferably hydrogen, methyl or ethyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₃is Cy₁which is optionally substituted with one or more R₁₀;

R₄is hydrogen, C_1-4alkyl, R₁₂R₇N—C_0-4alkyl or Cy₂-C_0-4alkyl, preferably hydrogen, C_1-4alkyl, —NR₇R₁₂or Cy₂; wherein Cy₂are optionally substituted with one or more R₁₁;

R₅is hydrogen; and

R₆is hydrogen, C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or R₁₂R₇N—C_1-4alkyl, preferably hydrogen or C_1-4alkyl and more preferably hydrogen, methyl or ethyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₄is hydrogen, C_1-4alkyl, R₁₂R₇N—C_0-4alkyl or Cy₂-C_0-4alkyl, preferably hydrogen, C_1-4alkyl, —NR₇R₁₂or Cy₂; wherein Cy₂are optionally substituted with one or more R₁₁;

R₅is hydrogen; and

R₆is hydrogen, C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or R₁₂R₇N—C_1-4alkyl, preferably hydrogen or C_1-4alkyl and more preferably hydrogen, methyl or ethyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₄is hydrogen, C_1-4alkyl, R₁₂R₇N—C_0-4alkyl or Cy₂-C_0-4alkyl, preferably hydrogen, C_1-4alkyl, —NR₇R₁₂or Cy₂; wherein Cy₂are optionally substituted with one or more R₁₁;

R₃is hydrogen; and

R₆is hydrogen, C_1-4alkyl, C_1-4alkoxy-C_1-4alkyl, hydroxyC_1-4alkyl or R₁₂R₇N—C_1-4alkyl, preferably hydrogen or C_1-4alkyl and more preferably hydrogen, methyl or ethyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein;

A is nitrogen and B is carbon;

R₁is hydrogen, halogen; —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₃is R₉—C_1-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₀;

R₄is hydrogen, C_1-4alkyl, R₁₂R₇N—C_0-4alkyl or Cy₂-C_0-4alkyl, preferably hydrogen, C_1-4alkyl, —NR₇R₁₂or Cy₂; wherein Cy₂are optionally substituted with one or more R₁₁;

R₅is hydrogen; and

R₆is hydrogen, C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or R₁₂R₇N—C_1-4alkyl, preferably hydrogen or C_1-4alkyl and more preferably hydrogen, methyl or ethyl,

In another embodiment, the invention relates to the compounds of formula I or II wherein:

A is nitrogen and B is carbon;

R₁and R₂are hydrogen;

R₃is R₉—C_1-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₀;

R₄is hydrogen, C_1-4alkyl, R₁₂R₇N—C_0-4alkyl or Cy₂-C_0-4alkyl, preferably hydrogen, C_1-4alkyl, —NR₇R₁₂or Cy₂; wherein Cy₂are optionally substituted with one or more R₁₁;

R₅is hydrogen; and

R₆is hydrogen, C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or R₁₂R₇N—C_1-4alkyl, preferably hydrogen or C_1-4alkyl and more preferably hydrogen, methyl or ethyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein;

A is nitrogen and B is carbon;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₃is Cy₁, which is optionally substituted with one or more R₁₀;

R₄is hydrogen, C_1-4alkyl, R₁₂R₇N—C_0-4alkyl or Cy₂-C_0-4alkyl, preferably hydrogen, C_1-4alkyl, —NR₇R₁₂or Cy₂; wherein Cy₂are optionally substituted with one or more R₁₁;

R₅is hydrogen; and

R₆is hydrogen, C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or R₁₂R₇N—C_1-4alkyl, preferably hydrogen or C_1-4alkyl and more preferably hydrogen, methyl or ethyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

A is nitrogen and B is carbon;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₃is Cy₁, wherein Cy₁in R₃is a 3- to 7-membered monocyclic ring, which is saturated, partially unsaturated or aromatic, and which is carbocyclic or heterocyclic containing from 1 to 3 heteroatoms independently selected from N, S and O, wherein said ring is bonded to the rest of the molecule through any available C atom, and wherein one or more C or S ring atoms are optionally oxidized forming CO, SO or SO₂; and wherein said Cy₂is optionally substituted with one or more R₁₀;

R₄is hydrogen, C_1-4alkyl, R₁₂R₇N—C_0-4alkyl or Cy₂-C_0-4alkyl, preferably hydrogen, C_1-4alkyl, —NR₇R₁₂or Cy₂; wherein Cy₂are optionally substituted with one or more R₁₁;

R₅is hydrogen; and

R₆is hydrogen, C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or R₁₂R₇N—C_1-4alkyl, preferably hydrogen or C_1-4alkyl and more preferably hydrogen, methyl or ethyl.

In another embodiment, the invention relates to the compounds of formula I or II wherein:

A is nitrogen and B is carbon;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₃is Cy₁, wherein Cy₁in R₃is a 3- to 7-membered, preferably 5- to 6-membered, saturated monocyclic ring, which is carbocyclic or heterocyclic containing from 1 to 3 heteroatoms independently selected from N, S and O, wherein said ring is bonded to the rest of the molecule through any available C atom; and wherein one or more C or S ring atoms are optionally oxidized forming CO, SO or SO₂; and more preferably Cy₁in R₃is piperidinyl or pyrrolidinyl, even more preferably piperidin-3-yl or pyrrolidin-3-yl; wherein said Cy₁is optionally substituted with one or more R₁₀;

R₄is hydrogen, C_1-4alkyl, R₁₂R₇N—C_0-4alkyl or Cy₂-C_0-4alkyl, preferably hydrogen, C_1-4alkyl, —NR₇R₁₂or Cy₂; wherein Cy₂are optionally substituted with one or more R₁₁;

R₅is hydrogen; and

R₆is hydrogen, C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or R₁₂R₇N—C_1-4alkyl, preferably hydrogen or C_1-4alkyl and more preferably hydrogen, methyl or ethyl.

In another embodiment, the invention relates to the compounds of formula I wherein:

A is nitrogen and B is carbon;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₃is R₉—C_1-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₀;

R₄is hydrogen, C_1-4alkyl, R₁₂R₇N—C_0-4alkyl or Cy₂-C_0-4alkyl, preferably hydrogen, C_1-4alkyl, —NR₇R₁₂or Cy₂; wherein Cy₂is optionally substituted with one or more R₁₁; and

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I wherein:

A is nitrogen and B is carbon;

R₁and R₂are hydrogen;

R₃is R₉—C_1-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₀;

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I wherein:

A is nitrogen and B is carbon;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₃is Cy₁, which is optionally substituted with one or more R₁₀;

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I wherein:

A is nitrogen and B is carbon;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula I wherein:

A is nitrogen and B is carbon;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₃is Cy₁, wherein Cy₁in R₃is a 3- to 7-membered, preferably 5- to 6-membered, saturated monocyclic ring, which is carbocyclic or heterocyclic containing from 1 to 3 heteroatoms independently selected from N, S and O, wherein said ring is bonded to the rest of the molecule through any available C atom, and wherein one or more C or S ring atoms are optionally oxidized forming CO, SO or SO₂; and more preferably Cy₁in R₃is piperidinyl or pyrrolidinyl; wherein said Cy₁is optionally substituted with one or more R₁₀;

R₅is hydrogen.

In another embodiment, the invention relates to the compounds of formula II wherein:

A is nitrogen and B is carbon;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₃is R₉—C_1-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₀;

R₅is hydrogen; and

R₆is hydrogen, C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or NR₇R₁₂—C_1-4alkyl, preferably hydrogen or C_1-4alkyl, more preferably C_1-4alkyl and even more preferably methyl or ethyl.

In another embodiment, the invention relates to the compounds of formula II wherein:

A is nitrogen and B is carbon;

R₁and R₂are hydrogen;

R₃is R₉—C_1-4alkyl, Cy₁or Cy₂-C_1-4alkyl, wherein Cy₁and Cy₂are optionally substituted with one or more R₁₀;

R₅is hydrogen; and

In another embodiment, the invention relates to the compounds of formula wherein:

A is nitrogen and B is carbon;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN, more preferably hydrogen; and R₂is hydrogen;

R₃is Cy₁, which is optionally substituted with one or more R₁₀;

R₅is hydrogen; and

In another embodiment, the invention relates to the compounds of formula II wherein:

A is nitrogen and B is carbon;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN, more preferably hydrogen; and R₂is hydrogen;

R₅is hydrogen; and

In another embodiment, the invention relates to the compounds of formula II wherein:

A is nitrogen and B is carbon;

R₁is hydrogen, halogen, —CN, —OR₈or —SR₈, preferably hydrogen or —CN; and R₂is hydrogen;

R₅is hydrogen; and

R₆is hydrogen, C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or NR₇R₁₂—C_1-4alkyl, preferably hydrogen or C_1-4alkyl, more preferably C_1-4alkyl, and even more preferably methyl or ethyl.

In another embodiment, the invention relates to the compounds of formula II wherein:

A is nitrogen and B is carbon;

R₁is hydrogen or —CN, preferably hydrogen; and R₂is hydrogen;

R₃is a cycle of formula Cy_1aor Cy_1b;

R₅is hydrogen; and

R₆is hydrogen, C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, R₁₂R₇N—C_1-4alkyl, R₁₆CO—C_0-4alkyl or R₁₆CO₂—C_0-4alkyl, preferably C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, R₁₂R₇C_1-4alkyl, R₁₆CO—C_0-4alkyl or R₁₆CO₂—C_0-4alkyl, more preferably C_1-4alkyl, and even more preferably methyl or ethyl.

In another embodiment, the invention relates to the compounds of formula II wherein:

A is nitrogen and B is carbon;

R₁is hydrogen or —CN, preferably hydrogen; and R₂is hydrogen;

R₃is a cycle of formula Cy_1a, preferably with (S)-stereochemistry;

R₅is hydrogen; and

R₆is hydrogen, C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, R₁₂R₇N—C_1-4alkyl, R₁₆CO—C_0-4alkyl or R₁₆CO₂—C_0-4alkyl, preferably C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, R₁₆CO—C_0-4alkyl or R₁₆CO₂—C_0-4alkyl, more preferably C_1-4alkyl, and even more preferably methyl or ethyl.

In another embodiment, the invention relates to the compounds of formula II wherein:

R₃is a cycle of formula Cy_1aor Cy_1b;

R₅is hydrogen;

R₁₀is —COR₁₃or —SO₂R₁₃and

R₁₃is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or cyanoC_1-4alkyl, preferably C_1-4alkyl or cyanoC_1-4alkyl, and more preferably methyl or cyanomethyl.

In another embodiment, the invention relates to the compounds of formula II wherein:

R₃is a cycle of formula Cy_1a, preferably with (S)-stereochemistry;

R₅is hydrogen;

R₁₀is —COR₁₃; and

R₁₃is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or cyanoC_1-4alkyl, preferably C_1-4alkyl or cyanoC_1-4alkyl, and more preferably methyl or cyanomethyl.

In another embodiment, the invention relates to the compounds of formula II wherein:

W is CH;

R₃is a cycle of formula Cy_1a, preferably with (S)-stereochemistry;

R₅is hydrogen;

R₁₀is —COR₁₃; and

R₁₃is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or cyanoC_1-4alkyl, preferably C_1-4alkyl or cyanoC_1-4alkyl, and more preferably methyl or cyanomethyl.

In another embodiment, the invention relates to the compounds of formula II wherein:

W is N;

R₃is a cycle of formula Cy_1a, preferably with (S)-stereochemistry;

R₅is hydrogen;

R₁₀is —COR₁₃; and

R₁₃is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or cyanoC_1-4alkyl, preferably C_1-4alkyl or cyanoC_1-4alkyl, and more preferably methyl or cyanomethyl.

In another embodiment, the invention relates to the compounds of formula II wherein:

A is nitrogen and B is carbon;

R₁is hydrogen or —CN, preferably hydrogen; and R₂is hydrogen;

R₃is a cycle of formula Cy_1a, preferably with (S)-stereochemistry;

R₅is hydrogen; and

R₁₀is —COR₁₃.

In another embodiment, the invention relates to the compounds of formula II wherein:

A is nitrogen and B is carbon;

R₁is hydrogen or —CN, preferably hydrogen; and R₂is hydrogen;

R₃is a cycle of formula Cy_1a, preferably with (S)-stereochemistry;

R₅is hydrogen;

R₁₀is —COR₁₃; and

R₁₃is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or cyanoC_1-4alkyl, preferably C_1-4alkyl or cyanoC_1-4alkyl, and more preferably methyl or cyanomethyl.

In another embodiment, the invention relates to the compounds of formula II wherein:

R₃is a cycle of formula Cy_1aor Cy_1b;

R₅is hydrogen;

R₆is hydrogen, C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, R₁₂R₇N—C_1-4alkyl, R₁₆CO—C_0-4alkyl or R₁₆CO₂—C_0-4alkyl, preferably C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, R₁₂R₇N—C_1-4alkyl: R₁₆CO—C_0-4alkyl or R₁₆CO₂—C_0-4alkyl, more preferably C_1-4alkyl, and even more preferably methyl or ethyl;

R₁₀is —COR₁₃or —SO₂R₁₃; and

R₁₃is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or cyanoC_1-4alkyl, preferably C_1-4alkyl or cyanoC_1-4alkyl, and more preferably methyl or cyanomethyl.

In another embodiment, the invention relates to the compounds of formula II wherein:

R₃is a cycle of formula Cy_1a, preferably with (S-stereochemistry;

R₅is hydrogen;

R₆is hydrogen, C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, R₁₂R₇N—C_1-4alkyl, R₁₆CO—C_0-4alkyl or R₁₆CO₂—C_0-4alkyl, preferably C_1-4alkyl, C_1-4alkoxy-C_1-4alkyl, hydroxyC_1-4alkyl, R₁₂R₇N—C_1-4alkyl, R₁₆CO—C_0-4alkyl or R₁₆CO₂—C_0-4alkyl, more preferably C_1-4alkyl, and even more preferably methyl or ethyl;

R₁₀is —COR₁₃; and

R₁₃is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or cyanoC_1-4alkyl, preferably C_1-4alkyl or cyanoC_1-4alkyl, and more preferably methyl or cyanomethyl.

In another embodiment, the invention relates to the compounds of formula II wherein:

A is nitrogen and B is carbon;

R₁is hydrogen or —CN, preferably hydrogen; and R₂is hydrogen;

R₃is a cycle of formula Cy_1aor Cy_1b;

R₅is hydrogen;

R₆is hydrogen, C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxy C_1-4alkyl, R₁₂R₇N—C_1-4alkyl, R₁₆CO—C_0-4alkyl or R₁₆CO₂—C_0-4alkyl, preferably C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, R₁₂R₇N—C_1-4alkyl, R₁₆CO—C_0-4alkyl or R₁₆CO₂—C_0-4alkyl, more preferably C_1-4alkyl, and even more preferably methyl or ethyl; and

R₁₀is —COR₁₃or —SO₂R₁₃.

In another embodiment, the invention relates to the compounds of formula II wherein:

A is nitrogen and B is carbon;

R₁is hydrogen or —CN, preferably hydrogen; and R₂is hydrogen;

R₃is a cycle of formula Cy_1a, preferably with (S)-stereochemistry;

R₅is hydrogen;

R₆is hydrogen, C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, R₁₂R₇N—C_1-4alkyl, R₁₆CO—C_0-4alkyl or R₁₆CO₂—C_0-4alkyl, preferably C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, R₁₂R₇N—C_1-4alkyl, R₁₆CO—C_0-4alkyl or R₁₆CO₂—C_0-4alkyl, more preferably C_1-4alkyl, and even more preferably methyl or ethyl;

R₁₀is —COR₁₃; and

R₁₃is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or cyanoC_1-4alkyl, preferably C_1-4alkyl or cyanoC_1-4alkyl, and more preferably methyl or cyanomethyl.

In another embodiment, the invention relates to the compounds of formula II wherein:

A is nitrogen and B is carbon;

W is CH;

R₁is hydrogen or —CN, preferably hydrogen; and R₂is hydrogen;

R₃is a cycle of formula Cy_1a, preferably with (S)-stereochemistry;

R₅is hydrogen;

R₆is hydrogen, C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, R₁₂R₇N—C_1-4alkyl, R₁₆CO—C_0-4alkyl or R₁₆CO₂—C_0-4alkyl, preferably C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, R₁₂R₇N—C_1-4alkyl, R₁₆CO—C_0-4alkyl or R₁₆CO₂—C_0-4alkyl, more preferably C_1-4alkyl, and even more preferably methyl or ethyl;

R₁₀is —COR₁₃; and

R₁₃is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxy-C_1-4alkyl, hydroxyC_1-4alkyl or cyanoC_1-4alkyl, preferably C_1-4alkyl or cyanoC_1-4alkyl and more preferably methyl or cyanomethyl.

In another embodiment, the invention relates to the compounds of formula II wherein:

A is nitrogen and B is carbon;

W is N;

R₁is hydrogen or —CN, preferably hydrogen; and R₂is hydrogen;

R₃is a cycle of formula Cy_1a, preferably with (S)-stereochemistry;

R₅is hydrogen;

R₆is hydrogen, C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, R₁₂R₇N—C_1-4alkyl, R₁₆CO—C_0-4alkyl or R₁₆CO₂—C_0-4alkyl, preferably C_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl, R₁₂R₇N—C_1-4alkyl, R₁₆CO—C_0-4alkyl or R₁₆CO₂—C_0-4alkyl, more preferably C_1-4alkyl, and even more preferably methyl or ethyl;

R₁₀is —COR₁₃; and

R₁₃is C_1-4alkyl, haloC_1-4alkyl, C_1-4alkoxyC_1-4alkyl, hydroxyC_1-4alkyl or cyanoC_1-4alkyl, preferably C_1-4alkyl or cyanoC_1-4alkyl, and more preferably methyl or cyanomethyl.

In another embodiment, the invention relates to the compounds of formula II wherein:

A is nitrogen and B is carbon;

R₁is hydrogen or —CN, preferably hydrogen; and R₂is hydrogen;

R₃is a cycle of formula Cy_1a, preferably with the (S)-stereochemistry;

R₅is hydrogen;

R₆is C_1-4alkyl, preferably methyl or ethyl;

R₁₀is —COR₁₃; and

R₁₃is C_1-4alkyl or cyanoC_1-4alkyl, preferably methyl or cyanomethyl.

In another embodiment, the invention relates to the compounds of formula II wherein:

A is nitrogen and B is carbon;

W is CH;

R₁is hydrogen or —CN, preferably hydrogen; and R₂is hydrogen;

R₃is a cycle of formula Cy_1a, preferably with the (S)-stereochemistry;

R₅is hydrogen;

R₆is C_1-4alkyl, preferably methyl or ethyl;

R₁₀is —COR₁₃; and

R₁₃is C_1-4alkyl or cyanoC_1-4alkyl, preferably methyl or cyanomethyl.

In another embodiment, the invention relates to the compounds of formula II wherein:

A is nitrogen and B is carbon;

W is N;

R₁is hydrogen or —CN, preferably hydrogen; and R₂is hydrogen;

R₃is a cycle of formula Cy_1a, preferably with the (S)-stereochemistry;

R₅is hydrogen;

R₆is C_1-4alkyl, preferably methyl or ethyl;

R₁₀is —COR₁₃; and

R₁₃is C_1-4alkyl or cyanoC_1-4alkyl, preferably methyl or cyanomethyl.

In another embodiment, the invention relates to the compounds of formula II wherein:

A is nitrogen and B is carbon;

R₁is hydrogen and R₂is hydrogen;

R₃is a cycle of formula Cy_1awith the (S)-stereochemistry;

R₅is hydrogen;

R₆is C_1-4alkyl, preferably methyl or ethyl;

R₁₀is —COR₁₃; and

R₁₃is C_1-4alkyl or cyanoC_1-4alkyl, preferably methyl or cyanomethyl.

In another embodiment, the invention relates to the compounds of formula II wherein:

A is nitrogen and B is carbon;

R₁is hydrogen or —CN, preferably hydrogen; and R₂is hydrogen;

R₃is a cycle of formula Cy_1b;

R₅is hydrogen;

R₆is C_1-4alkyl, preferably methyl or ethyl; and R₁₀is —SO₂R₁₃.

Furthermore, the present invention covers all possible combinations of the particular and preferred embodiments described above.

In another embodiment, the invention relates to a compound of formula I or II selected from the list of compounds described in examples 1 to 37.

In another embodiment, the invention relates to a compound of formula I or II that provides more than 50% inhibition of JAK3 activity at 10 μM, more preferably at 1 μM and still more preferably at 0.1 μM, in a JAK3 assay such as the one described in example 38.

In an additional embodiment, the invention relates to a compound according to formula I or II that provides more than 50% inhibition of JAK2 activity at 10 μM, more preferably at 1 μM and still more preferably at 0.1 μM, in a JAK2 assay such as the one described in example 39.

The compounds of the present invention contain one or more basic nitrogens and may, therefore, form salts with organic or inorganic acids. Examples of these salts include: salts with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, perchloric acid, sulfuric acid or phosphoric acid; and salts with organic acids such as methanesulfonic acid, trifluoromethanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, fumaric acid, oxalic acid, acetic acid, maleic acid, ascorbic acid, citric acid, lactic acid, tartaric acid, malonic acid, glycolic acid, succinic acid and propionic acid, among others. Some of the compounds of the present invention may contain one or more acidic protons and, therefore, they may also form salts with bases. Examples of these salts include: salts with inorganic cations such as sodium, potassium, calcium, magnesium, lithium, aluminium, zinc, et; and salts formed with pharmaceutically acceptable amines such as ammonia, alkylamines, hydroxylalkylamines, lysine, arginine, N-methylglucamine, procaine and the like.

There is no limitation on the type of salt that can be used, provided that these are pharmaceutically acceptable when they are used for therapeutic purposes. The term pharmaceutically acceptable salt refers to those salts which are, according to medical judgment, suitable for use in contact with the tissues of humans and other mammals without undue toxicity, irritation, allergic response and the like. Pharmaceutically acceptable salts are well known in the art.

The salts of a compound of formula I or II can be obtained during the final isolation and purification of the compounds of the invention or can be prepared by treating a compound of formula I or II with a sufficient amount of the desired acid or base to give the salt in the conventional manner. The salts of the compounds of formula I or II can be converted into other salts of the compounds of formula I or II by ion exchange using ionic exchange resins.

The compounds of formula I or II and their salts may differ in some physical properties but they are equivalent for the purposes of the present invention. All salts of the compounds of formula I or II are included within the scope of the invention.

The compounds of the present invention may form complexes with solvents in which they are reacted or from which they are precipitated or crystallized. These complexes are known as solvates. As used herein, the term solvate refers to a complex of variable stoichiometry formed by a solute (a compound of formula I or II or a salt thereof) and a solvent. Examples of solvents include pharmaceutically acceptable solvents such as water, ethanol and the like. A complex with water is known as a hydrate. Solvates of compounds of the invention (or salts thereof), including hydrates, are included within the scope of the invention.

The compounds of formula I or II may exist in different physical forms, i.e. amorphous and crystalline forms. Moreover, the compounds of the invention may have the ability to crystallize in more than one form, a characteristic which is known as polymorphism. Polymorphs can be distinguished by various physical properties well known in the art such as X-ray diffraction pattern, melting point or solubility. All physical forms of the compounds of formula I or N, including all polymorphic forms (“polymorphs”) thereof, are included within the scope of the invention.

Some of the compounds of the present invention may exist as several diastereoisomers and/or several optical isomers. Diastereoisomers can be separated by conventional techniques such as chromatography or fractional crystallization. Optical isomers can be resolved by conventional techniques of optical resolution to give optically pure isomers. This resolution can be carried out on any chiral synthetic intermediate or on products of formula I or II. Optically pure isomers can also be individually obtained using enantiospecific synthesis. The present invention covers all individual isomers as well as mixtures thereof (for example racemic mixtures or mixtures of diastereomers), whether obtained by synthesis or by physically mixing them.

The present invention further covers all unlabeled and isotopically labeled forms of the compounds of formula I or II.

The present invention further covers all tautomeric forms of the compounds of formula I or II.

The compounds of formula I or II can be obtained by following the processes described below. As it will be obvious to one skilled in the art, the exact method used to prepare a given compound may vary depending on its chemical structure. Moreover, in some of the processes described below it may be necessary or advisable to protect the reactive or labile groups with conventional protecting groups. Both the nature of these protecting groups and the procedures for their introduction and removal are well known in the art (see for example Greene T. W. and Wuts P. G. M, “Protecting Groups in Organic Synthesis”, John Wiley & Sons, 3^rdedition, 1999). As an example, as protecting group of an amino function the tert-butoxycarbonyl (BOO) group can be used. Whenever a protecting group is present, a later deprotection step will be required, which can be performed under standard conditions in organic synthesis, such as those described in the above-mentioned reference.

In general, compounds of formula I or II can be obtained from a compound of formula VI, as shown in the following scheme:

embedded image

wherein A, B, W, R₁, R₂, R₃R₄and R₅have the meaning previously described in relation with a compound of formula I or II; R₆in a compound of formula V or IIb has the meaning previously described in relation with a compound of formula I or II, except hydrogen; and X is a leaving group.

The compounds of formula I can be obtained by reacting a compound of formula VI with either the corresponding isothiocyanate III or aldehyde IV.

The reaction with an isothiocyanate III may be performed in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, in a suitable solvent such as dichloromethane, and heating at a suitable temperature usually comprised between 100 and 200° C. The heating may be thermal or by irradiating with microwaves at a wattage that allows reaching the temperature mentioned above.

The reaction between compounds of formula VI and IV can be carried out in a suitable solvent such as ethanol, butanol, N,N-dimethylformamide or dimethylacetamide, in the presence of an acid such as acetic acid, p-toluenesulfonic acid or sodium bisulfite, and heating, preferably at a temperature comprised between 100 and 200° C. The heating may be thermal or by irradiating with microwaves at a wattage that allows reaching the temperature mentioned above. When required, the reaction can be completed by subsequent addition of water.

The compounds of formula II (i.e. compounds of formula IIa and IIb) can be obtained from a compound of formula VI.

The compounds of formula IIa (i.e. a compound of formula II wherein R₆is hydrogen) can be obtained by reaction of a compound of formula VI with a synthetic equivalent for the CO synthon. Any such synthetic equivalent disclosed in the literature can in principle be used, for example 1,1-carbonyldiimidazole (CDI), phosgene, diphosgene or triphosgene. The reaction is conducted in the presence of a base such as N,N-diisopropylethylamine; and in a suitable solvent such as tetrahydrofuran (THF), and preferably at room temperature. The reaction can be completed by subsequent addition of water.

The compounds of formula IIb (i.e. a compound of formula II wherein R₆is different from hydrogen) can be obtained by alkylation of a compound of formula IIa with an alkylating agent R₆—X (V), wherein X represents a leaving group and R₆is different from H; suitable examples of X include among others halogen such as Cl, Br or I, mesylate, tosylate or triflate. This reaction may be carried out in the presence of a base such as Cs₂CO₃, K₂CO₃, NaOH, tert-BuOK or NaH, in a suitable solvent, such as acetone, toluene, 1,2-dimethoxyethane, and preferably dimethylformamide, at a suitable temperature, comprised between 0° C. and reflux.

The compounds of formula VI can be obtained by reduction of a compound of formula VII as shown in the following scheme:

embedded image

wherein A, B, W, R₁, R₂, R₃and R₅have the meaning previously described in relation with a compound of formula I or II.

The reaction may be carried out with hydrogen gas, using a platinum catalyst, such as PVC in the presence of thiophene in diisopropylethylamine; in a suitable solvent such as EtOH and preferably at room temperature.

The compounds of formula VII can be obtained by reacting a compound of formula VIII with either a compound of formula IX or X, as shown in the following scheme

embedded image

wherein A, B, W, R₁, R₂, R₃and R₅has the meaning previously described in relation with a compound of formula I or II; and BY₂is a boronic acid or ester.

The reaction between compounds of formula VIII and IX may be carried out using the conditions described in the Literature for Suzuki's coupling reactions. For example, the reaction may be carried out in the presence of a Pd catalyst such as Pd(PPh₃)₄; in the presence of a base such as Na₂CO₃; in a mixture of solvents such as a dimethoxyethane and water; and heating.

The direct coupling between compounds of formula VIII and X can be performed using a palladium catalyst such as for example tetrakis (triphenylphosphine)palladium(0) (Pd(PPh₃)₄) and preferably paladium (II) acetate Pd(OAc)₂in the presence of triphenylphosphine, and a base, such as for example triethylamine and preferably potassium acetate. The reaction is usually carried out under anhydrous and anaerobic conditions. The reaction may be carried out in a solvent such as dioxane, N,N-dimethylformamide, toluene and preferably in dimethylacetamide and heating at a temperature usually comprised between 60° C.-100° C.

Compounds of formula IX and formula X can be easily obtained from commercial compounds by known methods.

Additionally, the compounds of formula VII wherein A is nitrogen and B is carbon (i.e. VIIa) can be obtained by reacting a compound of formula XI with a compound of formula XII, as shown in the following scheme:

embedded image

wherein W, R₁, R₂, R₃and R₅have the meaning previously described in relation with a compound of formula I or II; and An is iodine, 2,4-dinitrophenolate, p-toluensulphonate or 2,4,6-trimethylbencenosulphonate.

The reaction may be carried out in the presence of tetra-n-butylammonium fluoride (TBAF) in THF and of a base such as 1,5-diazabicyclo[4.3.0]non-5-ene (DBN) or 1,4-diazabicyclo[2.2.2]octane (DABCO), preferably 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), in a solvent such as N,N-dimethylformamide, dimethylsulfoxide, dichloromethane, toluene or acetonitrile, preferably acetonitrile, and at a temperature comprised between −78° C. and room temperature.

Alternatively the compounds of formula VIIa can be obtained by reacting a compound of formula XII with the deprotected derivative of the compound of formula XI (XIb) obtained by using standard conditions.

The compounds of formula XII can be obtained by reaction of a compound of formula XIII with aminosulfonic acid in the presence of a HI aqueous solution; and of a base such as K₂CO₃, NaOH or KOH; in a solvent such as dichloromethane, tetrahydrofuran, water, ethanol, methanol, isopropanol or acetonitrile; and heating preferably at reflux, as shown in the following scheme:

embedded image

wherein R₁and R₂have the meaning previously described in relation with a compound of formula I or II; and An has the meaning described above.

The compounds of formula XI can be obtained by reaction of a compound of formula VIII with trimethylsilylacetylene, as shown in the following scheme:

embedded image

wherein W, R₃and R₅have the meaning previously described in relation with a compound of formula I or II.

The reaction with trimethylsilylacetylene may be carried out under Sonogashira conditions, using a palladium catalyst such as for example tetrakis (triphenylphosphino)palladium(0) (Pd(PPh₃)₄), preferably bis(triphenylphosphino)dichloropalladium(II) (Pd(Ph₃P)₂Cl₂) in the presence of triphenylphospine, a Cu (I) catalyst as a cocatalyst, such as CuI, and a base, such as diethylamine. N,N-diisopropylethylamine, triethylamine or isopropylethylamine. The reaction is usually carried out under anhydrous and anaerobic conditions. The reaction may be carried out in a solvent such as dioxane, N,N-dimethylformamide, tetrahydrofuran or toluene, at room temperature or by heating.

The compounds of formula VIII can be obtained by reaction of a compound of formula XIV with a compound of formula XV, as shown in the following scheme:

embedded image

wherein W, R₃and R₅have the meaning previously described in relation with a compound of formula I or II.

The reaction between the compounds of formula XIV and XV may be carried out in the presence of a base such as diisopropylethylamine, diethylamine or triethylamine, in a suitable solvent such as THF or acetonitrile, and at a temperature comprised between −78° C. and room temperature.

The compounds of formula XIV and XV are commercial or may be easily obtained from commercial compounds using standard procedures.

Furthermore, some compounds of the present invention can also be obtained from other compounds of formula I or II by appropriate conversion reactions of functional groups in one or several steps, using well-known reactions in organic chemistry under the standard experimental conditions. Said transformations can be carried out for example upon R₃and include, for example the substitution of a primary or secondary amine by treatment with an alkylating agent, the reaction of an acid or ester with an amine to obtain the corresponding amide, the conversion of an amine into a sulfonamide and the hydrolysis of an ester to obtain a carboxylic acid. In some of these conversions it may be necessary or advisable to protect the reactive or unstable groups by means of conventional protective groups.

As it will be obvious to those skilled in the art, these interconversion reactions can be carried out upon the compounds of formula I or II as well as upon any suitable synthesis intermediate thereof.

As mentioned above, the compounds of the present invention act by inhibiting JAK/STAT signaling pathways, particularly by inhibiting JAK3 activity. Therefore, the compounds of the invention are expected to be useful to treat or prevent diseases in which JAKs, particularly JAK3, play a role in mammals, including human beings. These diseases include, but are not limited to, transplant rejection; immune, autoimmune and inflammatory diseases; neurodegenerative diseases; and proliferative disorders (see e.g. O'Shea J. J. et al, Nat. Rev. Drug. Discov, 2004, 3(7):555-64; Cetkovic-Cvrlje M. et al, Curr. Pharm, Des, 2004, 10(15):1767-84; Cetkovic-Cvrlje M. at al, Arch. Immunol. Ther. Exp. (Warsz), 2004, 52(2):69-82).

Acute or chronic transplant rejection reactions that can be treated or prevented with the compounds of the present invention include any kind of cell, tissue or organ xenotransplants or allografts, such as of heart, lung, liver, kidney, pancreas, uterus, joints, pancreatic islets, bone marrow, limbs, cornea, skin, hepatocytes, pancreatic beta cells, pluripotential cells, neuronal cells and myocardial cells, as well as graft-versus-host reactions (see e.g. Rousvoal G. et al, Transpl. Int. 2006, 19(12):1014-21; Borie D C. at al, Transplantation 2005, 79(7):791-801; Paniagua R. at al, Transplantation 2005, 80(9):1283-92; Higuchi T. et al., J. Heart Lung Transplant. 2005, 24(10):1557-64; Sëmann M D, at al, Transpl Int 2004, 17(9):481-89; Silva Jr H T. at al, Drugs 2006, 66(13):1665-1684).

Immune, autoimmune or inflammatory diseases that can be treated or prevented with the compounds of the present invention include among others, rheumatic diseases (e.g. rheumatoid arthritis and psoriatic arthritis), autoimmune hematological disorders (e.g. hemolytic anemia, aplastic anemia, idiopathic thrombocytopenia, and neutropenia), autoimmune gastritis and inflammatory bowel diseases (e.g. ulcerative colitis and Crohn's disease), scleroderma, type I diabetes and complications from diabetes, type B hepatitis, type C hepatitis, primary biliary cirrhosis, myasthenia gravis, multiple sclerosis, systemic lupus erythematosus, psoriasis, atopic dermatitis, contact dermatitis, eczema, skin sunburns, suppression of HIV replication, infertility of autoimmune origin, autoimmune thyroid disease (Grave's disease), interstitial cystitis, mast cell-mediated allergic reactions such as asthma, angiodema, anaphylaxis, bronchitis, rhinitis and sinusitis, and inflammatory or autoimmune ocular diseases such as dry eye syndrome, glaucoma, Sjögren's syndrome, uveitis and retinopathy of prematurity (see e.g. Sorbera L A. at al, Drugs of the Future 2007, 32(4674-680; O'Shea J. J. et al, Nat. Rev. Drug. Discov. 2004, 3(7):555-64; Cetkovic-Cvrlje M. et al, Curr, Pharm. Des. 2004, 10(15):1767-84; Muller-Ladner U. et al, J. Immunol. 2000, 164(7): 3894-3901; Walker J G. at al, Ann. Rheum. Dis. 2006, 65(2):149-56; Milici A J. at al, Arthritis Rheum 0.2006, 54 (9, Suppl): abstr 789; Kremer J M. et al, Arthritis Rheum. 2006, 54, 4116, presentation no. L40; Cetkovic-Cvrlje M. et al, Arch Immunol. Ther. Exp. (Warsz), 2004, 52(2):69-82; Malaviya R. et al, J. Pharmacol. Exp. Ther. 2000, 295(3):912-26; Malaviya R. et al, J. Biol. Chem. 1999, 274(38):27028-38; Wilkinson B et al, Ann. Rheum. Dis. 2007, 66(Suppl 2): Abst, THU0099; Matsumoto M. et al, J. Immunol. 1999, 162(2):1056-63, West K., Curr Opin Inventig Drugs 2009:10(5):491-504, Huang Y. at al., Exp Eye res 2007:85(5):684-95, Killedar S Y et al, Laboratory investigation 2006:86:1243-1260, Egwuagu C. E., Cytokine 2009:47(3):149-156, Byfield G., Investigative Ophtalmology &Viral Science 2009:503360).

Neurodegenerative diseases that can be treated or prevented with the compounds of the present invention include, among others, amyotrophic lateral sclerosis and Alzheimer's disease (see e.g. Trieu V N. et al, Biochem. Biophys, Res. Commun. 2000, 267(1):22-5).

Proliferative disorders that can be treated or prevented with the compounds of the present invention include, among others, leukemias, lymphomas, glioblastoma multiforme, colon carcinoma, as well as thromboembolic and allergic complications associated with these diseases (see e.g. Sudbeck E A. et al, Clin. Cancer Res. 1999, 5(6):1569-82; Narla R K. et al, Olin. Cancer Res. 1998, 4(10):2463-71; Lin Q. at al, Am J. Pathol. 2005, 167(4):969-80; Tibbles H E. et al, J. Biol. Chem. 2001, 276(21):17815-22).

It has been found that certain compounds of formula I or II, besides inhibiting JAK3 activity, also inhibit JAK2 kinase to varying degrees, and therefore can also be useful for the treatment or prevention of any disease mediated by JAK2 kinase. A group of such JAK2-mediated diseases are myeloproliferative disorders, including polycythemia vera, essential thrombocytosis, idiopathic myelofibrosis, chronic myelogenous leukemia, hypereosinophilic syndrome, chronic neutrophilic leukemia, chronic myelomonocytic leukemia, myelofibrosis with myeloid metaplasia, chronic basophilic leukemia, chronic eosinophilic leukemia, systemic mastocytosis and myelodisplastic syndrome (see e.g. Geron I. et al, Cancer cell 2008, 13:321-330; Pardanani A. et al, Leukemia 2007, 21(8):1658-68; Mathur A. et al, Biochem Pharmacol 2009, 78(4):382-9; Manshouri T. at al, Cancer Sci, 2008, 99(6):1265-73; Wernig G. et al, Cancer cell 2008, 13(4):311-20. Elizabeth O. et al, Blood, 111(12: 5663-5671).

Compounds of formula I or II wherein R₁and R₂are hydrogen have been found to be particularly useful as JAK2 inhibitors, and thus can be particularly useful, in addition to treating or preventing all the diseases mentioned in the preceding paragraphs, also for the treatment or prevention of myeloproliferative disorders (MPD).

Thus, another aspect of the invention relates to a compound of formula I or II, or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of a disease mediated by JAK2. More preferably, the disease mediated by JAK2 is a myeloproliferative disorder. In a preferred embodiment, the compounds of formula I or II are those wherein R₁and R₂are hydrogen.

Another aspect of the present invention relates to a method of treating or preventing a disease mediated by JAK2 in a subject in need thereof, especially a human being, which comprises administering to said subject a compound of formula I or II, or a pharmaceutically acceptable salt thereof. More preferably, the disease mediated by JAK2 is a myeloproliferative disease. In a preferred embodiment, the compounds of formula I or II are those wherein R₁and R₂are hydrogen

Another aspect of the invention relates to a compound of formula I or II, or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of a myeloproliferative disorder. In a preferred embodiment, the myeloproliferative disorder is selected from polycythemia vera, essential thrombocytosis, idiopathic myelofibrosis, chronic myelogenous leukemia, hypereosinophilic syndrome, chronic neutrophilic leukemia, chronic myelomonocytic leukemia, myelofibrosis with myeloid metaplasia, chronic basophilic leukemia, chronic eosinophilic leukemia, systemic mastocytosis and myelodisplastic syndrome. In a preferred embodiment, the compounds of formula I or II are those wherein R₁and R₂are hydrogen.

Another aspect of the invention relates to the use of a compound of formula I or II or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment or prevention of a myeloproliferative disorder. In a preferred embodiment, the myeloproliferative disorder is selected from polycythemia vera, essential thrombocytosis, idiopathic myelofibrosis, chronic myelogenous leukemia, hypereosinophilic syndrome, chronic neutrophilic leukemia, chronic myelomonocytic leukemia, myelofibrosis with myeloid metaplasia, chronic basophilic leukemia, chronic eosinophilic leukemia, systemic mastocytosis and myelodisplastic syndrome. In a preferred embodiment, the compounds of formula I or II are those wherein R₁and R₂are hydrogen.

Another aspect of the present invention relates to a method of treating or preventing a myeloproliferative disorder in a subject in need thereof, especially a human being, which comprises administering to said subject a compound of formula I or II or a pharmaceutically acceptable salt thereof. In a preferred embodiment, the myeloproliferative disorder is selected from polycythemia vera, essential thrombocytosis, idiopathic myelofibrosis, chronic myelogenous leukemia, hypereosinophilic syndrome, chronic neutrophilic leukemia, chronic myelomonocytic leukemia, myelofibrosis with myeloid metaplasia, chronic basophilic leukemia, chronic eosinophilic leukemia, systemic mastocytosis and myelodisplastic syndrome. In a preferred embodiment, the compounds of formula I or II are those wherein R₁and R₂are hydrogen.

Biological assays that can be used to determine the ability of a compound to inhibit JAKs, particularly JAK3 and JAK2, are well known in the art. For example, a compound to be tested can be incubated in the presence of the desired JAK, such as JAK3 or JAK2, to determine whether inhibition of JAK enzymatic activity occurs, as described in the assay of examples 38 and 39 for JAK3 and JAK2, respectively. Other in vitro useful assays that can be used to measure JAK3-inhibitory activity include cellular assays, for example IL-2-induced proliferation of human T lymphocytes. The immunosuppressive activity of the compounds of the invention can be tested using standard in vivo animal models for immune and autoimmune diseases, which are well known in the art. For example, the following assays can be used: delayed-type hypersensitivity (DTH) (see e.g. the method disclosed in Kudlacz E. at al, Am J. Transplant, 2004, 4(1):51-7, the contents of which are incorporated herein by reference), rheumatoid arthritis models such as collagen-induced arthritis (see e.g. the method disclosed in Holmdahl R et al, APMIS, 1989, 97(7):575-84, the contents of which are incorporated herein by reference), multiple sclerosis models such as experimental autoimmune encephalomyelitis (EAE) (see e.g. the method disclosed in González-Rey et al, Am, J. Pathol. 2006, 168(4): 1179-88, the contents of which are incorporated herein by reference) and transplant rejection models (see e.g. the various animal models disclosed in the references listed above in relation to the treatment of transplant rejection, incorporated herein by reference). The antiproliferative activity of the compounds of the invention can be tested using standard in vivo animal models well known in the art, such as xenograft studies (see e.g Mohammad R H. et al, Pancreas. 1998; 16(1):19).

For selecting active compounds for JAK3, testing at 10 μM must result in an activity of more than 50% inhibition of JAK3 activity in the test provided in example 38. More preferably, when tested in this assay compounds should exhibit more than 50% inhibition at 1 μM, and still more preferably, they should exhibit more than 50% inhibition at 0.1 μM.

For selecting active compounds for JAK2, testing at 10 μM must result in an activity of more than 50% inhibition of JAK2 activity in the test provided in example 39 More preferably, when tested in this assay compounds should exhibit more than 50% inhibition at 1 μM, and still more preferably, they should exhibit more than 50% inhibition at 0.1 μM.

Assays that can be used to predict the PK profile of a compound are well known in the art. For example, a Caco-2 assay can be used to determine in vitro the potential for oral absorption of a compound. To show a good PK profile the compound must also exhibit a suitable clearance, as determined in a standard test using for example human liver microsomes in an assay such as the one described in example 40.

Standard assays can be used to assess potential toxic effects of drug candidates, all of which are well known in the art. Such tests include e.g. viability assays in different cell lines such as human hepatocyte carcinoma cells (Hep G2), which can be performed following standard procedures, such as the one described in example 41.

The present invention also relates to a pharmaceutical composition that comprises a compound of the present invention (or a pharmaceutically acceptable salt or solvate thereof) and one or more pharmaceutically acceptable excipients. The excipients must be “acceptable” in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipients thereof.

The compounds of the present invention can be administered in the form of any pharmaceutical formulation, the nature of which, as it is well known, will depend upon the nature of the active compound and its route of administration. Any route of administration may be used, for example oral, parenteral, nasal, ocular, rectal and topical administration.

Solid compositions for oral administration include tablets, granulates and capsules. In any case the manufacturing method is based on a simple mixture, dry granulation or wet granulation of the active compound with excipients. These excipients can be, for example, diluents such as lactose, microcrystalline cellulose, mannitol or calcium hydrogenphosphate; binding agents such as for example starch, gelatin or povidone; disintegrants such as sodium carboxymethyl starch or sodium croscarmeliose; and lubricating agents such as for example magnesium stearate, stearic acid or talc. Tablets can be additionally coated with suitable excipients by using known techniques with the purpose of delaying their disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period, or simply to improve their organoleptic properties or their stability. The active compound can also be incorporated by coating onto inert pellets using natural or synthetic film-coating agents. Soft gelatin capsules are also possible, in which the active compound is mixed with water or an oily medium, for example coconut oil, mineral oil or olive oil.

Powders and granulates for the preparation of oral suspensions by the addition of water can be obtained by mixing the active compound with dispersing or wetting agents; suspending agents and preservatives. Other excipients can also be added, for example sweetening, flavoring and colouring agents.

Liquid forms for oral administration include emulsions, solutions, suspensions, syrups and elixirs containing commonly used inert diluent, such as purified water, ethanol, sorbitol, glycerol, polyethylene glycols (macrogols) and propylene glycol. Said compositions can also contain coadjuvants such as wetting, suspending, sweetening, flavoring agents, preservatives and buffers.

Injectable preparations, according to the present invention, for parenteral administration, comprise sterile solutions, suspensions or emulsions, in an aqueous or non-aqueous solvent such as propylene glycol, polyethylene glycol or vegetable oils. These compositions can also contain coadjuvants, such as wetting, emulsifying, dispersing agents and preservatives. They may be sterilized by any known method or prepared as sterile solid compositions, which will be dissolved in water or any other sterile injectable medium immediately before use. It is also possible to start from sterile materials and keep them under these conditions throughout all the manufacturing process.

For the rectal administration, the active compound can be preferably formulated as a suppository on an oily base, such as for example vegetable oils or solid semisynthetic glycerides, or on a hydrophilic base such as polyethylene glycols (macrogol).

The compounds of the invention can also be formulated for their topical application for the treatment or prevention of pathologies occurring in zones or organs accessible through this route, such as eyes, skin and the intestinal tract. Formulations include creams, lotions, gels, powders, solutions and patches wherein the compound is dispersed or dissolved in suitable excipients.

For the nasal administration or for inhalation, the compound can be formulated as an aerosol and it can be conveniently released using suitable propellants.

The dosage and frequency of doses will depend upon the nature and severity of the disease to be treated, the age, the general condition and body weight of the patient, as well as the particular compound administered and the route of administration, among other factors. A representative example of a suitable dosage range is from about 0.01 mg/Kg to about 100 mg/Kg per day, which can be administered as a single or divided doses.

The following examples illustrate the scope of the invention.

EXAMPLES

The following abbreviations have been used in the examples:

AcOH: acetic acid

AcN: acetonitrile

DBU: 1,8-diazabicyclo[5.4.0]undec-7-ene

DIPEA: N,N-diisopropylethylamine
DMAC: N,N-dimethylacetamide
DMF: N,N-dimethylformamide

EDC: N-(3-dimethylaminopropyl)-N′-ethyloarbodiimide

EtOAc: ethyl acetate

EtOH: ethanol

HATU: 2-(1H-7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uranium hexafluorophosphate Methanaminium

HOBt: 1-hydroxybenzotriazole

HPLC: high performance liquid chromatography

LC-MS: liquid chromatography-mass spectroscopy

MeI: iodomethane

MeOH: methanol

PTSA: para-toluene sulfonic acid

TBAF: tetrabutylammonium fluoride

TBME: tert-butyl methyl ether

TEA: triethylamine

TFA: trifluoroacetic acid

THF: tetrahydrofurane

TLC: thin layer cromatography

t_R: retention time

One of the following methods was used to determine the LC-MS spectrums:

Method 1: Column SunFire C18 3.5 μm, (100 mm×2.1), flow rate: 0.3 mL/min, eluent A=CH3CN:MeOH 1:1 B=NH₄Ac 5 mM pH 7, gradient: 0 min 10% A; 17 min 95% A; 10 min 95% A.

Method 2: Column XBridge, 3.5 um (50 mm×4.6), temperature: 30° C., flow rate: 2 mL/min, eluent A=NH₄HCO₃10 mM (pH=9). B=AcN, gradient: 0 min 5% B; 4.8 min 100% B;

Method 3: Column XBridge, 3.5 μm (50 mm×4.6), temperature: 50° C., flow rate: 1.6 mL/min, eluent A=NH₄HCO₃10 mM (pH=9), B=AcN, gradient: 0 min 5% B; 3.5 min 1005% B;

Method 4 (Palau): Column Waters Acquity HPLC BEH C18 (1.7 μm, 2.1 mm×50 mm), temperature: 40° C., flow: 0.5 mL/min, eluent: ACN (A)/ammonium bicarbonate 10 mM (B), gradient: 0 min 10% A-3.75 min 90% A

Method 5:: Column YMC, 3.5 μm (50 mm×4.6), temperature; 50° C., flow rate: 1.3 mL/min, eluent A=H₂O (0.1% HCOOH), B=AcN (0.1% HCOOH), gradient: 0 min 5% B; 3.5 min 100% B.

Reference Example 1
1-Amino-4-trifluoromethylpyridinium 2,4,6-trimethylbenzenesulfonate

To a solution of 4-trifluoromethylpyridine (2.23 g, 15.2 mmol) in CH₂Cl₂(66 ml.) at 0° C., O-(mesitylsulfonyl)hydroxylamine (3.27 g, 15.2 mmol) was added. The reaction mixture was stirred at room temperature for 18 h. The reaction mixture was filtered to afford the desired product with quantitative yield.

LC-MS (method 4): t_R=1.07 min; m/z=199 (MH⁻).

Reference Example 2
(S)-3-(4-(1-Acetylpiperidin-3-ylamino)-5-aminopyrimidin-2-yl)pyrazolo[1,5-a]pyridine-5-carbonitrile

Following a similar procedure to that described in example 1 (section a to d), but using (S)-1-acetyl-3-aminopiperidine instead of tetrahydro-2H-pyran-4-amine, the desired compound was obtained.

LC-MS (method 3): t_R=1.59 min; m/z=377 (MH⁺).

Following a similar procedure to that described in reference example 2, but using in each case the corresponding starting materials, the following compounds were obtained:

Reference

HPLC
t_R

example
Name
Starting Materials
method
(min)
m/z

2a
(S)-tert-butyl 3-(5-amino-2-(5-
1-amino-4-
3
2.32
424

methylpyrazolo[1,5-a]pyridin-3-
methylpyridinium

yl)pyrimidin-4-ylamino)piperidine-1-
2,4,6-

carboxylate
trimethylbenzenesulfonate (1),,

(S)-3-amino-

(1-tert-

butoxycarbonyl)piperidine

and 2,4-dichloro-5-

nitropyrimidine

2b
tert-butyl 4-(5-amino-2-(pyrazolo[1,5-
1-aminopyridinium
4
2.00
410

a]pyridin-3-yl)pyrimidin-4-
iodide,, 4-amino-(1-

ylamino)piperidine-1-carboxylate
tert-

butoxycarbonyl)piperidine

and 2,4-dichloro-5-

nitropyrimidine

2c
2-(pyrazolo[1,5-a]pyridin-3-yl)-N4-
1-aminopyridinium
3
1.55
311

(tetrahydro-2H-pyran-4-yl)pyrimidine-
iodide, tetrahydro-2H-

4,5-diamine
pyran-4-amine and

2,4-dichloro-5-

nitropyrimidine

2d
(S)-tert-butyl 3-(3-amino-6-
1-aminopyridinium
3
2.43
409

(pyrazolo[1,5-a]pyridin-3-yl)pyridin-2-
iodide, (S)-3-amino-

ylamino)piperidine-1-carboxylate
(1-tert-

butoxycarbonyl)piperidine

and 2,6-dichloro-3-

nitropyridine

2e
3-(5-amino-4-(8-fluorochroman-4-
1-amino-4-
1
9.28
402

ylamino)pyrimidin-2-yl)pyrazolo[1,5-
cyanopyridinium 2,4,6-

a]pyridine-5-carbonitrile
trimethylbenzenesulfonate,

8-fluorochroman-

4-amine and 2,4-

dichloro-5-

nitropyrimidine

2f
(S)-3-(6-(1-acetylpiperidin-3-ylamino)-
1-amino-4-
3
1.58
377

5-aminopyridin-2-yl)pyrazolo[1,5-
cyanopyridinium 2,4,6-

a]pyridine-5-carbonitrile
trimethylbenzenesulfonate,

(S)-1-acetyl-3-

aminopiperidin and

2,6-dichloro-3-

nitropyridine

2g
6-(pyrazolo[1,5-a]pyridin-3-yl)-N2-
1-aminopyridinium
5
1.68
310

(tetrahydro-2H-pyran-4-yl)pyridine-
iodide, tetrahydro-2H-

2,3-diamine
pyran-4-amine and

2,6-dichloro-3-

nitropyridine

2h
(S)-tert-butyl 3-(3-amino-6-(5-
1-amino-4-
3
2.50
434

cyanopyrazolo[1,5-a]pyridin-3-
cyanopyridinium 2,4,6-

yl)pyridin-2-ylamino)piperidine-1-
trimethylbenzenesulfonate,

carboxylate
(S)-3-amino-(1-

tert-

butoxycarbonyl)piperidine

and 2,6-dichloro-3-

nitropyridine

2i
3-(5-amino-4-(trans-4-
1-amino-4-
3
1.45
350

hydroxycyclohexylamino)pyrimidin-2-
cyanopyridinium 2,4,6-

yl)pyrazolo[1,5-a]pyridine-5-
trimethylbenzenesulfonate,

carbonitrile
trans-4-

aminocyclohexanol

and 2,6-dichloro-3-

nitropyridine,

(1) described by Zhang at al Journal of Heterocyclic Chemistry: 44; 4; 2007; 919-922

Example 1
3-(8-Oxo-9-tetrahydro-2H-pyran-4-yl-8,9-dihydro-7H-purin-2-yl)pyrazolo[1,5-a]pyridine-5-carbonitrile
a) 2-Chloro-5-nitro-N-tetrahydro-2H-pyran-4-ylpyrimidin-4-amine

To a solution of 2,4-dichloro-5-nitropyrimidine (1.03 g, 5.15 mmol) in THF (40 mL) at −78° C., DIPEA (2.0 mL, 11.86 mmol) and tetrahydro-2H-pyran-4-amine (0.54 mL, 5.15 mmol) were added. The reaction mixture was stirred from −78 to −50° C. for 5 h. The crude mixture was quenched with H₂O (50 mL), extracted with EtOAc (3×40 mL) and the combined organic phases were dried over anhydrous Na₂SO₄, filtered and concentrated. The crude product thus obtained was chromatographed over silica gel using EtOAc/hexanes mixtures of increasing polarity as eluent, to afford 1.04 g of the desired compound (78% yield).

b) 5-Nitro-N-(tetrahydro-2H-pyran-4-yl)-2-[(trimethylsilyl)ethynyl]pyrimidin-4-amine

To a suspension of the compound obtained in the previous section (1.01 g, 3.90 mmol), Pd(PPh₃)₂Cl₂(137 mg, 0.19 mmol) and CuI (37 mg, 0.19 mmol) in toluene (40 mL), TEA (1.6 mL, 11.7 mmol) and trimethylsilylacetylene (0.7 mL, 5.07 mmol) were added. The reaction mixture was stirred at room temperature for 18 h, quenched with saturated NH₄Cl aqueous solution (70 mL) and extracted with EtOAc (3×40 mL). The combined organic phases were dried over anhydrous Na₂SO₄, filtered and concentrated. The crude residue was cromatographed on a silica gel flash system (SP1 Biotage) using EtOAc/hexanes mixtures of increasing polarity as eluent to afford 0.96 g of the desired product (77% yield).

c) 3-[5-Nitro-4-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl]pyrazolo[1,5-a]pyridine-5-carbonitrile

To a suspension of the compound obtained in the previous section (500 mg, 1.56 mmol) and 1-amino-4-cyanopyridinium 2,4,6-trimethylbenzenesulfonate (498 mg, 1.56 mmol) in AcN (30 mL), at 0° C., 1 M TBAF solution in THF (1.56 mL, 1.56 mmol) and a solution of DBU (0.47 mL, 3.12 mmol) in AcN (10 mL) were added. The reaction mixture was stirred at 0° C. for 5 min and 3 h at room temperature. The reaction mixture was evaporated to dryness. The crude product thus obtained was chromatographed over silica gel using EtOAc/hexanes mixtures of increasing polarity as eluent, to afford 227 mg of the desired compound (48% yield).

d) 3-[5-Amino-4-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl]pyrazolo[1,5-a]pyridine-5-carbonitrile

A mixture of the compound obtained in the previous section (119 mg, 0.32 mmol) in EtOH (12 mL) was hydrogenated with Pt/C₅% (149 mg, 0.02 mmol) as a catalyst in the presence of thiophene in DIRER (4% v/v, 9 drops). The reaction mixture was stirred under H₂(g) atmosphere at room temperature for 1.5 h. The reaction mixture was filtered through a plug of Celite® and the solvent was concentrated off to afford 78 mg of the desired product (71% yield).

e) 3-(8-Oxo-9-tetrahydro-2H-pyran-4-yl-8,9-dihydro-7H-purin-2-yl)pyrazolo[1,5-a]pyridine-5-carbonitrile

To a solution of the compound obtained in the previous section (78 mg, 0.23 mmol) in THF (7 mL), 1,1″-carbonyldiimidazole. (188 mg, 1.16 mmol) was added. The reaction mixture was stirred at room temperature thr 4 h, quenched with saturated NaCl aqueous solution (15 mL) and extracted with EtOAc (3×15 mL). The combined organic phases were dried over anhydrous Na₂SO₄, filtered and concentrated. The crude product thus obtained was chromatographed over silica gel using MeOH/CH₂Cl₂mixtures of increasing polarity as eluent, to afford 5.1 mg of the desired compound (61% yield).

LC-MS (method 1): t_R=14.25 min; m/z=362 (MH⁺).

Following a similar procedure to that described in example 1, but using in each case the corresponding starting materials, the following compounds were obtained:

HPLC
t_R

Example
Name
Starting Material
method
(min)
m/z

1a
methyl (2R)-2-[2-(5-
D-alanine methyl ester
1
14.48
364

cyanopyrazolo[1,5-a]pyridin-3-yl)-8-
hydrochloride

oxo-7,8-dihydro-9H-purin-9-

yl]propanoate

1b
(S)-tert-butyl 3-(2-(5-
(S)-tert-butyl 3-
2
2.23
461

cyanopyrazolo[1,5-a]pyridin-3-yl)-8-
aminopiperidine-1-

oxo-7H-purin-9(8H)-yl)piperidine-1-
carboxylate

carboxylate

1c
(R)-tert-butyl 3-(2-(5-
(R)-tert-butyl 3-
2
2.23
461

cyanopyrazolo[1,5-a]pyridin-3-yl)-8-
aminopiperidine-1-

oxo-7H-purin-9(8H)-yl)piperidine-1-
carboxylate

carboxylate

1d
(S)-3-(9-(1-methoxypropan-2-yl)-8-
(S)-1-methoxypropan-
2
1.82
350

oxo-8,9-dihydro-7H-purin-2-
2-amine

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

1e
3-(9-(4,4-difluorocyclohexyl)-8-oxo-
4,4-
2
2.03
396

8,9-dihydro-7H-purin-2-
difluorocyclohexanamine

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

1f
3-(9-(1,1-dioxotetrahydrothien-3-yl)-8-
3-amino-1,1-
2
1.43
396

oxo-8,9-dihydro-7H-purin-2-
dioxotetrahydrothiophene

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

1g
3-(9-(2-fluorobenzyl)-8-oxo-8,9-
2-fluorobenzylamine
1
16.58
386

dihydro-7H-purin-2-yl)pyrazolo[1,5-

a]pyridine-5-carbonitrile

1h
3-(9-(4-methoxybut-1-yl)-8-oxo-8,9-
4-methoxybutan-1-
1
15.15
396

dihydro-7H-purin-2-yl)pyrazolo[1,5-
amine

a]pyridine-5-carbonitrile

1i
methyl (2S)-2-[2-(5-
L-alanine methyl ester
3
1.83
436

cyanopyrazolo[1,5-a]pyridin-3-yl)-8-
hydrochloride

oxo-7,8-dihydro-9H-purin-9-

yl]propanoate

1j
9-(1-acetylpiperidin-4-yl)-2-(5-
1-acetyl-4-
4
1.68
446

(trifluoromethyl)pyrazolo[1,5-a]pyridin-
aminopiperidine

3-yl)-7H-purin-8(9H)-one (1)
hydrochloride

1k
(S)-tert-butyl 3-(2-(5-
(S)-tert-butyl 3-
5
2.72
447

cyanopyrazolo[1,5-a]pyridin-3-yl)-8-
aminopyrrolidine-1-

oxo-7H-purin-9(8H)-yl)pyrrolidine-1-
carboxylate

carboxylate

1l
(R)-tert-butyl 3-(2-(5-
(R)-tert-butyl 3-
3
2.25
447

cyanopyrazolo[1,5-a]pyridin-3-yl)-8-
aminopyrrolidine-1-

oxo-7H-purin-9(8H)-yl)pyrrolidine-1-
carboxylate

carboxylate

1m
(S)-tert-butyl 3-(2-(5-
(S)-tert-butyl 3-
3
2.47
450

methylpyrazolo[1,5-a]pyridin-3-yl)-8-
aminopiperidine-1-

oxo-7H-purin-9(8H)-yl)piperidine-1-
carboxylate

carboxylate (2)

1n
ethyl 2-(2-(5-cyanopyrazolo[1,5-
ethyl 2-aminoacetate
3
1.82
364

a]pyridin-3-yl)-8-oxo-7H-purin-9(8H)-

yl)acetate

1o
3-(9-(trans-4-hydroxycyclohexyl)-8-
trans-4-
3
1.55
376

oxo-8,9-dihydro-7H-purin-2-
aminocyclohexanol

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

1p
3-(9-(8-fluorochroman-4-yl)-8-oxo-8,9-
8-fluorochroman-4-
1
15.43
428

dihydro-7H-purin-2-yl)pyrazolo[1,5-
amine

a]pyridine-5-carbonitrile

1q
tert-butyl 4-(2-(5-cyanopyrazolo[1,5-
tert-butyl 4-
3
2.33
461

a]pyridin-3-yl)-8-oxo-7H-purin-9(8H)-
aminopiperidine-1-

yl)piperidine-1-carboxylate
carboxylate

1r
tert-butyl 3-(2-(5-cyanopyrazolo[1,5-
tert-butyl 3-
3
2.20
433

a]pyridin-3-yl)-8-oxo-7H-purin-9(8H)-
aminoazetidine-1-

yl)azetidine-1-carboxylate
carboxylate

1s
9-(1-acetylpiperidin-4-yl)-2-(5-
1-acetyl-4-
4
1.38
392

methylpyrazolo[1,5-a]pyridin-3-yl)-7H-
aminopiperidine

purin-8(9H)-one (2)
hydrochloride

(1) step c) was performed using reference example 1 instead of 1-amino-4-cyanopyridinium 2,4,6-trimethylbenzenesulfonate

(2) step c) was performed using 1-amino-4-methylpyridinium 2,4,6-trimethylbenzenesulfonate (described by Zhang et al Journal of Heterocyclic Chemistry; 44; 4; 2007; 919-922) instead of 1-amino-4-cyanopyridinium 2,4,6-trimethylbenzenesulfonate

Example 2
3-(2-oxo-3-(tetrahydro-2H-pyran-4-yl)-2,3-dihydro-1H-imidazo[4,5-b]pyridin-5-yl)pyrazolo[1,5-a]pyridine-5-carbonitrile
a) 6-Chloro-3-nitro-N-(tetrahydro-2H-pyran-4-yl)pyridin-2-amine

To a suspension of 2,6-dichloro-3-nitropyridine (6 g, 31.1 mmol) in AcN (200 mL) at 0° C., TEA (9 mL, 62.2 mmol) and tetrahydro-2H-pyran-4-amine (3.15 g, 31.1 mmol) were added. The reaction mixture was stirred at 0° C. for 1.5 h. The reaction crude was tempered and stirred at room temperature for 18 h.

The reaction mixture was evaporated under reduced pressure, dissolved in EtOAc, and washed thrice with saturated NaHCO₃aqueous solution. The combined organic phases were dried over MgSO₄and concentrated to dryness.

The crude residue was cromatographed on a silica gel flash system (ISCO Cornbiflash) using hexanes/TBME mixtures of increasing polarity as eluent to afford 5.23 g of the desired product (65% yield).

b) 3-Nitro-N-(tetrahydro-2H-pyran-4-yl)-6-((trimethylsilyl)ethynyl)pyridin-2-amine

Following a similar procedure to that described in example 1, section b, but using the compound obtained in previous section as starting material, the desired compound was obtained (87% yield).

c) 3-(5-Nitro-6-(tetrahydro-2H-pyran-4-ylamino)pyridin-2-yl)pyrazolo[1,5-a]pyridine-5-carbonitrile

Following a similar procedure to that described in example 1, section c, but using the compound obtained in previous section as starting material, the desired compound was obtained (16% yield).

d) 3-(5-Amino-6-(tetrahydro-2H-pyran-4-ylamino)pyridin-2-yl)pyrazolo[1,5-a]pyridine-5-carbonitrile

Following a similar procedure to that described in example 1, section d, but using the compound obtained in previous section as starting material, the desired compound was obtained (19% yield).

e) Title Compound

Following a similar procedure to that described in example 1, section e, but using the compound obtained in previous section as starting material, the desired compound was obtained (23% yield).

LC-MS (method 3): t_R=1.83 min; m/z=361 (MH⁺)

Following a similar procedure to that described in example 2, but using in each case the corresponding starting materials, the following compounds were obtained:

HPLC
t_R
m/z

Example
Name
Starting Material
method
(min)
(MH⁺)

2a
(S)-tert-butyl 3-(2-oxo-5-
(S)-3-amino-(1-tert-
3
2.47
435

(pyrazolo[1,5-a]pyridin-3-yl)-1H-
butoxycarbonyl)piperidine

imidazo[4,5-b]pyridin-3(2H)-
and 1-

yl)piperidine-1-carboxylate
aminopyridinium

iodide

2b
(R)-tert-butyl 3-(2-oxo-5-
(R)-tert-butyl 3-
3
2.27
421

(pyrazolo[1,5-a]pyridin-3-yl)-1H-
aminopyrrolidine-1-

imidazo[4,5-b]pyridin-3(2H)-
carboxylate and 1-

yl)pyrrolidine-1-carboxylate
aminopyridinium

iodide

2c
(S)-tert-butyl 3-(2-oxo-5-
(S)-tert-butyl 3-
3
2.27
421

(pyrazolo[1,5-a]pyridin-3-yl)-1H-
aminopyrrolidine-1-

imidazo[4,5-b]pyridin-3(2H)-
carboxylate and 1-

yl)pyrrolidine-1-carboxylate
aminopyridinium

iodide

2d
(S)-tert-butyl 3-(5-(5-
(S)-3-amino-(1-tert-
3
2.50
434

cyanopyrazolo[1,5-a]pyridin-3-yl)-2-
butoxycarbonyl)piperidine

oxo-1H-imidazo[4,5-b]pyridin-
and

3(2H)-yl)piperidine-1-carboxylate
1-amino-4-

cyanopyridinium 2,4,6-

trimethylbenzenesulfonate

2e
5-(pyrazolo[1,5-a]pyridin-3-yl)-3-
tetrahydro-2H-pyran-4-
3
1.80
336

(tetrahydro-2H-pyran-4-yl)-1H-
amine and 1-

imidazo[4,5-b]pyridin-2(3H)-one
aminopyridinium

iodide

2f
(R)-tert-butyl 3-(2-oxo-5-
(R)-3-amino-(1-tert-
4
2.15
435

(pyrazolo[1,5-a]pyridin-3-yl)-1H-
butoxycarbonyl)piperidine

imidazo[4,5-b]pyridin-3(2H)-
and 1-

yl)piperidine-1-carboxylate
aminopyridinium

iodide

Example 3
2-(Pyrazolo[1,5-a]pyridin-3-yl)-9-(tetrahydro-2H-pyran-4yl)-7H-purin-8(9H)-one

Following a similar procedure to that described in example 1, but using 1-aminopyridinium iodide instead of 1-amino-4-cyanopyridinium 2,4,6-trimethylbenzenesulfonate, the desired compound was obtained (84% yield).

LC-MS (method 3): t_R=1.62 min; m/z=337 (MH⁺).

Following a similar procedure to that described in example 3, but using in each case the corresponding starting materials, the following compounds were obtained:

HPLC
t_R
m/z

Example
Name
Starting Material
method
(min)
(MH⁺)

3a
2-(pyrazolo[1,5-a]pyridin-3-yl)-9-
(tetrahydro-2H-pyran-
2
1.63
351

((tetrahydro-2H-pyran-4-yl)methyl)-
4-yl)methanamine

7H-purin-8(9H)-one

3b
(S)-tert-butyl 3-(8-oxo-2-
(S)-tert-butyl-3-
2
2.33
436

(pyrazolo[1,5-a]pyridin3-yl)-7H-
aminopiperidine-1-

purin-9(8H)-yl)piperidine-1-
carboxylate

carboxylate

3c
9-(2-methoxyethyl)-2-(pyrazolo[1,5-
2-methoxyethylamine
2
1.55
311

a]pyridin-3-yl)-7H-purin-8(9H)-one

3d
9-(8-fluorochroman-4-yl)-2-
8-fluorochroman-4-
1
16.07
403

(pyrazolo[1,5-a]pyridin-3-yl)-7H-
amine

purin-8(9H)-one

3e
methyl (2S)-2-(8-oxo-2-
L-alanine methyl ester
3
1.73
339

(pyrazolo[1,5-a]pyridin-3-yl)-7,8-
hydrochloride

dihydro-9H-purin-9-yl)propanoate

3f
(S)-tert-butyl 3-(8-oxo-2-
(S)-tert-butyl 3-
3
2.13
422

(pyrazolo[1,5-a]pyridin-3-yl)-7H-
aminopyrrolidine-1-

purin-9(8H)-yl)pyrrolidine-1-
carboxylate

carboxylate

3g
tert-butyl 4-(8-oxo-2-(pyrazolo[1,5-
tert-butyl 4-
3
2.35
461

a]pyridin-3-yl)-7H-purin-9(8H)-
aminopiperidine-1-

yl)piperidine-1-carboxylate
carboxylate

3h
9-(1-methylpiperidin-4-yl)-2-
1-methylpiperidin-4-
4
1.38
350

(pyrazolo[1,5-a]pyridin-3-yl)-7H-
amine

purin-8(9H)-one

3i
5-(pyrazolo[1,5-a]pyridin-3-yl)-3-
2,2,6,6-
4
1.48
391

(2,2,6,6-tetramethylpiperidin-4-yl)-
tetramethylpiperidin-4-

1H-imidazo[4,5-b]pyridin-2(3H)-one
amine

Example 4
3-(7-Methyl-8-oxo-9-tetrahydro-2H-pyran-4-yl-8,9-dihydro-7H-purin-2-yl)pyrazolo[1,5-a]pyridine-5-carbonitrile

To a solution of example 1 (48 mg. 0.13 mmol) in DMF (6 mL), 55-65% NaH dispersion in mineral oil (7.3 mg, 0.18 mmol) was added and the resulting solution was stirred at room temperature for 10 min. Then MeI (0.015 mL, 0.25 mmol) was added and the reaction mixture was stirred for 15 h at room temperature. The reaction mixture was quenched with saturated NaCl aqueous solution (10 mL) and extracted with EtOAc (3×10 mL) and CH₂Cl₂(2×10 mL), The combined organic phases were dried over anhydrous Na₂SO₄, filtered and concentrated. The crude product thus obtained was chromatographed over silica gel using MeOH/CH₂Cl₂mixtures of increasing polarity as eluent, to afford 50 mg of the desired compound (quantitative yield).

LC-MS (method 1): t_R=15.48 min: m/z=376 (MH⁺).

Following a similar procedure to that described in example 4, but using in each case the corresponding starting materials, the following compounds were obtained:

Ex-

am-

Starting
HPLC
t_R

ple
Name
Material
method
(min)
m/z

4a
(S)-tert-butyl 3-(2-(5-
Example
2
3.22
475

cyanopyrazolo[1,5-a]pyridin-
1b

3-yl)-7-methyl-8-oxo-7H-

purin-9(8H)-yl)piperidine-1-

carboxylate

4b
(R)-tert-butyl 3-(2-(5-
Example
2
3.22
475

cyanopyrazolo[1,5-a]pyridin-
1c

3-yl)-7-methyl-8-oxo-7H-

purin-9(8H)-yl)piperidine-

1-carboxylate

4c
9-(8-fluorochroman-4-yl)-7-
Example
1
16.83
417

methyl-2-(pyrazolo[1,5-
3d

a]pyridin-3-yl)-7H-

purin-8(9H)-one

Example 5
(S)-tert-Butyl 3-(7-methyl-8-oxo-2-(pyrazolo[1,5-a]pyridine-3-yl)-7H-purin-9(8H)-yl)piperidine-1-carboxylate

To a solution of example 3b (70 mg, 0.160 mmol) in DMF (3.5 mL), at 0° C., ^tBuOK (27 mg, 0.24 mmol) and MeI (0.019 mL, 0.32 mmol) were added. The reaction mixture was stirred at room temperature for 20 min and evaporated to dryness. The crude residue was chromatographed on a silica gel flash system (ISCO Rf) using CH₂Cl₂/MeOH mixtures of increasing polarity as eluent to afford 64 mg of the desired product (89% yield).

LC-MS (method 3): t_R=2.58 min; m/z=450 (MH⁺).

Following a similar procedure to that described in example 5, but using in each case the corresponding starting materials, the following compounds were obtained:

HPLC
t_R
m/z

Example
Name
Starting Material
method
(min)
(MH⁺)

5a
7-methyl-2-(pyrazolo[1,5-a]pyridin-
example 3
2
1.83
351

3-yl)-9-(tetrahydro-2H-pyran-4-yl)-

7H-purin-8(9H)-one

5b
3-(1-methyl-2-oxo-3-(tetrahydro-2H-
example 2
2
2.62
375

pyran-4-yl)-2,3-dihydro-1H-

imidazo[4,5-b]pyridin-5-

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

5c
9-(2-methoxyethyl)-7-methyl-2-
Example 3c
2
1.77
325

(pyrazolo[1,5-a]pyridin-3-yl)-7H-

purin-8(9H)-one

5d
7-methyl-2-(pyrazolo[1,5-a]pyridin-
Example 3a
2
1.87
365

3-yl)-9-[(tetrahydro-2H-pyran-4-

yl)methyl]-7H-purin-8(9H)-one

5e
3-(9-(4,4-difluorocyclohexyl)-7-
Example 1e
2
2.32
410

methyl-8-oxo-8,9-dihydro-7H-purin-

2-yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

5f
3-(9-(1,1-dioxotetrahydrothien-3-yl)-
Example 1f
2
1.75
410

8,9-dihydro-7-methyl-8-oxopurin-2-

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile.

5g
(S)-tert-butyl 3-(5-(5-
Example 2d
2
2.54
474

cyanopyrazolo[1,5-a]pyridin-3-yl)-1-

methyl-2-oxo-1H-imidazo[4,5-

b]pyridin-3(2H)-yl)piperidine-1-

carboxylate

5h
3-(9-(2-fluorobenzyl)-7-methyl-8-
Example 1g
1
17.66
400

oxo-8,9-dihydro-7H-purin-2-

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

5i
9-(1-acetylpiperidin-4-yl)-7-methyl-
Example 1j
4
1.85
460

2-(5-(trifluoromethyl)pyrazolo[1,5-

a]pyridin-3-yl)-7H-purin-8(9H)-one

5j
(S)-tert-butyl 3-(1-methyl-2-oxo-5-
Example 2a
3
2.73
449

(pyrazolo[1,5-a]pyridin-3-yl)-1H-

imidazo[4,5-b]pyridin-3(2H)-

yl)piperidine-1-carboxylate

5k
(S)-tert-butyl 3-(2-(5-
Example 1k
3
2.52
461

cyanopyrazolo[1,5-a]pyridin-3-yl)-7-

methyl-8-oxo-7H-purin-9(8H)-

yl)pyrrolidine-1-carboxylate

5l
(R)-tert-butyl 3-(2-(5-
Example 1l
3
2.50
461

cyanopyrazolo[1,5-a]pyridin-3-yl)-7-

methyl-8-oxo-7H-purin-9(8H)-

yl)pyrrolidine-1-carboxylate

5m
(S)-tert-butyl 3-(7-methyl-8-oxo-2-
Example 3f
3
2.40
436

(pyrazolo[1,5-a]pyridin-3-yl)-7H-

purin-9(8H)-yl)pyrrolidine-1-

carboxylate

5n
(R)-tert-butyl 3-(1-methyl-2-oxo-5-
Example 2b
3
2.50
435

(pyrazolo[1,5-a]pyridin-3-yl)-1H-

imidazo[4,5-b]pyridin-3(2H)-

yl)pyrrolidine-1-carboxylate

5o
(S)-tert-butyl 3-(1-methyl-2-oxo-5-
Example 2c
5
2.98
436

(pyrazolo[1,5-a]pyridin-3-yl)-1H-

imidazo[4,5-b]pyridin-3(2H)-

yl)pyrrolidine-1-carboxylate

5p
(S)-tert-Butyl 3-(1-ethyl-2-oxo-5-
Example 2a
4
2.57
463

(pyrazolo[1,5-a]pyridin-3-yl)-1H-

imidazo[4,5-b]pyridin-3(2H)-

yl)piperidine-1-carboxylate (1)

5q
tert-butyl 4-(7-methyl-8-oxo-2-
Example 3g
3
2.68
475

(pyrazolo[1,5-a]pyridin-3-yl)-7H-

purin-9(8H)-yl)piperidine-1-

carboxylate

5r
(S)-tert-butyl 3-(7-methyl-8-oxo-2-
Example 3b
3
2.62
450

(pyrazolo[1,5-a]pyridin-3-yl)-7H-

purin-9(8H)-yl)piperidine-1-

carboxylate

5s
1-methyl-5-(pyrazolo[1,5-a]pyridin-
Example 2e
3
2.02
350

3-yl)-3-(tetrahydro-2H-pyran-4-yl)-

1H-imidazo[4,5-b]pyridin-2(3H)-one

5t
(R)-tert-butyl 3-(1-methyl-2-oxo-5-
Example 2f
3
2.73
449

(pyrazolo[1,5-a]pyridin-3-yl)-1H-

imidazo[4,5-b]pyridin-3(2H)-

yl)piperidine-1-carboxylate

5u
tert-butyl 4-(2-(5-
Example 1q
3
2.68
475

cyanopyrazolo[1,5-a]pyridin-3-yl)-7-

methyl-8-oxo-7H-purin-9(8H)-

yl)piperidine-1-carboxylate

5v
tert-butyl 3-(2-(5-
Example 1r
3
2.47
447

cyanopyrazolo[1,5-a]pyridin-3-yl)-7-

methyl-8-oxo-7H-purin-9(8H)-

yl)azetidine-1-carboxylate

(1) ethyl iodide instead of methyl iodide as starting material.

Example 6
(S)-3-(8-oxo-9-(piperidin-3-yl)-8,9-dihydro-7H-purin-2-yl)pyrazolo[1,5-a]pyridine-5-carbonitrile hydrochloride

To a solution of example 1b (45 mg, 0.10 mmol) in dioxane (3 mL), 4 M HCl solution in dioxane (2 mL, 8.0 mmol) was added. The reaction mixture was stirred at room temperature for 1 h. The reaction mixture was evaporated to dryness to give 48 mg of the desired compound (100% yield).

LC-MS (method 2): t_R=1.73 min; m/z=361 (MH⁺).

Following a similar procedure to that described in example 6, but using in each case the corresponding starting materials, the following compounds were obtained:

HPLC
t_R
m/z

Example
Compound name
Starting material
method
(min)
(MH⁺)

6a
(R)-3-(8-oxo-9-(piperidin-3-yl)-8,9-
Example 1c
2
1.73
361

dihydro-7H-purin-2-yl)pyrazolo[1,5-

a]pyridine-5-carbonitrile

hydrochloride

6b
(R)-3-(7-methyl-8-oxo-9-(piperidin-
Example 4b
2
2.05
375

3-yl)-8,9-dihydro-7H-purin-2-

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

hydrochloride

6c
(S)-3-(7-methyl-8-oxo-9-(piperidin-3-
Example 4a
2
2.05
375

yl)-8,9-dihydro-7H-purin-2-

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile hydrochloride

6d
9-(piperidin-4-yl)-2-(pyrazolo[1,5-
Example 3g
2
1.28
336

a]pyridin-3-yl)-7H-purin-8(9H)-one

6e
(S)-3-(2-oxo-3-(piperidin-3-yl)-2,3-
Example 2d
2
1.54
360

dihydro-1H-imidazo[4,5-b]pyridin-5-

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile hydrochloride

6f
(S)-3-(1-methyl-2-oxo-3-(piperidin-3-
Example 5g
2
1.68
374

yl)-2,3-dihydro-1H-imidazo[4,5-

b]pyridin-5-yl)pyrazolo[1,5-

a]pyridine-5-carbonitrile

hydrochloride

6g
(S)-1-methyl-3-(piperidin-3-yl)-5-
Example 5j
1
12.46
349

(pyrazolo[1,5-a]pyridin-3-yl)-1H-

imidazo[4,5-b]pyridin-2(3H)-one

hydrochloride

6h
(S)-3-(7-methyl-8-oxo-9-(pyrrolidin-
Example 5k
3
1.62
361

3-yl)-8,9-dihydro-7H-purin-2-

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile hydrochloride

6i
(R)-3-(7-methyl-8-oxo-9-(pyrrolidin-
Example 5l
3
1.62
361

3-yl)-8,9-dihydro-7H-purin-2-

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile hydrochloride

6j
(S)-2-(pyrazolo[1,5-a]pyridin-3-yl)-9-
Example 3f
3
1.23
322

(pyrrolidin-3-yl)-7H-purin-8(9H)-one

hydrochloride

6k
(S)-7-methyl-2-(pyrazolo[1,5-
Example 5m
3
1.48
336

a]pyridin-3-yl)-9-(pyrrolidin-3-yl)-7H-

purin-8(9H)-one hydrochloride

6l
(S)-3-(8-oxo-9-(pyrrolidin-3-yl)-8,9-
Example 1k
3
1.35
347

dihydro-7H-purin-2-yl)pyrazolo[1,5-

a]pyridine-5-carbonitrile

hydrochloride (1)

6m
(R)-1-methyl-5-(pyrazolo[1,5-
Example 5n
3
1.57
335

a]pyridin-3-yl)-3-(pyrrolidin-3-yl)-1H-

imidazo[4,5-b]pyridin-2(3H)-one

hydrochloride

6n
(R)-5-(pyrazolo[1,5-a]pyridin-3-yl)-3-
Example 2b
3
1.40
321

(pyrrolidin-3-yl)-1H-imidazo[4,5-

b]pyridin-2(3H)-one hydrochloride (1)

6o
(R)-3-(8-oxo-9-(pyrrolidin-3-yl)-8,9-
Example 1l
3
1.33
347

dihydro-7H-purin-2-yl)pyrazolo[1,5-

a]pyridine-5-carbonitrile

hydrochloride (1)

6p
(S)-2-(pyrazolo[1,5-a]pyridin-3-yl)-9-
Example 2c
3
1.40
321

(pyrrolidin-3-yl)-7H-purin-8(9H)-one

hydrochloride

6q
(S)-1-methyl-5-(pyrazolo[1,5-
Example 5o
3
1.57
335

a]pyridin-3-yl)-3-(pyrrolidin-3-yl)-1H-

imidazo[4,5-b]pyridin-2(3H)-one

hydrochloride

6r
(S)-2-(5-methylpyrazolo[1,5-
Example 1m
3
1.57
350

a]pyridin-3-yl)-9-(piperidin-3-yl)-7H-

purin-8(9H)-one hydrochloride

6s
(S)-1-ethyl-3-(piperidin-3-yl)-5-
Example 5p
4
1.56
363

(pyrazolo[1,5-a]pyridin-3-yl)-1H-

imidazo[4,5-b]pyridin-2(3H)-one

hydrochloride

6t
7-methyl-9-(piperidin-4-yl)-2-
Example 5q
4
1.23
350

(pyrazolo[1,5-a]pyridin-3-yl)-7H-

purin-8(9H)-one hydrochloride

6u
(S)-7-methyl-9-(piperidin-3-yl)-2-
Example 5r
3
1.67
350

(pyrazolo[1,5-a]pyridin-3-yl)-7H-

purin-8(9H)-one hydrochloride

6v
(S)-9-(piperidin-3-yl)-2-
Example 3b
3
1.43
336

(pyrazolo[1,5-a]pyridin-3-yl)-7H-

purin-8(9H)-one hydrochloride

6w
(R)-1-methyl-3-(piperidin-3-yl)-5-
Example 5t
3
1.77
349

(pyrazolo[1,5-a]pyridin-3-yl)-1H-

imidazo[4,5-b]pyridin-2(3H)-one

6x
(S)-3-(piperidin-3-yl)-5-
Example 2a
3
1.60
335

(pyrazolo[1,5-a]pyridin-3-yl)-1H-

imidazo[4,5-b]pyridin-2(3H)-one

hydrochloride

6y
3-(7-methyl-8-oxo-9-(piperidin-4-yl)-
Example 5u
3
1.67
375

8,9-dihydro-7H-purin-2-

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile hydrochloride

6z
(S)-3-(3-(piperidin-3-yl)-3H-
Example 18e
3
1.68
3.44

imidazo[4,5-b]pyridin-5-

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile hydrochloride

6aa
(S)-3-(2-methyl-3-(piperidin-3-yl)-
Example 18f
3
1.72
358

3H-imidazo[4,5-b]pyridin-5-

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile hydrochloride

6ab
3-(8-oxo-9-(piperidin-4-yl)-8,9-
Example 1q
1
11.13
361

dihydro-7H-purin-2-yl)pyrazolo[1,5-

a]pyridine-5-carbonitrile (1)

6ac
3-(9-(azetidin-3-yl)-7-methyl-8-oxo-
Example 5v
3
1.50
347

8,9-dihydro-7H-purin-2-

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile hydrochloride

6ad
(S)-3-(piperidin-3-yl)-5-
Example 18i
3
1.65
319

(pyrazolo[1,5-a]pyridin-3-yl)-3H-

imidazo[4,5-b]pyridine hydrochloride

6ae
(S)-2-methyl-3-(piperidin-3-yl)-5-
Example 21m
3
1.48
333

(pyrazolo[1,5-a]pyridin-3-yl)-3H-

imidazo[4,5-b]pyridine hydrochloride

(1) reaction performed with TFA/CH₂Cl₂instead of 4M HCl solution in dioxane, and washed with with saturated NaHCO₃aqueous solution.

Example 7
(S)-3-(9-(1-(2-Cyanoacetyl)piperidin-3-yl)-8-oxo-8,9-dihydro-7H-purin-2-yl)pyrazolo[1,5-a]pyridine-5-carbonitrile

To a solution of the compound obtained in example 6 (45 mg, 0.095 mmol) in anhydrous DMF (3 mL), 2,5-dioxopyrrolidin-1-yl 2-cyanoacetate (69 mg, 0.38 mmol) and anhydrous TEA (0.09 mL, 0.665 mmol) were added. The reaction mixture was stirred at room temperature for 18 h, and the solvent was concentrated off. It was quenched with saturated NaHCO₃aqueous solution (15 mL) and extracted with EtOAc (3×15 mL). The combined organic phases were dried over anhydrous Mg₂SO₄, filtered and concentrated. The crude residue was flash chromatographed on a silica gel flash system (ISCO Rf) using hexanes/acetone mixtures of increasing polarity as eluent to afford 11.7 mg of the desired compound (29% yield).

LC-MS (method 2): t_R=1.93 min; m/z=428 (MH⁺).

Following a similar procedure to that described in example 7, but using in each case the corresponding starting materials, the following compounds were obtained:

HPLC
t_R
m/z

Example
Compound name
Starting material
method
(min)
(MH⁺)

7a
(R)-3-(9-(1-(2-cyanoacetyl)piperidin-
Example 6a
2
1.93
428

3-yl)-8-oxo-8,9-dihydro-7H-purin-2-

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

7b
(R)-3-(9-(1-(2-cyanoacetyl)piperidin-
Example 6b
2
2.30
442

3-yl)-7-methyl-8-oxo-8,9-dihydro-

7H-purin-2-yl)pyrazolo[1,5-

a]pyridine-5-carbonitrile

7c
(S)-3-(9-(1-(2-cyanoacetyl)piperidin-
Example 6c
2
2.30
442

3-yl)-7-methyl-8-oxo-8,9-dihydro-

7H-purin-2-yl)pyrazolo[1,5-

a]pyridine-5-carbonitrile

7d
3-(9-(1-(2-cyanoacetyl)pyrrolidin-3-
3-(7-methyl-8-oxo-9-
2
1.68
428

yl)-7-methyl-8-oxo-8,9-dihydro-7H-
(pyrrolidin-3-yl)-8,9-

purin-2-yl)pyrazolo[1,5-a]pyridine-5-
dihydro-7H-purin-2-

carbonitrile
yl)pyrazolo[1,5-

a]pyridine-5-

carbonitrile

hydrochloride (1)

7e
3-(9-((1-(2-cyanoacetyl)piperidin-4-
3-(7-methyl-8-oxo-9-
2
1.80
456

yl)methyl)-7-methyl-8-oxo-8,9-
(piperidin-4-ylmethyl)-

dihydro-7H-purin-2-yl)pyrazolo[1,5-
8,9-dihydro-7H-purin-

a]pyridine-5-carbonitrile
2-yl)pyrazolo[1,5-

a]pyridine-5-

carbonitrile

hydrochloride (2)

7f
(S)-3-oxo-3-(3-(8-oxo-2-
Example 6v
2
2.05
403

(pyrazolo[1,5-a]pyridin-3-yl)-7H-

purin-9(8H)-yl)piperidin-1-

yl)propanenitrile

7g
(S)-3-(3-(7-methyl-8-oxo-2-
Eample 6u
2
2.58
417

(pyrazolo[1,5-a]pyridin-3-yl)-7H-

purin-9(8H)-yl)piperidin-1-yl)-3-

oxopropanenitrile

7h
(S)-3-(3-(1-(2-cyanoacetyl)piperidin-
Example 6e
2
1.64
427

3-yl)-2-oxo-2,3-dihydro-1H-

imidazo[4,5-b]pyridin-5-

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

7i
(S)-3-(3-(1-methyl-2-oxo-5-
Example 6g
5
1.95
416

(pyrazolo[1,5-a]pyridin-3-yl)-1H-

imidazo[4,5-b]pyridin-3(2H)-

yl)piperidin-1-yl)-3-oxopropanenitrile

7j
3-(9-(1-(2-cyanoacetyl)azetidin-3-
Example 6ac
2
2.10
414

yl)-7-methyl-8-oxo-8,9-dihydro-7H-

purin-2-yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

7k
(S)-3-(3-(2-(5-methylpyrazolo[1,5-
Example 6r
3
1.73
417

a]pyridin-3-yl)-8-oxo-7H-purin-

9(8H)-yl)piperidin-1-yl)-3-

oxopropanenitrile

7l
(S)-3-(3-(1-ethyl-2-oxo-5-
Example 6s
4
1.87
430

(pyrazolo[1,5-a]pyridin-3-yl)-1H-

imidazo[4,5-b]pyridin-3(2H)-

yl)piperidin-1-yl)-3-oxopropanenitrile

7m
3-oxo-3-(4-(8-oxo-2-(pyrazolo[1,5-
Example 6d
4
1.32
403

a]pyridin-3-yl)-7H-purin-9(8H)-

yl)piperidin-1-yl)propanenitrile

7n
(S)-3-(3-(1-(2-cyanoacetyl)piperidin-
Example 6f
3
2.02
441

3-yl)-1-methyl-2-oxo-2,3-dihydro-

1H-imidazo[4,5-b]pyridin-5-

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

7o
(R)-3-(3-(1-methyl-2-oxo-5-
Example 6w
4
1.71
416

(pyrazolo[1,5-a]pyridin-3-yl)-1H-

imidazo[4,5-b]pyridin-3(2H)-

yl)piperidin-1-yl)-3-oxopropanenitrile

7p
(S)-3-oxo-3-(3-(2-oxo-5-
Example 6x
3
1.75
402

(pyrazolo[1,5-a]pyridin-3-yl)-1H-

imidazo[4,5-b]pyridin-3(2H)-

yl)piperidin-1-yl)propanenitrile

7q
3-(9-(1-(2-cyanoacetyl)piperidin-4-
Example 6y
3
1.82
442

yl)-7-methyl-8-oxo-8,9-dihydro-7H-

purin-2-yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

7r
(S)-3-(3-(1-(2-cyanoacetyl)piperidin-
Example 6z
5
2.20
411

3-yl)-3H-imidazo[4,5-b]pyridin-5-

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

7s
(S)-3-(3-(1-(2-cyanoacetyl)piperidin-
Example 6aa
5
2.09
425

3-yl)-2-methyl-3H-imidazo[4,5-

b]pyridin-5-yl)pyrazolo[1,5-

a]pyridine-5-carbonitrile

7t
(S)-3-(3-(2-methyl-5-(pyrazolo[1,5-
Example 6ae
3
1.85
400

a]pyridin-3-yl)-3H-imidazo[4,5-

b]pyridin-3-yl)piperidin-1-yl)-3-

oxopropanenitrile

7u
(S)-3-oxo-3-(3-(5-(pyrazolo[1,5-
Example 6ad
3
1.77
386

a]pyridin-3-yl)-3H-imidazo[4,5-

b]pyridin-3-yl)piperidin-1-

yl)propanenitrile

(1) obtained as example 6, but using tert-butyl 3-aminopyrrolidine-1-carboxylate as starting material.

(2) obtained as example 6, but using tert-butyl 4-(aminomethyl)piperidine-1-carboxylate as starting material.

Example 8
(S)-3-(9-(1-Acetylpiperidin-3-yl)-8-oxo-8,9-dihydro-7H-purin-2-yl)pyrazolo[1,5-a]pyridine-5-carbonitrile

To a solution of the compound obtained in example 6 (31 mg, 0.063 mmol) in anhydrous DMF (3 mL), acetic anhydride (0.007 mL, 0.08 mmol) and anhydrous TEA (0.02 mL, 0,127 mmol) were added. The reaction mixture was stirred at room temperature for 18 h, and the solvent was concentrated off. It was quenched with saturated NaHCO₃aqueous solution (15 mL) and extracted with EtOAc (3×15 mL). The combined organic phases were dried over anhydrous Mg₂SO₄, filtered and concentrated. The crude residue was flash chromatographed on a silica gel flash system (ISCO Rf) using hexanes/acetone mixtures of increasing polarity as eluent to afford 14.5 mg of the desired compound (57% yield).

LC-MS (method 2): t_o=1.87 min; m/z=403 (MH⁺).

Following a similar procedure to that described in example 8, but using in each case the corresponding starting materials, the following compounds were obtained:

HPLC
t_R
m/z

Example
Compound name
Starting material
method
(min)
(MH⁺)

8a
(S)-9-(1-acetylpiperidin-3-yl)-2-
Example 6v
2
1.55
378

(pyrazolo[1,5-a]pyridin-3-yl)-7H-

purin-8(9H)-one

8b
3-(9-(1-acetylpiperidin-4-yl)-8-oxo-
Example 6ab
1
13.31
403

8,9-dihydro-7H-purin-2-

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

8c
9-(1-acetylpiperidin-4-yl)-2-
Example 6d
4
1.30
378

(pyrazolo[1,5-a]pyridin-3-yl)-7H-

purin-8(9H)-one

8d
(S)-3-(1-isobutyrylpiperidin-3-yl)-5-
Example 6x
3
2.00
405

(pyrazolo[1,5-a]pyridin-3-yl)-1H-

imidazo[4,5-b]pyridin-2(3H)-one (1)

8e
(S)-3-(9-(1-acetylpiperidin-3-yl)-7-
Example 6c
3
1.88
417

methyl-8-oxo-8,9-dihydro-7H-purin-

2-yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

8f
(S)-3-(1-acetylpiperidin-3-yl)-5-
Example 6x
3
1.72
377

(pyrazolo[1,5-a]pyridin-3-yl)-1H-

imidazo[4,5-b]pyridin-2(3H)-one

8g
3-(9-(1-acetylpiperidin-4-yl)-7-
Example 6y
3
1.78
417

methyl-8-oxo-8,9-dihydro-7H-purin-

2-yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

8h
3-(9-(1-acetylazetidin-3-yl)-7-
Example 6ac
3
1.62
389

methyl-8-oxo-8,9-dihydro-7H-purin-

2-yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

(1) using isobutyryl chloride instead of acetic anhydride as starting material.

Example 9

(S)-3-(9-(1-(Methylsulfonyl)piperidin-3-yl)-8-oxo-8,9-dihydro-7H-purin-2-yl)pyrazolo[1,5-a]pyridine-5-carbonitrile

To a solution of the compound obtained in example 6 (31 mg, 0.063 mmol) in anhydrous DMF (3 mL), methanesulphonic anhydride (13 mg, 0.08 mmol) and anhydrous TEA (0.02 mL, 0.127 mmol) were added. The reaction mixture was stirred at room temperature for 18 h, and the solvent was concentrated off. It was quenched with saturated NaHCO₃aqueous solution (15 mL) and extracted with EtOAc (3×15 mL). The combined organic phases were dried over anhydrous Mg₂SO₄, filtered and concentrated. The crude residue was chromatographed on a silica gel flash system (ISCO Rf) using hexanes/acetone mixtures of increasing polarity as eluent to afford 14.3 mg of the titled compound (52% yield).

LC-MS (method 1 PCB): t_R=2.08 min; m/z=439 (MH⁺).

Following a similar procedure to that described in example 9, but using the corresponding starting materials, the following compounds were obtained:

HPLC
t_R
m/z

Example
Compound name
Starting material
method
(min)
(MH⁺)

9a
(S)-9-(1-(methylsulfonyl)piperidin-3-
Example 6v and
2
1.70
414

yl)-2-(pyrazolo[1,5-a]pyridin-3-yl)-
methanesulphonyl

7H-purin-8(9H)-one
chloride

9b
(S)-3-(8-oxo-9-(1-
Example 6 and
5
2.48
467

(propylsulfonyl)piperidin-3-yl)-8,9-
propane-1-sulfonyl

dihydro-7H-purin-2-yl)pyrazolo[1,5-
chloride

a]pyridine-5-carbonitrile

9c
(S)-3-(8-oxo-9-(1-(2,2,2-
Example 6 and 2,2,2-
5
2.55
507

trifluoroethylsulfonyl)piperidin-3-yl)-
trifluoroethanesulfonyl

8,9-dihydro-7H-purin-2-
chloride

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

9d
(S)-3-(9-(1-
Example 6 and 2-
3
2.70
481

(isobutylsulfonyl)piperidin-3-yl)-8-
methylpropane-1-

oxo-8,9-dihydro-7H-purin-2-
sulfonyl chloride

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

9e
(S)-3-(8-oxo-9-(1-(3,3,3-
Example 6 and 3,3,3-
3
2.70
521

trifluoropropylsulfonyl)piperidin-3-
trifluoropropane-1-

yl)-8,9-dihydro-7H-purin-2-
sulfonyl chloride

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

9f
(S)-1-methyl-3-(1-
Example 6g and
4
1.81
427

(methylsulfonyl)piperidin-3-yl)-5-
methanesulphonyl

(pyrazolo[1,5-a]pyridin-3-yl)-1H-
chloride

imidazo[4,5-b]pyridin-2(3H)-one

9g
(S)-2-(5-methylpyrazolo[1,5-
Example 6r and
3
1.87
428

a]pyridin-3-yl)-9-(1-
methanesulphonyl

(methylsulfonyl)piperidin-3-yl)-7H-
chloride

purin-8(9H)-one

9h
7-(2-oxopropyl)-9-(1-(2-
Example 6d and 1-
4
1.66
448

oxopropyl)piperidin-4-yl)-2-
chloropropan-2-one

(pyrazolo[1,5-a]pyridin-3-yl)-7H-

purin-8(9H)-one

9i
9-(1-acetylpiperidin-4-yl)-7-methyl-
Example 6t and
4
1.42
392

2-(pyrazolo[1,5-a]pyridin-3-yl)-7H-
acetyl choride

purin-8(9H)-one

9j
(S)-3-(3-(1-isobutyrylpiperidin-3-yl)-
Example 6e and
5
2.52
430

2-oxo-2,3-dihydro-1H-imidazo[4,5-
isobutyryl chloride

b]pyridin-5-yl)pyrazolo[1,5-

a]pyridine-5-carbonitrile

9k
(S)-3-(3-(1-(methylsulfonyl)piperidin-
Example 6e and
3
1.92
438

3-yl)-2-oxo-2,3-dihydro-1H-
methanesulphonyl

imidazo[4,5-b]pyridin-5-
chloride

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

9l
(S)-3-(7-methyl-9-(1-
Example 6c and
3
2.05
453

(methylsulfonyl)piperidin-3-yl)-8-
methanesulphonyl

oxo-8,9-dihydro-7H-purin-2-
chloride

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

9m
(S)-3-(9-(1-(ethylsulfonyl)piperidin-
Example 6 and
3
1.90
453

3-yl)-8-oxo-8,9-dihydro-7H-purin-2-
ethylsulphonyl

yl)pyrazolo[1,5-a]pyridine-5-
chloride

carbonitrile

9n
(S)-3-(9-(1-isobutyrylpiperidin-3-yl)-
Example 6 and
3
1.95
431

8-oxo-8,9-dihydro-7H-purin-2-
isobutyryl chloride

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

9o
3-(7-methyl-9-(1-
Example 6y and
3
1.95
453

(methylsulfonyl)piperidin-4-yl)-8-
methanesulphonyl

oxo-8,9-dihydro-7H-purin-2-
chloride

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

9p
3-(9-(1-(methylsulfonyl)piperidin-4-
Example 6ab and
1
14.06
439

yl)-8-oxo-8,9-dihydro-7H-purin-2-
methanesulphonyl

yl)pyrazolo[1,5-a]pyridine-5-
chloride

carbonitrile

9q
(S)-3-(1-(methylsulfonyl)piperidin-3-
Example 6x and
3
1.85
413

yl)-5-(pyrazolo[1,5-a]pyridin-3-yl)-
methanesulphonyl

1H-imidazo[4,5-b]pyridin-2(3H)-one
chloride

9r
3-(7-methyl-9-(1-
Example 6ac and
3
2.30
425

(methylsulfonyl)azetidin-3-yl)-8-oxo-
methanesulphonyl

8,9-dihydro-7H-purin-2-
chloride

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

9s
(S)-3-(3-(1-acetylpiperidin-3-yl)-2-
Example 6e and
5
2.25
402

oxo-2,3-dihydro-1H-imidazo[4,5-
acetyl chloride

b]pyridin-5-yl)pyrazolo[1,5-

a]pyridine-5-carbonitrile

9t
(S)-3-(1-(2-methoxyacetyl)piperidin-
Example 6g and 2-
4
1.68
421

3-yl)-1-methyl-5-(pyrazolo[1,5-
methoxyacetyl

a]pyridin-3-yl)-1H-imidazo[4,5-
chloride

b]pyridin-2(3H)-one

9u
(S)-1-methyl-5-(pyrazolo[1,5-
Example 6g and
4
2.17
495

a]pyridin-3-yl)-3-(1-(2,2,2-
2,2,2-

trifluoroethylsulfonyl)piperidin-3-yl)-
trifluoroethanesulfonyl

1H-imidazo[4,5-b]pyridin-2(3H)-one
chloride

Example 10
(S)-3-(9-(1-(2-(Dimethylamino)acetyl)piperidin-3-yl)-8-oxo-8,9-dihydro-7H-purin-2-yl)pyrazolo[1,5-a]pyridine-5-carbonitrile

To a solution of N,N-dimethylglicine (10 mg, 0.095 mmol) in anhydrous DMF (2 mL). HOBt.H₂O was added. After 15 min, EDC.HCl (24 mg, 0.126 mmol) and the compound obtained in example 6 (31 mg, 0.063 mmol) were added. The reaction mixture was stirred at room temperature for 2.5 h and the solvent was concentrated off. It was quenched with saturated NaHCO₃aqueous solution (15 mL) and extracted with EtOAc (3×15 mL). The combined organic phases were dried over anhydrous Mg₂SO₄, filtered and concentrated. The crude residue was chromatographed on a silica gel flash system (ISCO Rf) using hexanes/acetone mixtures of increasing polarity as eluent to afford 8.2 mg of the titled compound (29% yield).

LC-MS (method 3): t_R=1.67 min: m/z=446 (MH⁺).

Following a similar procedure to that described in example 10, but using the corresponding starting material, the following compound was obtained:

HPLC
t_R
m/z

Example
Name
Starting Material
method
(min)
(MH⁺)

10a
(S)-3-(9-(1-(2-
Example 6 and
3
1.52
419

hydroxyacetyl)piperidin-3-yl)-8-oxo-
glicolic acid

8,9-dihydro-7H-purin-2-

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

10b
(S)-3-(9-(1-(2-hydroxy-2-
Example 6 and 2-
3
1.75
447

methylpropanoyl)piperidin-3-yl)-8-
hydroxy-2-

oxo-8,9-dihydro-7H-purin-2-
methylpropanoic

yl)pyrazolo[1,5-a]pyridine-5-
acid

carbonitrile

10c
3-(8-oxo-9-((S)-1-((S)-
Example 6 and (S)-
3
1.75
459

tetrahydrofuran-2-
tetrahydrofuran-2-

carbonyl)piperidin-3-yl)-8,9-dihydro-
carboxylic acid

7H-purin-2-yl)pyrazolo[1,5-

a]pyridine-5-carbonitrile

10d
(S)-3-(9-(1-(2-
Example 6 and 2-
3
1.65
433

methoxyacetyl)piperidin-3-yl)-8-
methoxyacetic acid

oxo-8,9-dihydro-7H-purin-2-

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

10e
(S)-3-(9-(1-(2-
Example 6 and 2-
3
2.20
459

ethylbutanoyl)piperidin-3-yl)-8-oxo-
ethylbutanoic acid

8,9-dihydro-7H-purin-2-

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

10f
(S)-3-(9-(1-(2-(3-methylisoxazol-5-
Example 6 and 2-(3-
3
1.82
484

yl)acetyl)piperidin-3-yl)-8-oxo-8,9-
methylisoxazol-5-

dihydro-7H-purin-2-yl)pyrazolo[1,5-
yl)acetic acid

a]pyridine-5-carbonitrile

10g
3-(9-((S)-1-((S)-2-
Example 6 and (S)-
5
2.23
447

methoxypropanoyl)piperidin-3-yl)-8-
2-methoxypropanoic

oxo-8,9-dihydro-7H-purin-2-
acid

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

10h
(S)-3-(8-oxo-9-(1-(3,3,3-
Example 6 and
3
1.97
471

trifluoropropanoyl)piperidin-3-yl)-
3,3,3-

8,9-dihydro-7H-purin-2-
trifluoropropanoic

yl)pyrazolo[1,5-a]pyridine-5-
acid

carbonitrile

10i
(S)-2-(5-methylpyrazolo[1,5-
Example 6r and
3
1.85
406

a]pyridin-3-yl)-9-(1-
propionic acid

propionylpiperidin-3-yl)-7H-purin-

8(9H)-one

10j
(S)-9-(1-(2-methoxyacetyl)piperidin-
Example 6r and 2-
3
1.72
422

3-yl)-2-(5-methylpyrazolo[1,5-
methoxyacetic acid

a]pyridin-3-yl)-7H-purin-8(9H)-one

10k
(S)-7-(2-methoxyacetyl)-9-(1-(2-
Example 6r and 2-
3
2.13
494

methoxyacetyl)piperidin-3-yl)-2-(5-
methoxyacetic acid

methylpyrazolo[1,5-a]pyridin-3-yl)-

7H-purin-8(9H)-one

10l
(S)-9-(1-acetylpiperidin-3-yl)-2-(5-
Example 6r and
3
1.70
392

methylpyrazolo[1,5-a]pyridin-3-yl)-
acetic acid

7H-purin-8(9H)-one

10m
(S)-9-(1-(2-hydroxyacetyl)piperidin-
Example 6r and 2-
3
1.60
408

3-yl)-2-(5-methylpyrazolo[1,5-
hydroxyacetic acid

a]pyridin-3-yl)-7H-purin-8(9H)-one

10n
(S)-3-(9-(1-
Example 6 and
3
1.88
429

(cyclopropanecarbonyl)piperidin-3-
cyclopropanecarboxylic

yl)-8-oxo-8,9-dihydro-7H-purin-2-
acid

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

10o
(S)-3-(1-(2-hydroxy-2-
Example 6g and 2-
4
1.76
435

methylpropanoyl)piperidin-3-yl)-1-
hydroxy-2-

methyl-5-(pyrazolo[1,5-a]pyridin-3-
methylpropanoic

yl)-1H-imidazo[4,5-b]pyridin-2(3H)-
acid

one

10p
(S)-3-(1-(2-hydroxyacetyl)piperidin-
Examle 6g and 2-
4
1.59
407

3-yl)-1-methyl-5-(pyrazolo[1,5-
hydroxyacetic acid

a]pyridin-3-yl)-1H-imidazo[4,5-

b]pyridin-2(3H)-one

10q
(S)-3-(1-(2-
Examle 6g and N,N-
4
1.65
434

(dimethylamino)acetyl)piperidin-3-
dimethylglicine

yl)-1-methyl-5-(pyrazolo[1,5-

a]pyridin-3-yl)-1H-imidazo[4,5-

b]pyridin-2(3H)-one

10r
1-methyl-5-(pyrazolo[1,5-a]pyridin-
Examle 6g and (S)-
4
1.76
447

3-yl)-3-((S)-1-((S)-tetrahydrofuran-
tetrahydrofuran-2-

2-carbonyl)piperidin-3-yl)-1H-
carboxylic acid

imidazo[4,5-b]pyridin-2(3H)-one

10s
(S)-1-methyl-5-(pyrazolo[1,5-
Example 6g and
4
1.99
459

a]pyridin-3-yl)-3-(1-(3,3,3-
3,3,3-

trifluoropropanoyl)piperidin-3-yl)-
trifluoropropanoic

1H-imidazo[4,5-b]pyridin-2(3H)-one
acid

Example 11
(S)-3-(2-(5-Cyanopyrazolo[1,5-a]pyridin-3-yl)-8-oxo-7H-purin-9(8H)-yl)-N,N-dimethyl piperidine-1-sulfonamide

To a solution of the compound obtained in example 6 (110 mg, 0.22 mmol) in anhydrous DMF (3 mL), N,N-dimethylsulfamoyl chloride (0.03 mL, 0.27 mmol) and anhydrous TEA (0.13 mL, 0.90 mmol) were added. The reaction mixture was stirred at room temperature for 18 h, and the solvent was concentrated off. It was quenched with saturated NaHCO₃aqueous solution (15 mL) and extracted with EtOAc (3×15 mL). The combined organic phases were dried over anhydrous Mg₂SO₄, filtered and concentrated. The crude residue was chromatographed on a silica gel flash system (ISCO Rf) using hexanes/acetone mixtures of increasing polarity as eluent to afford 39.2 mg of the titled compound (38% yield).

LC-MS (method 1): t_R=1.95 min; m/z=468 (MH⁺).

Following a similar procedure to that described in example 11, but using the corresponding starting materials, the following compound was obtained:

Starting
HPLC
tR
m/z

Example
Name
Materials
method
(min)
(MH+)

11a
(S)-N,N-dimethyl-3-
Example
4
2.05
456

(1-methyl-2-oxo-5-
6g

(pyrazolo[1,5-

a]pyridin-

3-yl)-1H-imidazo[4,5-

b]pyridin-3(2H)-

yl)piperidine-1-

sulfonamide

Example 12
3-(9-(1-Acetylpyrrolidin-3-yl)-7-methyl-8-oxo-8,9-dihydro-7H-purin-2-yl)pyrazolo[1,5-a]pyridine-5-carbonitrile
a) tert-Butyl 3-(2-(5-cyanopyrazolo[1,5-a]pyridin-3-yl)-8-oxo-TH-purin-9(8H)-yl)pyrrolidine-1-carboxylate

Following a similar procedure to that described in example 1, but using tert-butyl 3-aminopyrrolidine-1-carboxylate instead of tetrahydro-2H-pyran-4-amine, the desired compound was obtained.

b) tert-Butyl 3-(2-(5-cyanopyrazolo[1,5-a]pyridin-3-yl)-7-methyl-8-oxo-7H-purin-9(8H)-yl)pyrrolidine-1-carboxylate

Following a similar procedure to that described in example 5, but using the compound obtained in previous section as starting material, the desired compound was obtained (25% yield).

c) 3-(7-Methyl-8-oxo-9-(pyrrolidin-3-yl)-8,9-dihydro-7H-purin-yl)pyrazolo[1,5-a]pyridine-5-carbonitrile hydrochloride

Following a similar procedure to that described in example 6, but using the compound obtained in previous section as starting material, the desired compound was obtained (100% yield).

d) Title Compound

Following a similar procedure to that described in example 8, but using the compound obtained in previous section as starting material, the desired compound was obtained (22% yield).

LC-MS (method 2): t_R=1.67 min; m/z=403 (MH⁺).

Example 13
3-(7-Methyl-9-(1-(methylsulfonyl)pyrrolidin-3-yl)-8-oxo-8,9-dihydro-7H-purin-yl)pyrazolo[1,5-a]pyridine-5-carbonitrile

Following a similar procedure to that described in example 9, but using the compound obtained in example 12 section c as starting material, the desired compound was obtained (15% yield).

LC-MS (method 2): t_R=1.83 min; m/z=439 (MH⁺).

Following a similar procedure to that described in example 13, but using the corresponding starting materials, the following compounds were obtained;

HPLC
t_R
m/z

Example
Name
Starting Material
method
(min)
(MH⁺)

13a
(S)-3-(7-methyl-9-(1-
Example 6h
3
2.35
439

(methylsulfonyl)pyrrolidin-3-yl)-8-

oxo-8,9-dihydro-7H-purin-2-

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

13b
(R)-3-(7-methyl-9-(1-
Example 6i
3
2.35
439

(methylsulfonyl)pyrrolidin-3-yl)-8-

oxo-8,9-dihydro-7H-purin-2-

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

13c
(S)-9-(1-(methylsulfonyl)pyrrolidin-
Example 6j
3
1.53
400

3-yl)-2-(pyrazolo[1,5-a]pyridin-3-yl)-

7H-purin-8(9H)-one

13d
(S)-7-methyl-9-(1-
Example 6k
3
1.77
414

(methylsulfonyl)pyrrolidin-3-yl)-2-

(pyrazolo[1,5-a]pyridin-3-yl)-7H-

purin-8(9H)-one

13e
(S)-3-(9-(1-
Example 6l
3
1.63
425

(methylsulfonyl)pyrrolidin-3-yl)-8-

oxo-8,9-dihydro-7H-purin-2-

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

13f
(R)-1-methyl-3-(1-
Example 6m
3
1.90
413

(methylsulfonyl)pyrrolidin-3-yl)-5-

(pyrazolo[1,5-a]pyridin-3-yl)-1H-

imidazo[4,5-b]pyridin-2(3H)-one

13g
(R)-3-(1-(methylsulfonyl)pyrrolidin-
Example 6n
3
1.72
399

3-yl)-5-(pyrazolo[1,5-a]pyridin-3-yl)-

1H-imidazo[4,5-b]pyridin-2(3H)-one

13h
(R)-3-(9-(1-
Example 6o
3
1.62
425

(methylsulfonyl)pyrrolidin-3-yl)-8-

oxo-8,9-dihydro-7H-purin-2-

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

13i
(S)-3-(1-(methylsulfonyl)pyrrolidin-
Example 6p
3
1.72
399

3-yl)-5-(pyrazolo[1,5-a]pyridin-3-yl)-

1H-imidazo[4,5-b]pyridin-2(3H)-one

13j
(S)-1-methyl-3-(1-
Example 6q
3
1.92
413

(methylsulfonyl)pyrrolidin-3-yl)-5-

(pyrazolo[1,5-a]pyridin-3-yl)-1H-

imidazo[4,5-b]pyridin-2(3H)-one

13k
(S)-7-methyl-9-(1-
Example 6u
3
1.93
428

(methylsulfonyl)piperidin-3-yl)-2-

(pyrazolo[1,5-a]pyridin-3-yl)-7H-

purin-8(9H)-one

Example 14
(2R)-2-[2-(5-Cyanopyrazolo[1,5-a]pyridin-3-yl)-8-oxo-7,8-dihydro-9H-purin-9-yl]propanoic acid

To a suspension of example 1a (65 mg, 018 mmol) in dioxane (1.6 mL) and H₂O (0.8 mL) at 0° C., LiOH.H₂O (15 mg, 0.36 mmol) was added. The reaction mixture was stirred at 0° C. for 1 h and room temperature for 26 h. The pH of the solution was adjusted to 5 by adding 10% HCl aqueous solution. The solvent was removed under vacuum and the resulting solid was suspended in Et₂O (10 mL) and concentrated. The resulting solid was washed with water (2×5 mL), hexanes (3 mL) and Et₂O (2×5 mL) to afford 57 mg of the desired product (91%).

LC-MS (method 1): t_R=13.59 min; m/z=350 (MH⁺).

Following a similar procedure to that described in example 14, but using the corresponding starting materials, the following compounds were obtained:

Starting
HPLC
t_R
m/z

Example
Name
Material
method
(min)
(MH⁺)

14a
(2S)-2-[2-(5-
Example 1i
1
13.59
350

Cyanopyrazolo[1,5-

a]pyridin-3-yl)-8-

oxo-7,8-dihydro-

9H-purin-9-

yl]propanoic acid

14b
(S)-2-(8-oxo-2-
Example 3e
3
1.10
325

(pyrazolo[1,5-

a]pyridin-3-yl)-

7H-purin-9(8H)-

yl)propanoic acid

Example 15
(2R)-2-[2-(5-Cyanopyrazolo[1,5-a]pyridin-3-yl)-8-oxo-7,8-dihydro-9H-purin-9yl]-N-(2,2,2-trifluoroethyl)propanamide

To a solution of HOBt.H₂O (31 mg, 0.20 mmol) and TEA (0.068 mL, 0.49 mmol) in THF (1 mL), example 14 (70 mg, 0.20 mmol) was added. After 15 min, EDC.HCl (40 mg, 0.21 mmol) and 2,2,2-trifluoroethylamine hydrochloride (14.6 mg, 0.11 mmol) were added and the resulting mixture was stirred at room temperature for 3.5 days. Then, it was quenched with H₂O (5 mL) and extracted with EtOAc (3×15 mL). The combined organic phases were dried over anhydrous Na₂SO₄, filtered and concentrated. The crude product thus obtained was chromatographed over silica gel using MeOH/CH₂Cl₂mixtures of increasing polarity as eluent, to afford 18 mg of the desired compound (50% yield).

LC-MS (method 1): t_R=15.34 min; m/z=431 (MH⁺).

Following a similar procedure to that described in example 15, but using the corresponding starting material, the following compound was obtained:

HPLC
t_R
m/z

Example
Name
Starting Material
method
(min)
(MH⁺)

15a
(2R)-(2-(5-cyanopyrazolo[1,5-
Example 14 and N-
1
13.62
363

a]pyridin-3-yl)-8-oxo-7H-purin-
methylamine

9(8H)-yl)-N-methylpropanamide

15b
(2S)-2-[2-(5-cyanopyrazolo[1,5-
(2S)-2-[2-(5-
3
2.08
459

a]pyridin-3-yl)-8-oxo-7,8-dihydro-
cyanopyrazolo[1,5-

9H-purin-9-yl]-3-methyl-N-(2,2,2-
a]pyridin-3-yl)-8-oxo-

trifluoroethyl)butanamide
7,8-dihydro-9H-purin-

9-yl)-3-methylbutanoic

acid (1) and 2,2,2-

trifluoroethylamine

15c
(R)-2-(2-(5-cyanopyrazolo[1,5-
Example 14 and 2-
3
1.35
393

a]pyridin-3-yl)-8-oxo-7H-purin-
aminoethanol

9(8H)-yl)-N-(2-

hydroxyethyl)propanamide

15d
(R)-2-(2-(5-cyanopyrazolo[1,5-
Example 14 and
3
1.75
403

a]pyridin-3-yl)-8-oxo-7H-purin-
cyclopropylmethanamine

9(8H)-yl)-N-

(cyclopropylmethyl)propanamide

15e
(R)-2-(2-(5-cyanopyrazolo[1,5-
Example 14 and
3
1.48
420

a]pyridin-3-yl)-8-oxo-7H-purin-
N1,N1-

9(8H)-yl)-N-(2-
dimethylethane-1,2-

(dimethylamino)ethyl)propanamide
diamine

15f
(R)-2-(2-(5-cyanopyrazolo[1,5-
Example 14 and N-
3
1.57
377

a]pyridin-3-yl)-8-oxo-7H-purin-
ethylamine

9(8H)-yl)-N-ethylpropanamide

15g
(R)-2-(2-(5-cyanopyrazolo[1,5-
Example 14 and N-
3
1.70
391

a]pyridin-3-yl)-8-oxo-7H-purin-
isopropylamine

9(8H)-yl)-N-isopropylpropanamide

15h
(R)-2-(2-(5-cyanopyrazolo[1,5-
Example 14 and N,N-
3
1.53
377

a]pyridin-3-yl)-8-oxo-7H-purin-
dimethylamine

9(8H)-yl)-N,N-dimethylpropanamide

15i
(S)-2-(2-(5-cyanopyrazolo[1,5-
Example 14a and
3
1.72
431

a]pyridin-3-yl)-8-oxo-7H-purin-
2,2,2-

9(8H)-yl)-N-(2,2,2-
trifluoroethylamine

trifluoroethyl)propanamide

15j
(S)-N-methyl-2-(8-oxo-2-
Example 14b and N-
3
1.35
338

(pyrazolo[1,5-a]pyridin-3-yl)-7H-
methylamine

purin-9(8H)-yl)propanamide

15k
(S)-N,N-dimethyl-2-(8-oxo-2-
Example 14b and N,N-
5
1.90
352

(pyrazolo[1,5-a]pyridin-3-yl)-7H-
dimethylamine

purin-9(8H)-yl)propanamide

(1) Obtained as example 14 but using HCl/Dioxane 4M/H₂O (1:1) instead of LiOH•H2O, and L-Valine methyl ester hydrochloride as starting material.

Example 16
3-(7-(2-Methoxyethyl)-8-oxo-9-(tetrahydro-2H-pyran-4-yl)-8,9-dihydro-7H-purin-2-yl)pyrazolo[1,5-a]pyridine-5-carbonitrile

To a solution of example 1 (50 mg, 0.14 mmol) in DMF (8 mL), 55-65% NaH dispersion in mineral oil (6 mg, 0.15 mmol) was added and the resulting solution was stirred at room temperature for 10 min. Then 2-bromoethyl methyl ether (0.032 mL, 0.34 mmol) was added and the reaction mixture was stirred at 50° C. for 14.5 h. The reaction mixture was quenched with H₂O (10 mL) and extracted with EtOAc (3×10 mL). The combined organic phases were dried over anhydrous Na₂SO₄, filtered and concentrated. The crude product thus obtained was chromatographed over silica gel using EtOAc/hexanes mixtures of increasing polarity as eluent, to afford 36 mg of the desired compound (62% yield).

LC-MS (method 1): t_R=16.17 min; m/z=420 (MH⁺).

Following a similar procedure to that described in example 16, but using in each case the corresponding starting materials, the following compounds were obtained:

HPLC
t_R
m/z

Example
Name
Starting Material
method
(min)
(MH⁺)

16a
(S)-3-(9-(1-(2-
2-bromo-N,N-
2
1.95
499

cyanoacetyl)piperidin-3-yl)-7-(2-
dimethylethanamine

(dimethylamino)ethyl)-8-oxo-8,9-
and example 1b (1)

dihydro-7H-purin-2-yl)pyrazolo[1,5-

a]pyridine-5-carbonitrile

16b
(S)-3-(7-(2-(dimethylamino)ethyl)-8-
2-bromo-N,N-
2
1.83
432

oxo-9-(piperidin-3-yl)-8,9-dihydro-
dimethylethanamine

7H-purin-2-yl)pyrazolo[1,5-
and example 1b (2)

a]pyridine-5-carbonitrile

16c
7-(2-(dimethylamino)ethyl)-2-
2-bromo-N,N-
2
1.921
408

(pyrazolo[1,5-a]pyridin-3-yl)-9-
dimethylethanamine

(tetrahydro-2H-pyran-4-yl)-7H-
and example 3

purin-8(9H)-one)

16d
3-(7-(2-(dimethylamino)ethyl)-8-
2-bromo-N,N-
1
14.79
433

oxo-9-(tetrahydro-2H-pyran-4-yl)-
dimethylethanamine

8,9-dihydro-7H-purin-2-
and example 1

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

16e
3-(7-(2-(dimethylamino)ethyl)-9-(8-
2-bromo-N,N-
4
2.12
499

fluorochroman-4-yl)-8-oxo-8,9-
dimethylethanamine

dihydro-7H-purin-2-yl)pyrazolo[1,5-
and example 1p

a]pyridine-5-carbonitrile

16f
3-(9-(8-fluorochroman-4-yl)-7-(2-
2-bromoethyl methyl
4
2.20
486

methoxyethyl)-8-oxo-8,9-dihydro-
ether and example

7H-purin-2-yl)pyrazolo[1,5-
1p

a]pyridine-5-carbonitrile

16g
3-(9-(8-fluxrochroman-4-yl)-7-(3-
3-bromopropan-1-ol
4
1.96
486

hydroxypropyl)-8-oxo-8,9-dihydro-
and example 1p

7H-purin-2-yl)pyrazolo[1,5-

a]pyridine-5-carbonitrile

16h
(S)-3-(3-(1-(2-
2-bromo-N,N-
4
1.73
473

(dimethylamino)ethyl)-2-oxo-5-
dimethylethanamine

(pyrazolo[1,5-a]pyridin-3-yl)-1H-
and example 2a (1)

imidazo[4,5-b]pyridin-3(2H)-

yl)piperidin-1-yl)-3-

oxopropanenitrile

16i
(S)-3-(3-(1-(2-methoxyethyl)-2-oxo-
2-bromoethyl methyl
4
1.82
460

5-(pyrazolo[1,5-a]pyridin-3-yl)-1H-
ether and example

imidazo[4,5-b]pyridin-3(2H)-
2a (1)

yl)piperidin-1-yl)-3-

oxopropanenitrile

16j
(S)-3-(3-(1-(cyclopropylmethyl)-2-
(bromomethyl)cyclo
4
2.08
456

oxo-5-(pyrazolo[1,5-a]pyridin-3-yl)-
propane and

1H-imidazo[4,5-b]pyridin-3(2H)-
example 2a (1)

yl)piperidin-1-yl)-3-

oxopropanenitrile

(1) followew by a similar procedure to that described in example 6 (tert-butoxtcarbonyl cleavage) and 7 (amide formation).

(2) followew by tert-butoxycarbonyl cleavage as example 6

Example 17
3-(7-(2-Hydroxyethyl)-8-oxo-9-(tetrahydro-2H-pyran-4-yl)-8,9-dihydro-7H-purin-2-yl)pyrazolo[1,5-a]pyridine-5-carbonitrile
a) 3-(7-(2-(tert-Butyldimethylsilyloxy)ethyl)-8-oxo-9-(tetrahydro-2H-pyran-4-yl)-8,9-dihydro-7H-purin-2-yl)pyrazolo[1,5-a]pyridine-5-carbonitrile

To a solution of example 1 (50 mg, 0.14 mmol) in DMF (8 mL), 55-65% NaH dispersion in mineral oil (6 mg, 0.15 mmol) was added. The resulting solution was stirred at room temperature for 10 min. Then (2-bromoethoxy)-tert-butyldimethylsilane (0.074 mL, 0.34 mmol) was added and the reaction was stirred at 50° C. for 14.5 h. The reaction mixture was quenched with H₂O (10 mL) and extracted with EtOAc (3×10 mL). The combined organic phases were dried over anhydrous Na₂SO₄, filtered and concentrated. The crude product thus obtained was chromatographed over silica gel using hexanes/EtOAc mixtures of increasing polarity as eluent, to afford 55 mg of the desired compound (76% yield).

b) Title Compound

To a solution of the compound obtained in the previous section (55 mg, 0.10 mmol) in THF (5 mL) 1 M TBAF solution in THF (0.14 mL, 0.14 mmol) was added and the resulting solution was stirred at room temperature for 1 h. The reaction mixture was quenched with H₂O (10 mL) and extracted with EtOAc (3×10 mL) and CH₂Cl₂(2×10 mL). The combined organic phases were dried over anhydrous Na₂SO₄, filtered and concentrated. The crude product thus obtained was chromatographed over silica gel using MeOH/EtOAc mixtures of increasing polarity as eluent, to afford 39 mg of the desired compound (91% yield).

LC-MS (method 1): t_R=14.13 min: m/z=406 (MH⁺).

Following a similar procedure to that described in example 17, but using in each case the corresponding starting materials, the following compounds were obtained:

HPLC
t_R
m/z

Example
Name
Starting Material
method
(min)
(MH⁺)

17a
(S)-3-(9-(1-(2-
Example 1b (1)
1
1.68
472

cyanoacetyl)piperidin-3-yl)-7-(2-

hydroxyethyl)-8-oxo-8,9-dihydro-

7H-purin-2-yl)pyrazolo[1,5-

a]pyridine-5-carbonitrile

17b
(S)-3-(7-(2-hydroxyethyl)-8-oxo-9-
Example 1b (2)
1
1.55
405

(piperidin-3-yl)-8,9-dihydro-7H-

purin-2-yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile hydrochloride

17c
3-(9-(8-fluorochroman-4-yl)-7-(2-
Example 1p
1
15.99
472

hydroxyethyl)-8-oxo-8,9-dihydro-

7H-purin-2-yl)pyrazolo[1,5-

a]pyridine-5-carbonitrile

(1) Followed by a similar procedure to that described in example 6 (tert-butoxtcarbonyl cleavage) and 7 (amide formation).

(2) Followed by tert-butoxycarbonyl cleavage as example 6

Example 18
3-(9-Tetrahydro-2H-pyran-4-yl-9H-purin-211)pyrazolo[1,5-a]pyridine-5-carbonitrile

To a suspension of the compound obtained in example 1 section d (100 mg, 0.30 mmol) in EtOH (1 mL), PTSA monohydrate (5.7 mg, 0.03 mmol) and triethylorthoformate (1 mL) were added. The reaction mixture was heated in a OEM Explorer microwave oven at 123° C. and 270 W for 30 min. Then, it was evaporated to dryness. The crude product thus obtained was chromatographed over silica gel using MeOH/EtOAc mixtures of increasing polarity as eluent, to afford 81 mg of the desired compound (79% yield).

LC-MS (method 1): t_R=14.56 min; m/z=346 (MH⁺).

Following a similar procedure to that described in example 18, but using in each case the corresponding starting materials, the following compounds were obtained:

HPLC
t_R
m/z

Example
Name
Starting Material
method
(min)
(MH⁺)

18a
3-(8-methyl-9-tetrahydro-2H-pyran-
Example 1 section d
1
14.77
360

4-yl-9H-purin-2-yl)pyrazolo[1,5-
and

a]pyridine-5-carbonitrile
triethylorthoacetate

18b
3-(9-(4,4-difluorocyclohexyl)-8-
triethylorthoacetate
2
2.17
394

methyl-9H-purin-2-yl)pyrazolo[1,5-
and 3-(5-amino-4-(4,4-

a]pyridine-5-carbonitrile
difluorocyclohexylamino)pyrimidin-

2-

yl)pyrazolo[1,5-

a]pyridine-5-

carbonitrile (1)

18c
3-(9-(1,1-dioxotetrahydrothien-3-yl)-
triethylorthoacetate
2
1.65
394

8-methyl-9H-purin-2-
and 3-(5-amino-4-(1,1-

yl)pyrazolo[1,5-a]pyridine-5-
dioxotetrahydrothien-

carbonitrile
3-yl)aminopyrimidin-2-

yl)pyrazolo[1,5-

a]pyridine-5-

carbonitrile (2)

18d
5-(pyrazolo[1,5-a]pyridin-3-yl)-3-
Reference example 2g
3
1.85
320

(tetrahydro-2H-pyran-4-yl)-3H-
and

imidazo[4,5-b]pyridine
triethylorthoformate

18e
(S)-tert-butyl 3-(5-(5-
Reference example 2h
3
2.33
444

cyanopyrazolo[1,5-a]pyridin-3-yl)-
and

3H-imidazo[4,5-b]pyridin-3-
triethylorthoformate

yl)piperidine-1-carboxylate

18f
(S)-tert-butyl 3-(5-(5-
Reference example 2h
3
2.57
458

cyanopyrazolo[1,5-a]pyridin-3-yl)-2-
and

methyl-3H-imidazo[4,5-b]pyridin-3-
triethylorthoacetate

yl)piperidine-1-carboxylate

18g
2-methyl-5-(pyrazolo[1,5-a]pyridin-
Reference example 2g
3
1.92
334

3-yl)-3-(tetrahydro-2H-pyran-4-yl)-
and

3H-imidazo[4,5-b]pyridine
triethylorthoacetate

18h
3-(9-(trans-4-hydroxycyclohexyl)-8-
Reference example 2j
3
1.70
374

methyl-9H-purin-2-yl)pyrazolo[1,5-
and

a]pyridine-5-carbonitrile
triethylorthoacetate

18i
(S)-tert-butyl 3-(5-(pyrazolo[1,5-
Reference example 2d
3
1.77
386

a]pyridin-3-yl)-3H-imidazo[4,5-
and

b]pyridin-3-yl)piperidine-1-
triethylorthoformate

carboxylate

(1) obtained in example 1e section d

(2) obtained in example 1f section d

Example 19
3-(3-(Tetrahydro-2H-pyran-4-yl)-3H-imidazo[4,5-b]pyridin-5-yl)pyrazolo[1,5-a]pyridine-5-carbonitrile

To a suspension of the compound obtained in example 2 section d (33.6 mg, 0.1 mmol) in EtOH (1.5 mL), citric acid (2 mg, 0.1 mmol) and triethyl orthoformate (340 μL, 2 mmol) were added. The reaction mixture was heated in a CEM Explorer microwave oven at 145° C. and 270 W for 2.5 hours. The crude residue was cromatographed on a silica gel flash system (ISCO Rf) using hexanes/acetone mixtures of increasing polarity as eluent to afford 14.2 mg of the desired product (41% yield).

LC-MS (method 3): t_R=1.76 min; m/z=345 (MH⁺).

Following a similar procedure to that described in example 19, but using the corresponding starting material, the following compound was obtained:

Starting
HPLC
t_R
m/z

Example
Name
Material
method
(min)
(MH⁺)

19a
(S)-3-(3-(1-
Reference
5
2.22
386

acetylpiperidin-3-yl)-
example

3H-imidazo[4,5-
2f

b]pyridin-5-

yl)pyrazolo[1,5-

a]pyridine-5-

carbonitrile

Example 20
3-(2-Methyl-3-(tetrahydro-2H-pyran-4-yl)-3H-imidazo[4,5-b]pyridin-5-yl)pyrazolo[1,5-a]pyridine-5-carbonitrile

To a solution of the compound obtained in example 2 section d (56.4 mg, 0,169 mmol) in EtOH (1.5 mL), PTSA monohydrate (3.21 mg, 0.017 mmol) and triethyl orthoacetate (547 mg, 3.37 mmol) were added. The reaction mixture was heated in a OEM Explorer microwave oven at 145° C. and 270 W for 2.5 hours. The crude residue was cromatographed on a silica gel flash system (ISCO Rf) using CH₂Cl₂/MeOH mixtures of increasing polarity a eluent to afford the desired product (15% yield).

LC-MS (method 3): t_R=1.79 min; m/z=359.5 (MH⁺).

Example 21
3-(8-(1-Methyl-1H-imidazol-2-yl)-9-(tetrahydro-2H-pyran-4-yl)-9H-purin-2-yl)pyrazolo[1,5-a]pyridine-5-carbonitrile

To a solution of the compound obtained in example 1 section d (100 mg, 0.30 mmol) in AcOH (0.025 mL) and DMA (2.5 mL), 1-methyl-1H-imidazole-2-carbaldehyde (46 mg, 0.42 mmol) was added. The reaction mixture was stirred in a sealed tube at 140 c′C for 19 h. The crude mixture was quenched with H₂O (10 mL), extracted with EtOAc (3×10 mL) and the combined organic phases were dried over anhydrous Na₂SO₄, filtered and concentrated. The crude product thus obtained was chromatographed over silica gel using hexanes/EtOAc mixtures of increasing polarity as eluent, to afford 40 mg of the desired compound (31% yield).

LC-MS (method 1): t_R=16.436 min; m/z=426 (MH⁺).

Following a similar procedure to that described in example 21, but using the corresponding starting material, the following compound was obtained:

HPLC
t_R
m/z

Example
Name
Starting Material
method
(min)
(MH⁺)

21a
3-(8-(pyrimidin-5-yl)-9-(tetrahydro-
Example 1 section d
4
1.67
424

2H-pyran-4-yl)-9H-purin-2-
and pyrimidine-5-

yl)pyrazolo[1,5-a]pyridine-5-
carbaldehyde

carbonitrile

21b
3-(9-(8-fluorochroman-4-yl)-8-
Reference example
1
16.34
490

(pyrimidin-5-yl)-9H-purin-2-
2e and pyrimidine-5-

yl)pyrazolo[1,5-a]pyridine-5-
carbaldehyde

carbonitrile

21c
3-(9-(8-fluorochroman-4-yl)-8-(1-
Reference example
1
18.4
492

methyl-1H-imidazol-2-yl)-9H-purin-
2e and 1-methyl-1H-

2-yl)pyrazolo[1,5-a]pyridine-5-
imidazole-2-

carbonitrile
carbaldehyde

21d
2-(pyrazolo[1,5-a]pyridin-3-yl)-8-
Reference example
3
2.15
386

(1H-pyrrol-2-yl)-9-(tetrahydro-2H-
2c and 1H-pyrrole-2-

pyran-4-yl)-9H-purine
carbaldehyde

21e
8-(5-methylthiophen-2-yl)-2-
Reference example
3
2.52
417

(pyrazolo[1,5-a]pyridin-3-yl)-9-
2c and 5-

(tetrahydro-2H-pyran-4-yl)-9H-
methylthiophene-2-

purine
carbaldehyde

21f
8-(1-methyl-1H-imidazol-2-yl)-2-
Reference example
3
2.05
401

(pyrazolo[1,5-a]pyridin-3-yl)-9-
2c and 1-methyl-1H-

(tetrahydro-2H-pyran-4-yl)-9H-
imidazole-2-

purine
carbaldehyde

21g
2-(pyrazolo[1,5-a]pyridin-3-yl)-9-
Reference example
3
2.22
403

(tetrahydro-2H-pyran-4-yl)-8-(2,2,2-
2c and 3,3,3-

trifluoroethyl)-9H-purine
trifluoropropanal

21h
8-(1H-pyrazol-3-yl)-2-(pyrazolo[1,5-
Reference example
3
1.83
387

a]pyridin-3-yl)-9-(tetrahydro-2H-
2c and 1H-pyrazole-

pyran-4-yl)-9H-purine
3-carbaldehyde

21i
8-(1-methyl-1H-pyrrol-2-yl)-2-
Reference example
3
2.33
400

(pyrazolo[1,5-a]pyridin-3-yl)-9-
2c and 1-methyl-1H-

(tetrahydro-2H-pyran-4-yl)-9H-
pyrrole-2-

purine
carbaldehyde

21j
2-(2-(pyrazolo[1,5-a]pyridin-3-yl)-9-
Reference example
3
2.43
404

(tetrahydro-2H-pyran-4-yl)-9H-
2c and thiazole-2-

purin-8-yl)thiazole
carbaldehyde

21k
2-(pyrazolo[1,5-a]pyridin-3-yl)-9-
Reference example
3
2.32
403

(tetrahydro-2H-pyran-4-yl)-8-
2c and thiophene-2-

(thiophen-2-yl)-9H-purine
carbaldehyde

21l
(S)-3-(9-(1-acetylpiperidin-3-yl)-8-
Reference example
3
1.8
465

(pyrimidin-5-yl)-9H-purin-2-
2 and pyrimidine-5-

yl)pyrazolo[1,5-a]pyridine-5-
carbaldehyde

carbonitrile

21m
(S)-tert-butyl 3-(2-methyl-5-
Reference example
3
2.60
433

(pyrazolo[1,5-a]pyridin-3-yl)-3H-
2d and

imidazo[4,5-b]pyridin-3-
acetaldehydee

yl)piperidine-1-carboxylate

Example 22
3-[8-(Ethylamino)-9-tetrahydro-2H-pyran-4-yl-9H-purin-2-yl]pyrazolo[1,5-a]pyridine-5-carbonitrile

To a suspension of the compound obtained in example 1 section d (100 mg, 0.30 mmol) in CH₂Cl₂(2 mL), ethyl isothiocyanate (0.042 ml, 0.48 mmol), EDC.HCl (171 mg, 0.89 mmol) and DIPEA (0.25 ml, 1.49 mmol) were added. The reaction mixture was heated in a CEM Explorer microwave oven at 80° C. and 150 W for 30 min. Then, it was evaporated to dryness. The crude product thus obtained was chromatographed over silica gel using MeOH/EtOAc mixtures of increasing polarity as eluent, to afford 42 mg of the desired compound (36% yield).

LC-MS (method 1): t_R=15.64 min; m/z=389 (MH⁺).

Following a similar procedure to that described in example 22, but using the corresponding starting material, the following compound was obtained:

HPLC
t_R
m/z

Example
Name
Starting Material
method
(min)
(MH⁺)

22a
3-(8-(pyridin-3-ylamino)-9-
Example 1 section
1
16.20
438

(tetrahydro-2H-pyran-4-yl)-9H-
d, pyridine-3-

purin-2-yl)pyrazolo[1,5-a]pyridine-5-
isothiocyanate

carbonitrile

22b
3-(8-(ethylamino)-9-(8-
Reference example
1
17.07
455

fluorochroman-4-yl)-9H-purin-2-
2e and ethyl

yl)pyrazolo[1,5-a]pyridine-5-
isothiocyanate

carbonitrile

22c
3-(9-(8-fluorochroman-4-yl)-8-
Reference example
1
17.22
504

(pyridin-3-ylamino)-9H-purin-2-
2e and pyridine-3-

yl)pyrazolo[1,5-a]pyridine-5-
isothiocyanate

carbonitrile

Example 23
8-Cyclopentyl-2-(pyrazolo[1,5-a]pyridin-3-yl)-9-(tetrahydro-2H-pyran-4-yl)-9H-purine

To a solution of reference example 2c (0.05 g, 0.16 mmol) in DMF (1 mL), cyclopentanecarbaldehyde (0.018 mL, 0.17 mmol) and sodium bisulfite (0.030 g, 0.29 mmol) were added. The reaction mixture was stirred at 130° C. for 6 h. The solvent was concentrated off and the crude residue was cromatographed on a silica gel flash system (ISCO Companion) using CH₂Cl₂/MeOH mixtures of increasing polarity as eluent to afford 37 mg of the desired product (60% yield).

LC-MS (method 3): =2.40 min; m/z=389 (MH⁺).

Following a similar procedure to that described in example 23, but using in each case the corresponding starting materials, the following compounds were obtained:

HPLC
t_R
m/z

Example
Name
Starting Material
method
(min)
(MH⁺)

23a
(S)-3-(9-(1-acetylpiperidin-3-yl)-8-
Reference example 2
5
2.42
415

ethyl-9H-purin-2-yl)pyrazolo[1,5-
and propionaldehyde

a]pyridine-5-carbonitrile

23b
(S)-3-(9-(1-acetylpiperidin-3-yl)-8-
Reference example 2
5
2.57
429

isopropyl-9H-purin-2-
and isobutyraldehyde

yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

23c
(S)-3-(9-(1-acetylpiperidin-3-yl)-8-
Reference example 2
3
1.78
401

methyl-9H-purin-2-yl)pyrazolo[1,5-
and acetaldehyde

a]pyridine-5-carbonitrile

23d
8-cyclopropyl-2-(pyrazolo[1,5-
Reference example 2c
3
2.05
361

a]pyridin-3-yl)-9-(tetrahydro-2H-
and

pyran-4-yl)-9H-purine
cyclopropanecarbaldehyde

Example 24
(S)-3-(1-Acetylpiperidin-3-yl)-1-methyl-5-(pyrazolo[1,5-a]pyridin-3-yl)-1H-imidazo[4,5-b]pyridin-2(3H-one

To a solution of example 6g (250 mg, 0.65 mmol) in pyridine (10 mL), acetyl chloride (0.92 mL, 1.3 mmol) was added. The reaction mixture was stirred at room temperature for 5 h. The solvent was concentrated off and the crude residue was cromatographed on a silica gel flash system (SP1 Biotage) using EtOAc/MeOH mixtures of increasing polarity as eluent to afford 196 mg of the desired product (78% yield).

LC-MS (method 4): t_R=1.66 min; m/z=391 (MH⁺).

Following a similar procedure to that described in example 24, but using in each case the corresponding starting materials, the following compounds were obtained:

HPLC
t_R
m/z

Example
Name
Starting Material
method
(min)
(MH⁺)

24a
(S)-1-methyl-3-(1-pivaloylpiperidin-
Example 6g and
4
2.10
433

3-yl)-5-(pyrazolo[1,5-a]pyridin-3-yl)-
pivaloyl chloride

1H-imidazo[4,5-b]pyridin-2(3H)-one

24b
(S)-3-(1-(4-fluorobenzoyl)piperidin-
Example 6g and 4-
4
2.11
472

3-yl)-1-methyl-5-(pyrazolo[1,5-
fluorobenzoyl chloride

a]pyridin-3-yl)-1H-imidazo[4,5-

b]pyridin-2(3H)-one

24c
(S)-1-methyl-3-(1-
Example 6g and
4
1.79
405

propionylpiperidin-3-yl)-5-
propionyl chloride

(pyrazolo[1,5-a]pyridin-3-yl)-1H-

imidazo[4,5-b]pyridin-2(3H)-one

Example 25
(S)-1-(3-(1-Methyl-2-oxo-5-(pyrazolo[1,5-a]pyridin-3-yl)-1H-imidazo[4,5-b]pyridin-3(21-1)-yl)piperidine-1-carbonyl)cyclopropanecarbonitrile

To a solution of 1-cyano-1-cyclopropanecarboxylic acid (65 mg, 0.58 mmol), in DMF (7 mL), DIEA (0.31 mL, 1.7 mmol), example 6g (248 mg, 0.64 mmol) and HBTU (266 mg, 0.70 mmol) were added. The reaction mixture was stirred at room temperature overnight. The solvent was concentrated off and the crude residue was cromatographed on a silica gel flash system (SP1 Biotage) using EtOAc/MeOH mixtures of increasing polarity as eluent to afford the desired with quantitative yield.

LC-MS (method 4): t_R=1.92 min; m/z=442 (MH⁺).

Following a similar procedure to that described in example 25, but using in each case the corresponding staffing materials, the following compounds were obtained:

HPLC
t_R
m/z

Example
Name
Starting Materials
method
(min)
(MH⁺)

25a
9-(1-isobutyrylpiperidin-4-yl)-2-
Example 6d and
4
1.59
406

(pyrazolo[1,5-a]pyridin-3-yl)-7H-
isobutyric acid

purin-8(9H)-one

25b
9-(1-(2-
Example 6d and 2-
4
1.34
421

(dimethylamino)acetyl)piperidin-4-
(dimethylamino)acetic

yl)-2-(pyrazolo[1,5-a]pyridin-3-yl)-
acid

7H-purin-8(9H)-one

Example 26
(S)-Methyl 3-(2-(5-cyanopyrazolo[1,5-a]pyridin-311)-8-oxo-7H-purin-9(8H)-yl)piperidine-1-carboxylate

To a solution of example 6 (200 mg, 0.26 mmol) in DMF (2.6 mL), methyl chloroformate (27 mg, 0.28 mmol) and DIPEA (0.068 mL, 0.39 mmol) were added. The reaction mixture was stirred at room temperature overnight. The reaction mixture was evaporated under reduced pressure, dissolved in CH₂Cl₂, and washed thrice with saturated NaHCO₃aqueous solution. The combined organic phases were dried over MgSO₄and concentrated to dryness. The crude residue was cromatographed on a silica gel flash system (ISCO Combiflash) using CH₂Cl₂/MeOH mixtures of increasing polarity as eluent to afford 36 mg of the desired product (32% yield).

LC-MS (method 5): t_R=2.37 min; m/z=419 (MH⁺).

Following a similar procedure to that described in example 26, but using in each case the corresponding starting materials, the following compounds were obtained:

HPLC
t_R
m/z

Example
Name
Starting Materials
method
(min)
(MH⁺)

26a
(S)-ethyl 3-(2-(5-cyanopyrazolo[1,5-
Example 6 and ethyl
5
2.53
433

a]pyridin-3-yl)-8-oxo-7H-purin-
chloroformate

9(8H)-yl)piperidine-1-carboxylate

26b
(S)-isobutyl 3-(2-(5-
Example 6 and
5
2.82
461

cyanopyrazolo[1,5-a]pyridin-3-yl)-8-
isobutyl chloroformate

oxo-7H-purin-9(8H)-yl)piperidine-1-

carboxylate

26c
(S)-3-(2-(5-cyanopyrazolo[1,5-
Example 6 and
5
2.33
446

a]pyridin-3-yl)-8-oxo-7H-purin-
isopropyl isocyanate

9(8H)-yl)-N-isopropylpiperidine-1-

carboxamide

26d
(S)—N-tert-butyl-3-(2-(5-
Example 6 and tert-
5
2.52

460°

cyanopyrazolo[1,5-a]pyridin-3-yl)-8-
butyl isocyanate

oxo-7H-purin-9(8H)-yl)piperidine-1-

carboxamide

26e
(S)-ethyl 9-(1-(2-
Example 7f and ethyl
5
2.62
475

cyanoacetyl)piperidin-3-yl)-8-oxo-2-
chloroformate

(pyrazolo[1,5-a]pyridin-3-yl)-8,9-

dihydro-7H-purine-7-carboxylate

26f
(S)-3-(3-(7-acetyl-8-oxo-2-
Example 7f and acetyl
5
2.60
445

(pyrazolo[1,5-a]pyridin-3-yl)-7H-
chloride

purin-9(8H)-yl)piperidin-1-yl)-3-

oxopropanenitrile

26g
(S)-9-(1-acetylpiperidin-3-yl)-7-
Example 6u and acetyl
3
1.80
392

methyl-2-(pyrazolo[1,5-a]pyridin-3-
chloride

yl)-7H-purin-8(9H)-one

26h
(S)—N-isopropyl-3-(1-methyl-2-oxo-
Example 7p and
4
1.85
434

5-(pyrazolo[1,5-a]pyridin-3-yl)-1H-
isopropyl isocyanate

imidazo[4,5-b]pyridin-3(2H)-

yl)piperidine-1-carboxamide

26i
(S)-3-(3-(1-acetyl-2-oxo-5-
Example 7p and acetyl
4
2.01
444

(pyrazolo[1,5-a]pyridin-3-yl)-1H-
chloride

imidazo[4,5-b]pyridin-3(2H)-

yl)piperidin-1-yl)-3-

oxopropanenitrile

26j
(S)-ethyl 3-(1-(2-
Example 7p and ethyl
4
1.97
474

cyanoacetyl)piperidin-3-yl)-2-oxo-5-
chloroformate

(pyrazolo[1,5-a]pyridin-3-yl)-2,3-

dihydro-1H-imidazo[4,5-b]pyridine-

1-carboxylate

Example 27
(S)-3-(9-(1-(1-Cyanocyclopropanecarbonyl)piperidin-3-yl)-8-oxo-8,9-dihydro-7H-purin-2-yl)pyrazolo[1,5-a]pyridine-5-carbonitrile

Following a similar procedure to that described in example 25, but using HATU instead of HBTU, and example 6 instead of example 6g, the desired compound was obtained (30% yield).

LC-MS (method 3): t_R=1.87 min; m/z=454 (MH⁺).

Following a similar procedure to that described in example 27, but using the corresponding starting materials, the following compound was obtained:

HPLC
tR
m/z

Example
Name
Starting Materials
method
(min)
(MH+)

27a
(S)-3-(9-(1-(1-
Example 6 and 1-
3
1.7
455

hydroxycyclopropanecarbonyl)piperidin-
hydroxycyclopropanecarboxylic

3-yl)-8-oxo-8,9-dihydro-7H-
acid

purin-2-yl)pyrazolo[1,5-a]pyridine-5-

carbonitrile

Example 28
(R)-3-(9-(1-Hydroxypropan-2-yl)-8-oxo-8,9-dihydro-7H-purin-2H)pyrazolo[1,5-a]pyridine-5-carbonitrile

To a solution of example 14 (60 mg, 0.17 mmol) in THF (10 mL) at 0° C., 1 M THF borane complex solution in THF (0.69 mL, 0.69 mmol) was added. The reaction mixture was stirred at room temperature overnight, quenched with MeOH (10 mL) and the reaction mixture was evaporated under reduced pressure. The crude residue was cromatographed on a silica gel flash system (ISCO Combiflash) using CH₂Cl₂/MeOH mixtures of increasing polarity as eluent to afford 4 mg of the desired product (7% yield).

LC-MS (method 3): t_R=2.02 min; m/z=336 (MH⁺).

Example 29
(S)-3-(3-(2-(5-Methylpyrazolo[1,5-a]pyridin-3-yl)-9H-purin-9-yl)piperidin-1-yl)-3-oxopropanenitrile
a) (S)-tert-Butyl 3-(2-(5-methylpyrazolo[1,5-a]pyridin-3-yl)-9H-purin-9-yl)piperidine-1-carboxylate

Following a similar procedure to that described in example 18, but using reference example 2a instead of the compound obtained in example 1 section d, the desired compound was obtained (10% yield).

LC-MS (method 3): t_R=2.53 min; m/z=434 (MH⁺).

b) (S)-2-(5-Methylpyrazolo[1,5-a]pyridin-3-yl)-9-(piperidin-3-yl)-9H-purine hydrochloride

Following a similar procedure to that described in example 6, but using the compound obtained in the previous section, the desired compound was obtained (quantitative yield).

LC-MS (method 3): t_R=1.7 min; m/z=334 (MH⁺).

c) Title Compound

Following a similar procedure to that described in example 7, but using the compound obtained in the previous section, the desired compound was obtained (57% yield).

LC-MS (method 3); t_R=1.78 min; m/z=401 (MH⁺).

Example 30
1-(4-(2-(Pyrazolo[1,5-a]pyridin-3-yl)-9H-purin-9-yl)piperidin-1-yl)ethanone
a) 9-(Piperidin-4-yl)-2-(pyrazolo[1,5-a]pyridin-3-yl)-9H-purine hydrochloride

Following a similar procedure to that described in example 29 section a and b, but using the compound obtained in reference example 2b instead of reference example 2a, the desired compound was obtained (10% yield).

b) Title Compound

Following a similar procedure to that described in example 24, but using the compound obtained in the previous section, the desired compound was obtained (quantitative yield).

LC-MS (method 4): t_R=1.35 min; m/z=362 (MH⁺),

Example 31
(S)-(9-(1-(2-Cyanoacetyl)piperidin-3-yl)-B-oxo-2-(pyrazolo[1,5-a]pyridin-3-yl)-8,9-dihydro-7H-purin-7-yl)methyl acetate
a) (S)-tert-Butyl 3-(7-(acetoxymethyl)-8-oxo-2-(pyrazolo[1,5-a]pyridin-3-yl)-7H-purin-9(81-1)-yl)piperidine-1-carboxylate

Following a similar procedure to that described in example 4, but using the compound obtained in example 3b instead of example 1 and bromomethyl acetate instead of methyl iodide, the desired compound was obtained (83% yield).

LC-MS (method 3): t_R=2/2 min; m/z=508 (MH⁺).

b) (S)-(8-Oxo-9-(piperidin-3-yl)-2-(pyrazolo[1,5-a]pyridin-3-yl)-8,9-dihydro-7H-purin-7-yl)methyl acetate hydrochloride

Following a similar procedure to that described in example 6, but using the compound obtained in the previous section, the desired compound was obtained (quantitative yield).

LC-MS (method 3): t_R=1.80 min; m/z=408 (MH⁺).

c) Title Compound

Following a similar procedure to that described in example 7, but using the compound obtained in the previous section, the desired compound was obtained (36% yield).

LC-MS (method 3): t_R=1.82 min; m/z=475 (MH⁺).

Following a similar procedure to that described in example 31, but using the corresponding starting materials, the following compound was obtained:

Starting
HPLC
tR
m/z

Example
Name
Materials
method
(min)
(MH+)

31a
(S)-(3-(1-(2-
Example
4
1.84
474

cyanoacetyl)piperidin-
7p

3-yl)-2-oxo-5-

(pyrazolo[1,5-

a]pyridin-3-yl)-2,3-

dihydro-1H-

imidazo[4,5-b]pyridin-

1-yl)methyl acetate

Example 32
(R)-3-(9-(1-Hydroxypropan-2-yl)-7-methyl-8-oxo-8,9-dihydro-7H-purin-2-yl)pyrazolo[1,5-a]pyridine-5-carbonitrile

To a solution of example 28 (20 mg, 0.06 mmol) in AcN (2 mL) and DMF (0.5 mL) silver (I) oxide (28 mg, 0.12 mmol) and methyl iodide (0.006 mL, 0.09 mmol) were added. The reaction mixture was stirred at room temperature overnight. The reaction mixture was filtered through a plug of Celite® and the solvent was evaporated under reduced pressure. The crude residue was cromatographed on a silica gel flash system (ISCO Combiflash) using CH₂Cl₂/MeOH mixtures of increasing polarity as eluent to afford 6 mg of the desired product (29% yield).

LC-MS (method 3): t_R=1.75 min; m/z=350 (MH⁺).

Example 33
2-(Pyrazolo[1,5-a]pyridin-3-yl)-9-(tetrahydro-2H-pyran-4yl)-9H-purin-8-amine

To a solution of reference example 2c (144 mg, 0.46 mmol) in EtOH (4 mL), cyanogen bromide (147 mg, 1.39 mmol) was added. The reaction mixture was stirred at 70° C. overnight. The reaction mixture was evaporated under reduced pressure, dissolved in EtOAc, and washed thrice with saturated NaHCO₃aqueous solution. The combined organic phases were dried over MgSO₄and concentrated to dryness. The reaction crude was used in next step without further purification.

LC-MS (Method 3): t_R=1.53 min; m/z=336 (MH⁺)

Example 34
1-(2-(Pyrazolo[1,5-a]pyridin-3-yl)-9-(tetrahydro-2H-pyran-4-yl)-9H-purin-8-yl)pyrrolidin-2-one

To a suspension of example 33 (25 mg, 0.075 mmol) in DMF (1.5 mL), DIPEA (0.04 mL, 0.22 mmol) and 4-bromobutyryl chloride (0.01 mL, 0.082 mmol) were added. The reaction mixture was stirred at room temperature overnight. The solvent was evaporated to dryness and 1.7 mg of the title compound were obtained (yield 6%) after HPLC preparative purification.

LC-MS (method 3): t_R=1.82 min; m/z=404 (MH⁺)

Following a similar procedure to that described in example 34, but using in each case the corresponding starting materials, the following compounds were obtained:

HPLC
t_R
m/z

Example
Name
Starting Materials
method
(min)
(MH⁺)

34a
N-(2-(pyrazolo[1,5-a]pyridin-3-yl)-9-
Example 33 and
3
1.97
406

(tetrahydro-2H-pyran-4-yl)-9H-
isobutyryl chloride

purin-8-yl)isobutyramide

34b
N-(2-(pyrazolo[1,5-a]pyridin-3-yl)-9-
Example 33 and
3
1.77
392

(tetrahydro-2H-pyran-4-yl)-9H-
propionyl chloride

purin-8-yl)propionamide

34c
N-(2-(pyrazolo[1,5-a]pyridin-3-yl)-9-
Example 33 and acetyl
3
1.60
378

(tetrahydro-2H-pyran-4-yl)-9H-
chloride

purin-8-yl)acetamide

Example 35
3-(9-(trans-4-Hydroxycyclohexyl)-7-methyl-5-oxo-8,9-dihydro-7H-purin-2-yl)pyrazolo[1,5-a]carbonitrile
a) 3-(9-trans-4-(tert-butyldimethylsilyloxy)cyclohexyl)-8-oxo-8,9-dihydro-7H-purin-2-yl)pyrazolo[1,5-a]pyridine-5-carbonitrile

To a suspension of example 1o (584 mg, 1.55 mmol) in DMF (15 mL), imidazole (265 mg, 3.89 mmol) and tert-butylchlorodimethylsilane (281 mg, 1.86 mmol) were added. The reaction mixture was stirred at room temperature overnight. The solvent was evaporated to dryness, dissolved in CH₂Cl₂and washed thrice with water. The combined organic phases were dried over MgSO₄and concentrated to dryness. The reaction crude was used in next step without further purification

LC-MS (method 3): t_R=3.38 min; m/z=490 (MH⁺)

b) 3-(9-(trans-4-(tert-butyldimethylsilyloxy)cyclohexyl)-7-methyl-8-oxo-8,9-dihydro-7H-purin-2-yl)pyrazolo[1,5-a]pyridine-5-carbonitrile

Following a similar procedure to that described in example 5, but using the compound obtained in the previous section, the desired compound was obtained (72% yield).

LC-MS (method 2): t_R=3.67 min; m/z=504 (MH⁺).

c) Title Compound

To a suspension of the compound obtained in the previous section (246 mg, 0.488 mmol) in AcN (10 mL), at 0° C., 1 M TBAF solution in THF (0.73 mL, 0.73 mmol) was added. The reaction mixture was stirred at room temperature overnight. The solvent was evaporated to dryness, dissolved in EtOAc and washed thrice with water. The combined organic phases were dried over MgSO4 and concentrated to dryness. The crude residue was cromatographed on a silica gel flash system (ISCO Combiflash) using CH₂Cl₂/MeOH mixtures of increasing polarity as eluent to afford 77 mg of the desired product (40% yield).

LC-MS (method 3): t_R=1.82 min; m/z=390 (MH⁺).

Example 36
2-(2-(5-Cyanopyrazolo[1,5-a]pyridin-3yl)-8-oxo-7H-purin-9(8H)-yl)-N-(2,2,2-trifluoroethyl)acetamide
a) 2-(2-(5-cyanopyrazolo[1,5-a]pyridin-3-yl)-8-oxo-7H-purin-9(8H)-yl)acetic acid

Following a similar procedure to that described in example 14, but using the compound obtained in example in instead of example 1a, the desired compound was obtained

LC-MS (method 3): t_R=1.05 min; m/z=336 (MH⁺).

b) Title Compound

Following a similar procedure to that described in example 15, but using the compound obtained in the previous section and 2,2,2-trifluoroethylamine, the desired compound was obtained.

LC-MS (method 3): t_R=1.065 min; m/z=417 (MH⁺).

Following a similar procedure to that described in example 36, but using the corresponding starting materials, the following compound was obtained:

Starting
HPLC
tR
m/z

Example
Name
Materials
method
(min)
(MH+)

36a
2-(2-(5-
N-
3
1.40
363

cyanopyrazolo[1,5-
ethylamine

a]pyridin-3-yl)-

8-oxo-7H-purin-

9(8H)-yl)-N-

ethylacetamide

Example 37
2-(imidazo[1,2-a]pyridin-3-yl)-7-methyl-9-(tetrahydro-2H-pyran-4-yl)-7H-purin-8(9H)-one
a) 2-Chloro-N4-(tetrahydro-2H-pyran-4-yl)pyrimidine-4,5-diamine

Following a similar procedure to that described in example 1 section d, but using the compound obtained in example 1 section a instead of the compound obtained in example 1 section c, the desired compound was obtained (quantitative yield).

LC-MS (method 1): t_R=6/3 min; m/z=229 (MH⁺).

b) 2-Chloro-9-(tetrahydro-2H-pyran-4-yl)-7H-purin-8(9H)-one

Following a similar procedure to that described in example 1 section e, but using the compound obtained in the previous section instead of the compound obtained in example 1 section d, the desired compound was obtained (83% yield).

LC-MS (method 1): t_R=7.16 min; m/z=254 (MH⁺).

c) 2-chloro-7-methyl-9-(tetrahydro-2H-pyran-4-yl)-7H-purin-8(9H)-one

Following a similar procedure to that described in example 5, but using the compound obtained in the previous section instead of the compound obtained in example 3b, the desired compound was obtained (58% yield).

LC-MS (method 1): t_R=7.51 min; m/z=268 (MH⁺).

d) Title Compound

To a suspension of the compound obtained the previous section (30 mg, 0.11 mmol) in EtOH (0.5 mL) and dioxane (1 mL), imidazo[1,2-a]pyridine (16 mg, 0.13 mmol), triphenylphosphine (5.8 mg, 0.02 mmol), potassium carbonate (3.1 mg, 0.22 mmol) and palladium (II) acetate (2.5 mg, 0.01 mmol) were added. The reaction mixture was heated in a CEM Explorer microwave oven at 110° C. for 10 min and at 90° C. for 3 h. The reaction mixture was filtered through a plug of Celite® and the solvent was concentrated off. A sample was purified by preparative HPLC.

LC-MS (method 4): t_R=1.55 min; m/z=351 (MH⁺).

Example 38
Inhibition of JAK3 Activity

The inhibition of JAK3 kinase activity was determined in 384-well assay microplates using the Z′-Lyte® Kinase Assay kit-Tyr 6 Peptide kit, supplied by invitrogen (Ref: PV4122), following the manufacturer's instructions, in a final volume of 10 μL per well, 2.5 μL of the product to be tested dissolved in 4% DMSO (final concentration of the product to be tested, 0.1-10000 nM) was incubated with 0.3 μg/mL of the catalytic domain of human JAK3 (amino acid sequence 281-1124), 2 μM of the substrate peptide Z′-Lyte® Tyr 6 and 4 μM of ATP; all components were dissolved in 50 mM pH 7.5 Hepes buffer, 10 mM Magnesium chloride (II), 1 mM EGTA and 0.01% Brij® 35. The reaction was started by the addition of said 4 μM ATP; after incubation for 1 hour at 25° C., 5 μL of A Z′-Lyte® Tyr 6 development reagent was added and the mixture was incubated for 1 hour at 25° C. Phosphorylation was then quantified in each well using a Safire2® fluorescence microplate reader from Tecan.

The compounds 1 to 1b, 1d to 1j, 1n to 1p, 1s, 2, 2e, 3 to 3e, 3h to 3i, 4, 4b to 5i, 5s, 6 to 6b, 6d to 6f, 6x, 7 to 7d, 7f to 16a, and 16c to 17a, 17c to 19, 20 to 29, 31 to 37 showed more than 50% inhibition of JAK3 activity at 1 μM in this assay.

Example 39
Inhibition of JAK2 Activity

The inhibition of JAK2 kinase activity was determined in 384-well assay microplates using the Z-Lyte® Kinase Assay kit-Tyr 6 Peptide kit, supplied by Invitrogen (Ref: PV4122), following the manufacturer's instructions. In a final volume of 10 μL per well, 2.5 μL of the product to be tested dissolved in 4% DMSO (final concentration of the product to be tested, 0.1-10000 nM) was incubated with 0.5 μg/well of the catalytic domain of human JAK2, 2 μM of the substrate peptide Z′-Lyte® Tyr 6 and 16 μM of ATP; all components were dissolved in 50 mM pH 7.5 Hepes buffer, 10 mM Magnesium chloride (II), 1 mM EGTA and 0.01% Brij® 35. The reaction was started by the addition of said 16 μM ATP; after incubation for 1 hour at 25° C., 5 μL of A Z′-Lyte® Tyr 6 development reagent was added and the mixture was incubated for 1 hour at 25° C. Phosphorylation was then quantified in each well using a Safire2® fluorescence microplate reader from Tecan.

The compounds 1 to 1b, 1e to 1g, 1n to 1p, 1s, 2, 2e, 3, 3b, 3d, 3e, 4, 4c, 5, 5a, 5b, 5e, 5f, 5h, 5i, 5s, 7 to 7c, 7f to 7n, 7p, 7r to 7u, 8 to 8c, 8d, 8f to 8h, 9a, 9b, 9c, 9f, 9g, 9i to 9k, 9m to 9s, 10a, 10b, 10e, 10h, 10i, 10k, 10l, 10m, 10n, 13b to 13k, 15 to 15b, 15 f, 15 h, 15i, 15k, 16, 16a, 16d to 16f, 17 to 17c, 18a, 18b, 18d to 18i, 19, 20, 21a to 21d, 21g to 21i, 21k, 22 to 23, 23d, 24, 24a, 24b, 24c, 25, 26, 26a, 26c, 26d, 26e, 26f, 26g, 27, 27a, 29, 31, 33, 34, 34b, and 35 to 36a showed more than 50% inhibition of JAK2 activity at 1 μM in this assay.

Example 40
Determination of Clearance in Human Liver Microsomes

A single concentration (1 μM in pH7.4 buffer) of a compound to be tested was incubated with human liver microsomes for 0, 10, 30 and 60 minutes at 37° C. (0.4 mg protein/mL). The degree of hepatic metabolism was measured by LC-MS/MS as the decrease in the peak area of the parent compound and expressed as the intrinsic clearance.

Several compounds of the invention were tested in this assay.

Example 41
Cytotoxicity in Hep G2 Cells Assay

Alamar blue (AB) was used to evaluate the possible toxicity of a compound to be tested on Human hepatocyte carcinoma cells (HepG2). The cells (20000 cells/well) were cultured in 96-well plates in the presence of the compound at different concentrations (1 to 20 μM) containing 0.2% DMSO for 72 h at 37° C. After addition of AB, fluorescence was measured. EC₅₀value, defined as the concentration of the compound that results in a decrease in AB fluorescence equivalent to 50% of the control, was calculated.

Several compounds of the invention were tested in this assay.

	Number	Date	Country
	61291051	Dec 2009	US
	61329927	Apr 2010	US

N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS

Information

Publication Number

Date Filed

Date Published

Inventors

CPC

US Classifications

International Classifications

Abstract

Description

Claims

Priority Claims (1)

PCT Information

Provisional Applications (2)